[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 3951
1. Kishikawa M, Koyama K, Iseki M, Kobuke T, Yonehara S, Soda M, Ron E, Tokunaga M, Preston DL, Mabuchi K, Tokuoka S: Histologic characteristics of skin cancer in Hiroshima and Nagasaki: background incidence and radiation effects. Int J Cancer; 2005 Nov 10;117(3):363-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Skin tumor incident cases diagnosed between 1958 and 1987 were ascertained by linkage to the Hiroshima and Nagasaki tumor registries augmented by searches of other data sources.
  • Study pathologists reviewed tumor specimens and pathology reports and classified tumors using the World Health Organization classification scheme.
  • They identified 274 primary incident skin cancers, of which 106 were basal cell carcinoma (BCC), 81 were squamous cell carcinoma (SCC), and 14 were malignant melanomas.
  • [MeSH-major] Nuclear Warfare. Skin Neoplasms / epidemiology. Skin Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Cohort Studies. Female. Humans. Incidence. Japan / epidemiology. Male. Middle Aged. Neoplasms, Radiation-Induced. Radioactive Fallout

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15900592.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CP / N01-CP-31012; United States / NCI NIH HHS / CP / N01-CP-71015
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radioactive Fallout
  •  go-up   go-down


2. Younis LK, El Sakka H, Haque I: The Prognostic Value of E-cadherin Expression in Breast Cancer. Int J Health Sci (Qassim); 2007 Jan;1(1):43-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among the novel prognostic markers is E-cadherin; a calcium-dependent epithelial cell adhesion molecule.
  • The median tumor size was 3cms.
  • However, there was no correlation between the E-cadherin and other prognostic parameters as tumor size, tumor grade, ER, PR, and HER-2 expression.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1993 Dec;143(6):1731-42 [8256859.001]
  • [Cites] Mod Pathol. 2003 Nov;16(11):1067-75 [14614045.001]
  • [Cites] Surg Oncol. 2000 Dec;9(4):151-71 [11476987.001]
  • [Cites] EMBO J. 1995 Dec 15;14(24):6107-15 [8557030.001]
  • [Cites] J Pathol. 2001 Apr;193(4):433-41 [11276001.001]
  • [Cites] Saudi Med J. 2001 Feb;22(2):110-3 [11299401.001]
  • [Cites] Saudi Med J. 2000 Sep;21(9):869-72 [11376366.001]
  • [Cites] J Pak Med Assoc. 2001 Jul;51(7):243-7 [11558215.001]
  • [Cites] Br J Cancer. 2001 Dec 14;85(12):1958-63 [11747340.001]
  • [Cites] Ann Surg. 2002 Jan;235(1):10-26 [11753038.001]
  • [Cites] Saudi Med J. 2002 Oct;23(10):1210-3 [12436125.001]
  • [Cites] Saudi Med J. 2003 Jun;24(6):623-7 [12847591.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Jan;131(1):14-8 [15459769.001]
  • [Cites] Curr Opin Cell Biol. 2005 Oct;17(5):499-508 [16107313.001]
  • [Cites] Indian J Med Sci. 1991 Apr;45(4):85-7 [1660447.001]
  • [Cites] Curr Opin Cell Biol. 1993 Oct;5(5):806-11 [8240824.001]
  • [Cites] Int J Cancer. 1992 Aug 19;52(1):48-51 [1500227.001]
  • [Cites] Am J Pathol. 1993 Apr;142(4):987-93 [7682767.001]
  • [Cites] Anticancer Res. 1997 Jan-Feb;17(1B):561-7 [9066580.001]
  • (PMID = 21475451.001).
  • [ISSN] 1658-3639
  • [Journal-full-title] International journal of health sciences
  • [ISO-abbreviation] Int J Health Sci (Qassim)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Other-IDs] NLM/ PMC3068666
  • [Keywords] NOTNLM ; E-cadherin / breast cancer / immunohistochemistry / immunostaining / prognostic factors
  •  go-up   go-down


3. Gambichler T, Skrygan M, Kaczmarczyk JM, Hyun J, Tomi NS, Sommer A, Bechara FG, Boms S, Brockmeyer NH, Altmeyer P, Kreuter A: Increased expression of TGF-beta/Smad proteins in basal cell carcinoma. Eur J Med Res; 2007 Oct 30;12(10):509-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of TGF-beta/Smad proteins in basal cell carcinoma.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common cancer in humans placing a significant burden on healthcare services worldwide.
  • Punch biopsies were harvested from the centre of the tumour (lesional) as well as an adjacent healthy skin site (non-lesional controls).
  • Immunohistochemistry demonstrated marked protein overexpression of Smad3 in tumour tissue as compared to non-lesional skin.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Skin Neoplasms / metabolism. Smad Proteins / metabolism. Transforming Growth Factor beta / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18024258.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Smad Proteins; 0 / Transforming Growth Factor beta
  •  go-up   go-down


Advertisement
4. Kuijpers DI, Thissen MR, Thissen CA, Neumann MH: Similar effectiveness of methyl aminolevulinate and 5-aminolevulinate in topical photodynamic therapy for nodular basal cell carcinoma. J Drugs Dermatol; 2006 Jul-Aug;5(7):642-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Similar effectiveness of methyl aminolevulinate and 5-aminolevulinate in topical photodynamic therapy for nodular basal cell carcinoma.
  • BACKGROUND: Photodynamic therapy (PDT) for basal cell carcinoma (BCC) is a treatment modality that is increasingly used in dermato-oncology.
  • RESULTS: Residual tumor tissue was detected in 6 BCCs of each study group.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Aminolevulinic Acid / therapeutic use. Carcinoma, Basal Cell / drug therapy. Photochemotherapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16865869.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


5. Behrendt U, Schumann P, Stieglmeier M, Pukall R, Augustin J, Spröer C, Schwendner P, Moissl-Eichinger C, Ulrich A: Characterization of heterotrophic nitrifying bacteria with respiratory ammonification and denitrification activity--description of Paenibacillus uliginis sp. nov., an inhabitant of fen peat soil and Paenibacillus purispatii sp. nov., isolated from a spacecraft assembly clean room. Syst Appl Microbiol; 2010 Oct;33(6):328-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of heterotrophic nitrifying bacteria with respiratory ammonification and denitrification activity--description of Paenibacillus uliginis sp. nov., an inhabitant of fen peat soil and Paenibacillus purispatii sp. nov., isolated from a spacecraft assembly clean room.
  • In the course of studying the influence of N-fertilization on N(2) and N(2)O flux rates in relation to soil bacterial community composition of a long-term fertilization experiment in fen peat grassland, a strain group was isolated that was related to a strain isolated from a spacecraft assembly clean room during diversity studies of microorganisms, which withstood cleaning and bioburden reduction strategies.
  • Both the fen soil isolates and the clean room strain revealed versatile physiological capacities in N-transformation processes by performing heterotrophic nitrification, respiratory ammonification and denitrification activity.
  • Phylogenetic analysis based on 16S rRNA gene sequences demonstrated that the investigated isolates belonged to the genus Paenibacillus.
  • Sequence similarities lower than 97% in comparison to established species indicated a separate species position.
  • Except for the peptidoglycan type (A4alpha L-Lys-D-Asp), chemotaxonomic features of the isolates matched the genus description, but differences in several physiological characteristics separated them from related species and supported their novel species status.
  • Despite a high 16S rRNA gene sequence similarity between the clean room isolate ES_MS17(T) and the representative fen soil isolate N3/975(T), DNA-DNA hybridization studies revealed genetic differences at the species level.
  • These differences were substantiated by MALDI-TOF MS analysis, ribotyping and several distinct physiological characteristics.
  • On the basis of these results, it was concluded that the fen soil isolates and the clean room isolate ES_MS17(T) represented two novel species for which the names Paenibacillus uliginis sp. nov. (type strain N3/975(T)=DSM 21861(T)=LMG 24790(T)) and Paenibacillus purispatii sp. nov. (type strain ES_MS17(T)=DSM 22991(T)=CIP 110057(T)) are proposed.
  • [MeSH-major] Air Microbiology. Nitrification. Paenibacillus / classification. Paenibacillus / isolation & purification. Soil Microbiology
  • [MeSH-minor] Bacterial Typing Techniques. Cluster Analysis. DNA, Bacterial / chemistry. DNA, Bacterial / genetics. DNA, Ribosomal / chemistry. DNA, Ribosomal / genetics. Denitrification. Environment, Controlled. Molecular Sequence Data. Nucleic Acid Hybridization. Phylogeny. RNA, Ribosomal, 16S / genetics. Sequence Analysis, DNA. Soil. Spacecraft

  • SILVA. SILVA SSU Database .
  • StrainInfo. culture/stock collections - online strain list (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier GmbH. All rights reserved.
  • (PMID = 20813476.001).
  • [ISSN] 1618-0984
  • [Journal-full-title] Systematic and applied microbiology
  • [ISO-abbreviation] Syst. Appl. Microbiol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ EU888513/ FN556467
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Bacterial; 0 / DNA, Ribosomal; 0 / RNA, Ribosomal, 16S; 0 / Soil
  •  go-up   go-down


6. Ma Y, Hu C, Riegel AT, Fan S, Rosen EM: Growth factor signaling pathways modulate BRCA1 repression of estrogen receptor-alpha activity. Mol Endocrinol; 2007 Aug;21(8):1905-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Cell Line, Tumor. Female. Humans. Male. Phosphatidylinositol 3-Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism


7. Wakai K, Tamakoshi K, Date C, Fukui M, Suzuki S, Lin Y, Niwa Y, Nishio K, Yatsuya H, Kondo T, Tokudome S, Yamamoto A, Toyoshima H, Tamakoshi A, JACC Study Group: Dietary intakes of fat and fatty acids and risk of breast cancer: a prospective study in Japan. Cancer Sci; 2005 Sep;96(9):590-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Breast Neoplasms / epidemiology. Dietary Fats. Fatty Acids / physiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Dietary Fats.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (Cancer Sci 2005; 96: 590 - 599).
  • (PMID = 16128744.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dietary Fats; 0 / Fatty Acids
  •  go-up   go-down


8. Zhou Y, Eppenberger-Castori S, Eppenberger U, Benz CC: The NFkappaB pathway and endocrine-resistant breast cancer. Endocr Relat Cancer; 2005 Jul;12 Suppl 1:S37-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, initial preclinical studies suggest that treatment strategies designed to prevent or interrupt activation of NFkappaB in cell-line models of these more aggressive, ER-positive breast cancers can restore their sensitivity to such standard endocrine agents as tamoxifen.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / metabolism. NF-kappa B / antagonists & inhibitors
  • [MeSH-minor] Drug Resistance, Neoplasm / drug effects. Female. Humans. Neoplasms, Hormone-Dependent / drug therapy. Neoplasms, Hormone-Dependent / metabolism. Receptors, Estrogen / antagonists & inhibitors. Receptors, Estrogen / metabolism. Signal Transduction / drug effects

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16113098.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50-CA58207; United States / NIA NIH HHS / AG / R01-AG20521; United States / NCI NIH HHS / CA / R01-CA36773; United States / NCI NIH HHS / CA / R01-CA71468
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / NF-kappa B; 0 / Receptors, Estrogen
  • [Number-of-references] 59
  •  go-up   go-down


9. Ishikawa T, Momiyama N, Hamaguchi Y, Tanabe M, Tomita S, Ichikawa Y, Nakatani Y, Sasaki T, Nozawa A, Inayama Y, Inui K, Shimada H: Blue-dye technique complements four-node sampling for early breast cancer. Eur J Surg Oncol; 2005 Dec;31(10):1119-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Breast Neoplasms / pathology. Coloring Agents. Lymph Nodes / pathology. Sentinel Lymph Node Biopsy / methods
  • [MeSH-minor] Adult. Aged. Axilla. Feasibility Studies. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Surg Oncol. 2007 Jun;33(5):670 [17344016.001]
  • (PMID = 16005597.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Coloring Agents
  •  go-up   go-down


10. Anim JT, John B, Abdulsathar S SA, Prasad A, Saji T, Akhtar N, Ali V, Al-Saleh M: Relationship between the expression of various markers and prognostic factors in breast cancer. Acta Histochem; 2005;107(2):87-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The immunohistochemical detection of six markers of breast cancer has been compared in the present study with known prognostic factors of the disease to establish locally a standard panel of markers for the management of breast cancer.
  • Using the chi(2)-test, relationships were determined between marker labelling and histological type of cancer, tumour grade, tumour size, axillary lymph node status and age of patient.
  • All markers showed no significant relationship with size of tumour, presence of axillary node metastasis or age of patient.
  • We found no relationship between the markers and tumour size, axillary lymph node status or age.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / metabolism. Breast Neoplasms / pathology
  • [MeSH-minor] Adult. Humans. Immunohistochemistry. Lymphatic Metastasis / pathology. Middle Aged. Neoplasm Staging. Prognosis


11. Gottwald D, Likos CN, Kahl G, Löwen H: Ionic microgels as model systems for colloids with an ultrasoft electrosteric repulsion: structure and thermodynamics. J Chem Phys; 2005 Feb 15;122(7):074903
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ionic microgels as model systems for colloids with an ultrasoft electrosteric repulsion: structure and thermodynamics.
  • We present a theoretical analysis of the structural properties and phase behavior of spherical, loosely cross-linked ionic microgels that possess a low monomer concentration.
  • The analysis is based on the recently derived effective interaction potential between such particles [A. R.
  • Denton, Phys. Rev. E 67, 011804 (2003)].
  • By employing standard tools from the theory of the liquid state, we quantitatively analyze the pair correlations in the fluid and find anomalous behavior above the overlap concentration, similar to the cases of star-branched neutral and charged polymers.
  • We also employ an evolutionary algorithm in order to predict the crystalline phases of the system without any a priori assumptions regarding their symmetry class.
  • A very rich phase diagram is obtained, featuring two reentrant melting transitions and a number of unusual crystal structures.
  • At high densities, both the Hansen-Verlet freezing criterion [J.-P. Hansen and L.
  • Verlet, Phys. Rev. 184, 151 (1969)] and the Lindemann melting criterion [F. A.
  • Lindemann, Phys. Z. 11, 609 (1910)] lose their validity.
  • The topology of the phase diagram is altered when the steric interactions between the polymer segments become strong enough, in which case the lower-density reentrant melting disappears and the region of stability of the fluid is split into two disconnected domains, separated by intervening fcc and bcc regions.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15743266.001).
  • [ISSN] 0021-9606
  • [Journal-full-title] The Journal of chemical physics
  • [ISO-abbreviation] J Chem Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Gorey KM, Luginaah IN, Schwartz KL, Fung KY, Balagurusamy M, Bartfay E, Wright FC, Anucha U, Parsons RR: Increased racial differences on breast cancer care and survival in America: historical evidence consistent with a health insurance hypothesis, 1975-2001. Breast Cancer Res Treat; 2009 Feb;113(3):595-600
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: This study examined whether race/ethnicity had differential effects on breast cancer care and survival across age strata and cohorts within stages of disease.
  • Within node positive disease all treatment disadvantages among younger African American women disappeared with socioeconomic adjustment.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Health Disparities.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2007 Jun 1;109(11):2161-70 [17455219.001]
  • [Cites] Breast Cancer Res Treat. 2006 May;97(2):149-55 [16322888.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2516-21 [17577028.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2522-7 [17577029.001]
  • [Cites] Breast Cancer Res Treat. 2008 Jun;109(3):545-57 [17659438.001]
  • [Cites] Arch Fam Med. 1999 Nov-Dec;8(6):521-8 [10575392.001]
  • [Cites] Med Care. 2000 Jul;38(7):705-18 [10901354.001]
  • [Cites] Am J Public Health. 2000 Dec;90(12):1866-72 [11111258.001]
  • [Cites] Cancer. 2000 Dec 1;89(11):2202-13 [11147590.001]
  • [Cites] J Gen Intern Med. 2001 Mar;16(3):189-99 [11318915.001]
  • [Cites] Am J Public Health. 2002 Jan;92(1):64-70 [11772763.001]
  • [Cites] Am J Epidemiol. 2002 Mar 15;155(6):534-45 [11882527.001]
  • [Cites] J Natl Cancer Inst. 2002 Apr 3;94(7):490-6 [11929949.001]
  • [Cites] JAMA. 2002 Apr 24;287(16):2106-13 [11966385.001]
  • [Cites] Cancer. 2002 Jun 1;94(11):2844-54 [12115371.001]
  • [Cites] Am J Epidemiol. 2002 Sep 1;156(5):471-82 [12196317.001]
  • [Cites] Milbank Q. 2002;80(4):677-707, iv [12532644.001]
  • [Cites] Ann Epidemiol. 2003 Jan;13(1):32-41 [12547483.001]
  • [Cites] Med Care. 2003 Jun;41(6):722-8 [12773838.001]
  • [Cites] J Clin Epidemiol. 2003 Jul;56(7):678-85 [12921937.001]
  • [Cites] Am J Public Health. 2003 Oct;93(10):1655-71 [14534218.001]
  • [Cites] Arch Intern Med. 2003 Oct 13;163(18):2135-44 [14557210.001]
  • [Cites] J Health Care Poor Underserved. 2003 Nov;14(4):503-15 [14619552.001]
  • [Cites] Cancer Causes Control. 2003 Oct;14(8):761-6 [14674740.001]
  • [Cites] Am J Public Health. 2004 Oct;94(10):1795-9 [15451752.001]
  • [Cites] Am J Public Health. 2004 Nov;94(11):1992-7 [15514242.001]
  • [Cites] Med Care Rev. 1989 Winter;46(4):349-85 [10304178.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1297-301 [2400978.001]
  • [Cites] Health Policy. 1991;19(2-3):91-118 [10115996.001]
  • [Cites] Am J Epidemiol. 1992 Mar 15;135(6):609-18 [1580237.001]
  • [Cites] J Natl Cancer Inst. 1993 Jun 16;85(12):979-87 [8496983.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):788-98 [8334632.001]
  • [Cites] Am J Public Health. 1994 Jun;84(6):1003-6 [8203664.001]
  • [Cites] JAMA. 1994 Sep 28;272(12):947-54 [8084062.001]
  • [Cites] Med Care Res Rev. 1995 Sep;52(3):389-408 [10144870.001]
  • [Cites] Cancer. 1997 Jul 1;80(1):80-90 [9210712.001]
  • [Cites] Am J Obstet Gynecol. 1997 Jun;176(6):S233-9 [9215214.001]
  • [Cites] Am J Public Health. 1997 Jul;87(7):1156-63 [9240106.001]
  • [Cites] Ann Epidemiol. 2006 Oct;16(10):789-91; author reply 792-3 [16882472.001]
  • [Cites] Breast Cancer Res Treat. 2007 Jan;101(2):207-14 [16838114.001]
  • [Cites] Ethn Dis. 1997 Spring-Summer;7(2):137-49 [9386954.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1310-8 [9529023.001]
  • [Cites] Am J Public Health. 1999 Jan;89(1):36-42 [9987462.001]
  • [Cites] Health Serv Res. 1999 Apr;34(1 Pt 2):271-9 [10199674.001]
  • [Cites] Surgery. 1999 Apr;125(4):375-9 [10216527.001]
  • [Cites] JAMA. 1999 Jul 14;282(2):159-63 [10411197.001]
  • [Cites] Am J Clin Oncol. 1999 Oct;22(5):436-40 [10521053.001]
  • [Cites] Milbank Q. 1999;77(3):401-7 [10526551.001]
  • [Cites] Breast J. 2005 Mar-Apr;11(2):124-8 [15730458.001]
  • [Cites] Breast Cancer Res Treat. 2005 Jun;91(3):243-8 [15952057.001]
  • [Cites] Am J Public Health. 2006 Jan;96(1):160-6 [16317209.001]
  • [Cites] Breast Cancer Res Treat. 2006 Jan;95(1):89-95 [16244785.001]
  • [Cites] Am J Epidemiol. 2007 Jul 1;166(1):71-8 [17426038.001]
  • (PMID = 18330694.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] ENG
  • [Grant] Canada / Canadian Institutes of Health Research / / 42633-1; Canada / Canadian Institutes of Health Research / / 67161; Canada / Canadian Institutes of Health Research / / 67161-1; Canada / Canadian Institutes of Health Research / / 42633; None / None / / 42633-1; None / None / / 42633; None / None / / N01 PC065064; None / None / / 67161-1; None / None / / 67161; United States / NCI NIH HHS / PC / N01-PC 65064
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ CAMS1396; NLM/ PMC2909273
  •  go-up   go-down


13. Pant K, Dutta U: Understanding and management of male breast cancer: a critical review. Med Oncol; 2008;25(3):294-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Breast cancer is a rare disease in men representing nearly 1% of the total breast cancer cases worldwide.
  • While treatments developed for women with breast cancer are often applied to treat men with breast cancer, however, lack of awareness of this disease leads to its detection at a later stage in men.
  • This review discusses male breast cancer and draws comparisons with female breast cancer and discusses current treatments available to treat this disease.
  • [MeSH-major] Breast Neoplasms / therapy. Breast Neoplasms, Male / epidemiology. Breast Neoplasms, Male / therapy
  • [MeSH-minor] Antineoplastic Agents, Hormonal / therapeutic use. Aromatase Inhibitors / therapeutic use. Chemotherapy, Adjuvant. Estrogens / metabolism. Female. Humans. Male. Neoplasm Staging. Sex Characteristics. Tamoxifen / therapeutic use

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Breast Cancer, Male.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 1997 Jan;82(1):70-4 [8989235.001]
  • [Cites] Eur J Cancer. 1995 Nov;31A(12):1960-4 [8562148.001]
  • [Cites] Cancer. 1999 Feb 1;85(3):629-39 [10091736.001]
  • [Cites] J Clin Endocrinol Metab. 1974 Mar;38(3):476-9 [4815174.001]
  • [Cites] Int J Oncol. 2004 Mar;24(3):663-70 [14767551.001]
  • [Cites] Nat Genet. 1994 May;7(1):103-7 [8075631.001]
  • [Cites] Endocrinology. 1996 Dec;137(12):5739-42 [8940410.001]
  • [Cites] Br J Cancer. 1985 Jan;51(1):115-9 [3966965.001]
  • [Cites] Am J Hum Genet. 2001 Feb;68(2):410-9 [11170890.001]
  • [Cites] Cancer. 1989 Oct 15;64(8):1583-5 [2676137.001]
  • [Cites] Cancer. 1996 Feb 1;77(3):490-8 [8630956.001]
  • [Cites] Endocrinology. 1985 Jan;116(1):38-46 [2981072.001]
  • [Cites] Endocr Relat Cancer. 1999 Jun;6(2):131-7 [10731101.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2750-6 [16782915.001]
  • [Cites] Endocrinology. 1997 Dec;138(12):5125-35 [9389492.001]
  • [Cites] Bull Cancer. 2005 Mar;92(3):281-5 [15820923.001]
  • [Cites] Am J Clin Oncol. 1987 Feb;10(1):55-60 [3825994.001]
  • [Cites] J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):225-30 [14623515.001]
  • [Cites] Eur J Cancer. 1998 Aug;34(9):1341-7 [9849414.001]
  • [Cites] Expert Opin Pharmacother. 2007 Feb;8(2):193-202 [17257089.001]
  • [Cites] J Health Psychol. 2002 May;7(3):209-17 [22114245.001]
  • [Cites] Med Oncol. 2008;25(2):113-24 [17973095.001]
  • [Cites] Ann Intern Med. 2002 Oct 15;137(8):678-87 [12379069.001]
  • [Cites] Mol Cell Endocrinol. 1998 Apr 30;139(1-2):117-29 [9705080.001]
  • [Cites] Int J Cancer. 1996 Feb 8;65(4):446-9 [8621225.001]
  • [Cites] BMJ. 2001 Nov 3;323(7320):1055-8 [11691767.001]
  • [Cites] Eur J Cancer. 2006 Feb;42(3):334-41 [16377181.001]
  • [Cites] Cancer Treat Rev. 2006 Apr;32(2):101-5 [16472925.001]
  • [Cites] Cancer Detect Prev. 2006;30(6):530-4 [17113724.001]
  • [Cites] Recent Prog Horm Res. 1997;52:185-213; discussion 213-4 [9238853.001]
  • [Cites] Gynecol Obstet Fertil. 2006 May;34(5):413-9 [16630739.001]
  • [Cites] BMJ. 1998 Oct 17;317(7165):1072-5 [9774301.001]
  • [Cites] Endocrinology. 1993 Mar;132(3):1396-401 [8440194.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):39-44 [16434584.001]
  • [Cites] Cancer. 2004 Jul 1;101(1):51-7 [15221988.001]
  • [Cites] Oncologist. 2005 Aug;10(7):471-9 [16079314.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2359-64 [16270318.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1687-717 [15894097.001]
  • [Cites] Breast Cancer Res Treat. 2007 May;103(1):11-21 [17033919.001]
  • [Cites] J Endocrinol. 2000 Feb;164(2):225-38 [10657858.001]
  • [Cites] Lancet. 2006 Feb 18;367(9510):595-604 [16488803.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2109-11 [9187104.001]
  • (PMID = 18074245.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Aromatase Inhibitors; 0 / Estrogens; 094ZI81Y45 / Tamoxifen
  • [Number-of-references] 43
  •  go-up   go-down


14. Brinckmann S, Kim JY, Greer JR: Fundamental differences in mechanical behavior between two types of crystals at the nanoscale. Phys Rev Lett; 2008 Apr 18;100(15):155502
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fundamental differences in mechanical behavior between two types of crystals at the nanoscale.
  • We present differences in the mechanical behavior of nanoscale gold and molybdenum single crystals.
  • A significant strength increase is observed as the size is reduced to 100 nm.
  • Both nanocrystals exhibit discrete strain bursts during plastic deformation.
  • We postulate that they arise from significant differences in the dislocation behavior.
  • Dislocation starvation is the predominant mechanism of plasticity in nanoscale fcc crystals, while junction formation and hardening characterize bcc plasticity.
  • A statistical analysis of strain bursts is performed as a function of size and compared with stochastic models.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18518121.001).
  • [ISSN] 0031-9007
  • [Journal-full-title] Physical review letters
  • [ISO-abbreviation] Phys. Rev. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


15. Mariolis-Sapsakos T, Theodoropoulos G, Flessas II, Orfanos F, Orfanos N, Konstantinou EA, Zagouri F, Vlachodimitropoulos D, Zografos GC: Lobular breast cancer in men: case report and review of the literature. Onkologie; 2010;33(12):698-700
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Breast Neoplasms, Male / diagnosis. Carcinoma, Lobular / diagnosis
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Breast / pathology. Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Karyotyping. Male. Mastectomy, Modified Radical. Neoplasm Invasiveness. Neoplasm Staging


16. Della Puppa A, Dal Pos S, Zovato S, Orvieto E, Ciccarino P, Manara R, Zustovich F, Berti F, Gardiman MP, Scienza R: Solitary intra-ventricular brain metastasis from a breast carcinoma. J Neurooncol; 2010 Mar;97(1):123-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Brain Neoplasms / secondary. Breast Neoplasms / pathology. Carcinoma / pathology. Lateral Ventricles / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] No Shinkei Geka. 1999 Apr;27(4):359-63 [10347852.001]
  • [Cites] J Neurooncol. 1999;45(3):237-40 [10845394.001]
  • [Cites] South Med J. 1998 Dec;91(12 ):1159-62 [9853731.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Jun-Jul;26(6):1475-8 [15956518.001]
  • [Cites] Neurol Med Chir (Tokyo). 1997 Dec;37(12 ):916-9 [9465591.001]
  • [Cites] Neurol India. 2008 Apr-Jun;56(2):179-81 [18688144.001]
  • [Cites] Magn Reson Med Sci. 2003 Oct 1;2(3):155-8 [16222108.001]
  • [Cites] J Clin Neurosci. 2004 Jun;11(5):521-3 [15177398.001]
  • [Cites] J Neurosurg. 2000 Mar;92(3):506 [10701550.001]
  • [Cites] J Neurooncol. 2005 Jan;71(2):157-60 [15690132.001]
  • [Cites] J Neurooncol. 1996 Jan;27(1):47-52 [8699225.001]
  • [Cites] J Clin Neurosci. 2008 May;15(5):594-7 [18313927.001]
  • (PMID = 19727563.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Cheng NX, Liu LG, Hui L, Chen YL, Xu SL: Breast cancer following augmentation mammaplasty with polyacrylamide hydrogel (PAAG) injection. Aesthetic Plast Surg; 2009 Jul;33(4):563-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The delayed diagnosis and more aggressive disease due to PAAG injection should be cause for concern.
  • [MeSH-major] Acrylic Resins / administration & dosage. Acrylic Resins / adverse effects. Breast Neoplasms / chemically induced. Gels / administration & dosage. Gels / adverse effects. Mammaplasty / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Reconstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19156460.001).
  • [ISSN] 1432-5241
  • [Journal-full-title] Aesthetic plastic surgery
  • [ISO-abbreviation] Aesthetic Plast Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acrylic Resins; 0 / Gels; 0 / polyacrylamide gels
  •  go-up   go-down


18. Paavilainen V, Tuominen J, Aho VV, Saari KM: Long-term results after treatment of basal cell carcinoma of the eyelid in South-Western Finland. Eur J Ophthalmol; 2007 Jul-Aug;17(4):494-500
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results after treatment of basal cell carcinoma of the eyelid in South-Western Finland.
  • PURPOSE: Basal cell carcinoma (BCC) is the most common skin cancer of the eyelid, showing an increasing incidence in the white population.
  • RESULTS: The 191 patients had altogether 194 BCC tumors of the eyelid with the mean diameter of the tumor being smaller than 10 mm in 77.3% of cases.
  • [MeSH-major] Carcinoma, Basal Cell / therapy. Eyelid Neoplasms / therapy. Neoplasm Recurrence, Local / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17671921.001).
  • [ISSN] 1120-6721
  • [Journal-full-title] European journal of ophthalmology
  • [ISO-abbreviation] Eur J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


19. Amnuaykanjanasin A, Punya J, Paungmoung P, Rungrod A, Tachaleat A, Pongpattanakitshote S, Cheevadhanarak S, Tanticharoen M: Diversity of type I polyketide synthase genes in the wood-decay fungus Xylaria sp. BCC 1067. FEMS Microbiol Lett; 2005 Oct 1;251(1):125-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The finding of 11 distinct PKS genes solely by means of PCR cloning supports that PKS genes are highly diverse in fungi.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • StrainInfo. culture/stock collections - online strain list (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] FEMS Microbiol Lett. 2006 Jan;254(2):333
  • (PMID = 16112817.001).
  • [ISSN] 0378-1097
  • [Journal-full-title] FEMS microbiology letters
  • [ISO-abbreviation] FEMS Microbiol. Lett.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AF395534/ AY445825/ AY965071/ AY971512/ AY971872/ DQ003485/ DQ011042/ DQ011043/ DQ011045/ DQ011595/ DQ011596
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Fungal; 0 / Fungal Proteins; 79956-01-7 / Polyketide Synthases
  •  go-up   go-down


20. Davidchack RL, Laird BB: Crystal structure and interaction dependence of the crystal-melt interfacial free energy. Phys Rev Lett; 2005 Mar 4;94(8):086102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Crystal structure and interaction dependence of the crystal-melt interfacial free energy.
  • We examine via molecular simulation the dependence of the crystal-melt interfacial free energy gamma on molecular interaction and crystal structure (fcc vs bcc) for systems interacting with inverse-power repulsive potentials, u(r)=epsilon(sigma/r)(n), 6< or =n< or =100.
  • Both the magnitude and anisotropy of gamma are found to increase as the range of the potential increases.
  • Also we find that gamma(bcc)<gamma(fcc), consistent with recent observations that some fcc forming fluids nucleate via formation of metastable bcc nuclei.
  • The anisotropy in gamma is also seen to be smaller in the bcc systems.
  • By extrapolation, we also obtain an improved estimate of gamma for hard spheres.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15783906.001).
  • [ISSN] 0031-9007
  • [Journal-full-title] Physical review letters
  • [ISO-abbreviation] Phys. Rev. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Kwon S, Kim TS, Yu GH, Jung JH, Park HD: Bacterial community composition and diversity of a full-scale integrated fixed-film activated sludge system as investigated by pyrosequencing. J Microbiol Biotechnol; 2010 Dec;20(12):1717-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bacterial community composition and diversity of a full-scale integrated fixed-film activated sludge system as investigated by pyrosequencing.
  • The integrated fixed-film activated sludge (IFAS) system is a variation of the activated sludge wastewater treatment process, in which hybrid suspended and attached biomass is used to treat wastewater.
  • Although the function and performance of the IFAS system are well studied, little is known about its microbial community structure.
  • In this study, the composition and diversity of the bacterial community of suspended and attached biomass samples were investigated in a full-scale IFAS system using a highthroughput pyrosequencing technology.
  • Distinct bacterial community compositions were examined for each sample and appeared to be important for its features different from conventional activated sludge processes.
  • The abundant bacterial groups were Betaproteobacteria (59.3%), Gammaproteobacteria (8.1%), Bacteroidetes (5.2%), Alphaproteobacteria (3.9%), and Actinobacteria (3.2%) in the suspended sample, whereas Actinobacteria (14.6%), Firmicutes (13.6%), Bacteroidetes (11.6%), Betaproteobacteria (9.9%), Gammaproteobacteria (9.25%), and Alphaproteobacteria (7.4%) were major bacterial groups in the attached sample.
  • Regarding the diversity, totals of 3,034 and 1,451 operational taxonomic units were identified at the 3% cutoff for the suspended and attached samples, respectively.
  • Rank abundance and community analyses demonstrated that most of the diversity was originated from rare species in the samples.
  • Taken together, the information obtained in this study will be a base for further studies relating to the microbial community structure and function of the IFAS system.
  • [MeSH-major] Bacteria / classification. Bacteria / genetics. Biodiversity. Sewage / microbiology
  • [MeSH-minor] Cluster Analysis. DNA, Bacterial / chemistry. DNA, Bacterial / genetics. DNA, Ribosomal / chemistry. DNA, Ribosomal / genetics. Molecular Sequence Data. Phylogeny. RNA, Ribosomal, 16S / genetics. Sequence Analysis, DNA. Water Purification

  • SILVA. SILVA SSU Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21193829.001).
  • [ISSN] 1738-8872
  • [Journal-full-title] Journal of microbiology and biotechnology
  • [ISO-abbreviation] J. Microbiol. Biotechnol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ GU539392/ GU539393/ GU539394/ GU539395/ GU539396/ GU539397/ GU539398/ GU539399/ GU539400/ GU539401/ GU539402/ GU539403/ GU539404/ GU539405/ GU539406/ GU539407/ GU539408/ GU539409/ GU539410/ GU539411/ GU539412/ GU539413/ GU539414/ GU539415/ GU539416/ GU539417/ GU539418/ GU539419/ GU539420/ GU539421/ GU539422/ GU539423/ GU539424/ GU539425/ GU539426/ GU539427/ GU539428/ GU539429/ GU539430/ GU539431/ GU539432/ GU539433/ GU539434/ GU539435/ GU539436/ GU539437/ GU539438/ GU539439/ GU539440/ GU539441/ GU539442/ GU539443/ GU539444/ GU539445/ GU539446/ GU539447/ GU539448/ GU539449/ GU539450/ GU539451/ GU539452/ GU539453/ GU539454/ GU539455/ GU539456/ GU539457/ GU539458/ GU539459/ GU539460/ GU539461/ GU539462/ GU539463/ GU539464/ GU539465/ GU539466/ GU539467/ GU539468/ GU539469/ GU539470/ GU539471/ GU539472/ GU539473/ GU539474/ GU539475/ GU539476/ GU539477/ GU539478/ GU539479/ GU539480/ GU539481/ GU539482/ GU539483/ GU539484/ GU539485/ GU539486/ GU539487/ GU539488/ GU539489/ GU539490/ GU539491/ GU539492/ GU539493/ GU539494/ GU539495/ GU539496/ GU539497/ GU539498/ GU539499/ GU539500/ GU539501/ GU539502/ GU539503/ GU539504/ GU539505/ GU539506/ GU539507/ GU539508/ GU539509/ GU539510/ GU539511/ GU539512/ GU539513/ GU539514/ GU539515/ GU539516/ GU539517/ GU539518/ GU539519/ GU539520/ GU539521/ GU539522/ GU539523/ GU539524/ GU539525/ GU539526/ GU539527/ GU539528/ GU539529/ GU539530/ GU539531/ GU539532/ GU539533/ GU539534/ GU539535/ GU539536/ GU539537/ GU539538/ GU539539/ GU539540/ GU539541/ GU539542/ GU539543/ GU539544/ GU539545/ GU539546/ GU539547/ GU539548/ GU539549/ GU539550/ GU539551/ GU539552/ GU539553/ GU539554/ GU539555/ GU539556/ GU539557/ GU539558/ GU539559/ GU539560/ GU539561/ GU539562/ GU539563/ GU539564/ GU539565/ GU539566/ GU539567/ GU539568/ GU539569/ GU539570/ GU539571/ GU539572/ GU539573/ GU539574/ GU539575/ GU539576/ GU539577/ GU539578/ GU539579/ GU539580/ GU539581/ GU539582/ GU539583/ GU539584/ GU539585/ GU539586/ GU539587/ GU539588/ GU539589/ GU539590/ GU539591/ GU539592/ GU539593/ GU539594/ GU539595/ GU539596/ GU539597/ GU539598/ GU539599/ GU539600/ GU539601/ GU539602/ GU539603/ GU539604/ GU539605/ GU539606/ GU539607/ GU539608/ GU539609/ GU539610/ GU539611/ GU539612/ GU539613/ GU539614/ GU539615/ GU539616/ GU539617/ GU539618/ GU539619/ GU539620/ GU539621/ GU539622/ GU539623/ GU539624/ GU539625/ GU539626/ GU539627/ GU539628/ GU539629/ GU539630/ GU539631/ GU539632/ GU539633/ GU539634/ GU539635/ GU539636/ GU539637/ GU539638/ GU539639/ GU539640/ GU539641/ GU539642/ GU539643/ GU539644/ GU539645/ GU539646/ GU539647/ GU539648/ GU539649/ GU539650/ GU539651/ GU539652/ GU539653/ GU539654/ GU539655/ GU539656/ GU539657/ GU539658/ GU539659/ GU539660/ GU539661/ GU539662/ GU539663/ GU539664/ GU539665/ GU539666/ GU539667/ GU539668/ GU539669/ GU539670/ GU539671/ GU539672/ GU539673/ GU539674/ GU539675/ GU539676/ GU539677/ GU539678/ GU539679/ GU539680/ GU539681/ GU539682/ GU539683/ GU539684/ GU539685/ GU539686/ GU539687/ GU539688/ GU539689/ GU539690/ GU539691/ GU539692/ GU539693/ GU539694/ GU539695/ GU539696/ GU539697/ GU539698/ GU539699/ GU539700/ GU539701/ GU539702/ GU539703/ GU539704/ GU539705/ GU539706/ GU539707/ GU539708/ GU539709/ GU539710/ GU539711/ GU539712/ GU539713/ GU539714/ GU539715/ GU539716/ GU539717/ GU539718/ GU539719/ GU539720/ GU539721/ GU539722/ GU539723/ GU539724/ GU539725/ GU539726/ GU539727/ GU539728/ GU539729/ GU539730/ GU539731/ GU539732/ GU539733/ GU539734/ GU539735/ GU539736/ GU539737/ GU539738/ GU539739/ GU539740/ GU539741/ GU539742/ GU539743/ GU539744/ GU539745/ GU539746/ GU539747/ GU539748/ GU539749/ GU539750/ GU539751/ GU539752/ GU539753/ GU539754/ GU539755/ GU539756/ GU539757/ GU539758/ GU539759/ GU539760/ GU539761/ GU539762/ GU539763/ GU539764/ GU539765/ GU539766/ GU539767/ GU539768/ GU539769/ GU539770/ GU539771/ GU539772/ GU539773/ GU539774/ GU539775/ GU539776/ GU539777/ GU539778/ GU539779/ GU539780/ GU539781/ GU539782/ GU539783/ GU539784/ GU539785/ GU539786/ GU539787/ GU539788/ GU539789/ GU539790/ GU539791/ GU539792/ GU539793/ GU539794/ GU539795/ GU539796/ GU539797/ GU539798/ GU539799/ GU539800/ GU539801/ GU539802/ GU539803/ GU539804/ GU539805/ GU539806/ GU539807/ GU539808/ GU539809/ GU539810/ GU539811/ GU539812/ GU539813/ GU539814/ GU539815/ GU539816/ GU539817/ GU539818/ GU539819/ GU539820/ GU539821/ GU539822/ GU539823/ GU539824/ GU539825/ GU539826/ GU539827/ GU539828/ GU539829/ GU539830/ GU539831/ GU539832/ GU539833/ GU539834/ GU539835/ GU539836/ GU539837/ GU539838/ GU539839/ GU539840/ GU539841/ GU539842/ GU539843/ GU539844/ GU539845/ GU539846/ GU539847/ GU539848/ GU539849/ GU539850/ GU539851/ GU539852/ GU539853/ GU539854/ GU539855/ GU539856/ GU539857/ GU539858/ GU539859/ GU539860/ GU539861/ GU539862/ GU539863/ GU539864/ GU539865/ GU539866/ GU539867/ GU539868/ GU539869/ GU539870/ GU539871/ GU539872/ GU539873/ GU539874/ GU539875/ GU539876/ GU539877/ GU539878/ GU539879/ GU539880/ GU539881/ GU539882/ GU539883/ GU539884/ GU539885/ GU539886/ GU539887/ GU539888/ GU539889/ GU539890/ GU539891/ GU539892/ GU539893/ GU539894/ GU539895/ GU539896/ GU539897/ GU539898/ GU539899/ GU539900/ GU539901/ GU539902/ GU539903/ GU539904/ GU539905/ GU539906/ GU539907/ GU539908/ GU539909/ GU539910/ GU539911/ GU539912/ GU539913/ GU539914/ GU539915/ GU539916/ GU539917/ GU539918/ GU539919/ GU539920/ GU539921/ GU539922/ GU539923/ GU539924/ GU539925/ GU539926/ GU539927/ GU539928/ GU539929/ GU539930/ GU539931/ GU539932/ GU539933/ GU539934/ GU539935/ GU539936/ GU539937/ GU539938/ GU539939/ GU539940/ GU539941/ GU539942/ GU539943/ GU539944/ GU539945/ GU539946/ GU539947/ GU539948/ GU539949/ GU539950/ GU539951/ GU539952/ GU539953/ GU539954/ GU539955/ GU539956/ GU539957/ GU539958/ GU539959/ GU539960/ GU539961/ GU539962/ GU539963/ GU539964/ GU539965/ GU539966/ GU539967/ GU539968/ GU539969/ GU539970/ GU539971/ GU539972/ GU539973/ GU539974/ GU539975/ GU539976/ GU539977/ GU539978/ GU539979/ GU539980/ GU539981/ GU539982/ GU539983/ GU539984/ GU539985/ GU539986/ GU539987/ GU539988/ GU539989/ GU539990/ GU539991/ GU539992/ GU539993/ GU539994/ GU539995/ GU539996/ GU539997/ GU539998/ GU539999/ GU540000/ GU540001/ GU540002/ GU540003/ GU540004/ GU540005/ GU540006/ GU540007/ GU540008/ GU540009/ GU540010/ GU540011/ GU540012/ GU540013/ GU540014/ GU540015/ GU540016/ GU540017/ GU540018/ GU540019/ GU540020/ GU540021/ GU540022/ GU540023/ GU540024/ GU540025/ GU540026/ GU540027/ GU540028/ GU540029/ GU540030/ GU540031/ GU540032/ GU540033/ GU540034/ GU540035/ GU540036/ GU540037/ GU540038/ GU540039/ GU540040/ GU540041/ GU540042/ GU540043/ GU540044/ GU540045/ GU540046/ GU540047/ GU540048/ GU540049/ GU540050/ GU540051/ GU540052/ GU540053/ GU540054/ GU540055/ GU540056/ GU540057/ GU540058/ GU540059/ GU540060/ GU540061/ GU540062/ GU540063/ GU540064/ GU540065/ GU540066/ GU540067/ GU540068/ GU540069/ GU540070/ GU540071/ GU540072/ GU540073/ GU540074/ GU540075/ GU540076/ GU540077/ GU540078/ GU540079/ GU540080/ GU540081/ GU540082/ GU540083/ GU540084/ GU540085/ GU540086/ GU540087/ GU540088/ GU540089/ GU540090/ GU540091/ GU540092/ GU540093/ GU540094/ GU540095/ GU540096/ GU540097/ GU540098/ GU540099/ GU540100/ GU540101/ GU540102/ GU540103/ GU540104/ GU540105/ GU540106/ GU540107/ GU540108/ GU540109/ GU540110/ GU540111/ GU540112/ GU540113/ GU540114/ GU540115/ GU540116/ GU540117/ GU540118/ GU540119/ GU540120/ GU540121/ GU540122/ GU540123/ GU540124/ GU540125/ GU540126/ GU540127/ GU540128/ GU540129/ GU540130/ GU540131/ GU540132/ GU540133/ GU540134/ GU540135/ GU540136/ GU540137/ GU540138/ GU540139/ GU540140/ GU540141/ GU540142/ GU540143/ GU540144/ GU540145/ GU540146/ GU540147/ GU540148/ GU540149/ GU540150/ GU540151/ GU540152/ GU540153/ GU540154/ GU540155/ GU540156/ GU540157/ GU540158/ GU540159/ GU540160/ GU540161/ GU540162/ GU540163/ GU540164/ GU540165/ GU540166/ GU540167/ GU540168/ GU540169/ GU540170/ GU540171/ GU540172/ GU540173/ GU540174/ GU540175/ GU540176/ GU540177/ GU540178/ GU540179/ GU540180/ GU540181/ GU540182/ GU540183/ GU540184/ GU540185/ GU540186/ GU540187/ GU540188/ GU540189/ GU540190/ GU540191/ GU540192/ GU540193/ GU540194/ GU540195/ GU540196/ GU540197/ GU540198/ GU540199/ GU540200/ GU540201/ GU540202/ GU540203/ GU540204/ GU540205/ GU540206/ GU540207/ GU540208/ GU540209/ GU540210/ GU540211/ GU540212/ GU540213/ GU540214/ GU540215/ GU540216/ GU540217/ GU540218/ GU540219/ GU540220/ GU540221/ GU540222/ GU540223/ GU540224/ GU540225/ GU540226/ GU540227/ GU540228/ GU540229/ GU540230/ GU540231/ GU540232/ GU540233/ GU540234/ GU540235/ GU540236/ GU540237/ GU540238/ GU540239/ GU540240/ GU540241/ GU540242/ GU540243/ GU540244/ GU540245/ GU540246/ GU540247/ GU540248/ GU540249/ GU540250/ GU540251/ GU540252/ GU540253/ GU540254/ GU540255/ GU540256/ GU540257/ GU540258/ GU540259/ GU540260/ GU540261/ GU540262/ GU540263/ GU540264/ GU540265/ GU540266/ GU540267/ GU540268/ GU540269/ GU540270/ GU540271/ GU540272/ GU540273/ GU540274/ GU540275/ GU540276/ GU540277/ GU540278/ GU540279/ GU540280/ GU540281/ GU540282/ GU540283/ GU540284/ GU540285/ GU540286/ GU540287/ GU540288/ GU540289/ GU540290/ GU540291/ GU540292/ GU540293/ GU540294/ GU540295/ GU540296/ GU540297/ GU540298/ GU540299/ GU540300/ GU540301/ GU540302/ GU540303/ GU540304/ GU540305/ GU540306/ GU540307/ GU540308/ GU540309/ GU540310/ GU540311/ GU540312/ GU540313/ GU540314/ GU540315/ GU540316/ GU540317/ GU540318/ GU540319/ GU540320/ GU540321/ GU540322/ GU540323/ GU540324/ GU540325/ GU540326/ GU540327/ GU540328/ GU540329/ GU540330/ GU540331/ GU540332/ GU540333/ GU540334/ GU540335/ GU540336/ GU540337/ GU540338/ GU540339/ GU540340/ GU540341/ GU540342/ GU540343/ GU540344/ GU540345/ GU540346/ GU540347/ GU540348/ GU540349/ GU540350/ GU540351/ GU540352/ GU540353/ GU540354/ GU540355/ GU540356/ GU540357/ GU540358/ GU540359/ GU540360/ GU540361/ GU540362/ GU540363/ GU540364/ GU540365/ GU540366/ GU540367/ GU540368/ GU540369/ GU540370/ GU540371/ GU540372/ GU540373/ GU540374/ GU540375/ GU540376/ GU540377/ GU540378/ GU540379/ GU540380/ GU540381/ GU540382/ GU540383/ GU540384/ GU540385/ GU540386/ GU540387/ GU540388/ GU540389/ GU540390/ GU540391
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / DNA, Bacterial; 0 / DNA, Ribosomal; 0 / RNA, Ribosomal, 16S; 0 / Sewage
  •  go-up   go-down


22. Stacey SN, Gudbjartsson DF, Sulem P, Bergthorsson JT, Kumar R, Thorleifsson G, Sigurdsson A, Jakobsdottir M, Sigurgeirsson B, Benediktsdottir KR, Thorisdottir K, Ragnarsson R, Scherer D, Rudnai P, Gurzau E, Koppova K, Höiom V, Botella-Estrada R, Soriano V, Juberías P, Grasa M, Carapeto FJ, Tabuenca P, Gilaberte Y, Gudmundsson J, Thorlacius S, Helgason A, Thorlacius T, Jonasdottir A, Blondal T, Gudjonsson SA, Jonsson GF, Saemundsdottir J, Kristjansson K, Bjornsdottir G, Sveinsdottir SG, Mouy M, Geller F, Nagore E, Mayordomo JI, Hansson J, Rafnar T, Kong A, Olafsson JH, Thorsteinsdottir U, Stefansson K: Common variants on 1p36 and 1q42 are associated with cutaneous basal cell carcinoma but not with melanoma or pigmentation traits. Nat Genet; 2008 Nov;40(11):1313-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Common variants on 1p36 and 1q42 are associated with cutaneous basal cell carcinoma but not with melanoma or pigmentation traits.
  • To search for new sequence variants that confer risk of cutaneous basal cell carcinoma (BCC), we conducted a genome-wide SNP association study of 930 Icelanders with BCC and 33,117 controls.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Chromosomes, Human, Pair 1 / genetics. Genetic Predisposition to Disease. Melanoma / genetics. Mutation / genetics. Pigmentation / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Adipose Tissue / metabolism. Adolescent. Adult. Aged. Aged, 80 and over. Aging. Alleles. Carcinoma, Squamous Cell / genetics. Chromosomal Proteins, Non-Histone / genetics. Chromosomal Proteins, Non-Histone / metabolism. Guanine Nucleotide Exchange Factors / genetics. Guanine Nucleotide Exchange Factors / metabolism. Humans. Middle Aged. Models, Genetic. Polymorphism, Single Nucleotide / genetics. Quantitative Trait, Heritable. RNA / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18849993.001).
  • [ISSN] 1546-1718
  • [Journal-full-title] Nature genetics
  • [ISO-abbreviation] Nat. Genet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / Guanine Nucleotide Exchange Factors; 0 / RCC2 protein, human; 63231-63-0 / RNA
  •  go-up   go-down


23. Liu Y, Nie H, Bansil R, Steinhart M, Bang J, Lodge TP: Kinetics of disorder-to-fcc phase transition via an intermediate bcc state. Phys Rev E Stat Nonlin Soft Matter Phys; 2006 Jun;73(6 Pt 1):061803
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kinetics of disorder-to-fcc phase transition via an intermediate bcc state.
  • Time-resolved small-angle x-ray scattering measurements reveal that a long-lived intermediate bcc state forms when a poly(styrene-b-isoprene) diblock copolymer solution in an isoprene selective solvent is rapidly cooled from the disordered micellar fluid at high temperature to an equilibrium fcc state.
  • The kinetics of the epitaxial growth of the [111] fcc peak from the [110] bcc peak was obtained by fitting the scattering data to a simple model of the transformation.
  • The growth of the [111] fcc peak agrees with the Avrami model of nucleation and growth kinetics with an exponent n=1.4, as does the initial decay of the [110] bcc peak, with an exponent n=1.3.
  • The data were also found to be in good agreement with the Cahn model of grain boundary nucleation and growth.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16906856.001).
  • [ISSN] 1539-3755
  • [Journal-full-title] Physical review. E, Statistical, nonlinear, and soft matter physics
  • [ISO-abbreviation] Phys Rev E Stat Nonlin Soft Matter Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Broers S, Smets E, Bindels P, Evertsz' FB, Calff M, de Haes H: Training general practitioners in behavior change counseling to improve asthma medication adherence. Patient Educ Couns; 2005 Sep;58(3):279-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Training general practitioners in behavior change counseling to improve asthma medication adherence.
  • OBJECTIVE: Adherence to asthma medication regimens is problematic in general practice.
  • We developed and evaluated a communication training for general practitioners (GPs) to help them address medication adherence during routine consultations.
  • This paper describes the development of the training and evaluation results of a pilot study.
  • METHODS: The training was based on behavior change counseling (BCC), a technique derived from motivational interviewing.
  • We developed a five phases BCC consultation model.
  • Participating GPs answered questions at baseline (T0), directly after (T1) and 4-10 months after (T2) the training that assessed their attitudes and confidence regarding adherence communication.
  • They completed evaluation forms at T1 and T2.
  • RESULTS: The 19 participating GPs were positive about the course and the feasibility of BCC in GP consultations.
  • Also, after the training, their attitudes and confidence had improved (p<0.05) and all reported to use BCC skills at least sometimes 4-10 months after the training.
  • CONCLUSION: These positive effects provide us with some hope that the training positively influenced the GP's communication behavior.
  • PRACTICE IMPLICATIONS: If further data on physician behavior and patient outcomes justify implementation of the training, it would then be worthwhile to also involve practice nurses.
  • [MeSH-major] Asthma / drug therapy. Counseling / education. Education, Medical, Continuing. Family Practice / education. Patient Compliance
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Netherlands. Pilot Projects. Statistics, Nonparametric

  • Genetic Alliance. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16024211.001).
  • [ISSN] 0738-3991
  • [Journal-full-title] Patient education and counseling
  • [ISO-abbreviation] Patient Educ Couns
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


25. Indananda C, Matsumoto A, Inahashi Y, Takahashi Y, Duangmal K, Thamchaipenet A: Actinophytocola oryzae gen. nov., sp. nov., isolated from the roots of Thai glutinous rice plants, a new member of the family Pseudonocardiaceae. Int J Syst Evol Microbiol; 2010 May;60(Pt 5):1141-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cell-wall amino acids contained meso-diaminopimelic acid, alanine, glutamic acid and acetylated muramic acid.
  • The whole-cell sugars were arabinose, galactose, mannose, rhamnose and ribose.

  • SILVA. SILVA SSU Database .
  • StrainInfo. culture/stock collections - online strain list (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19666784.001).
  • [ISSN] 1466-5026
  • [Journal-full-title] International journal of systematic and evolutionary microbiology
  • [ISO-abbreviation] Int. J. Syst. Evol. Microbiol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ EU420070
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Bacterial; 0 / DNA, Ribosomal; 0 / Fatty Acids; 0 / RNA, Ribosomal, 16S
  •  go-up   go-down


26. Martinsson H, Yhr M, Enerbäck C: Expression patterns of S100A7 (psoriasin) and S100A9 (calgranulin-B) in keratinocyte differentiation. Exp Dermatol; 2005 Mar;14(3):161-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They were both absent in undifferentiated basalioma and strongly expressed in carcinoma in situ, as well as in keratoacanthoma and differentiated squamous cell carcinoma.
  • In normal epithelium, they were expressed in the superficial, differentiated region of the epithelium rather than in the basal region.
  • [MeSH-minor] Blotting, Western. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Basal Cell / metabolism. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cell Differentiation / physiology. Cell Line. Computer Systems. Humans. Immunohistochemistry. Keratoacanthoma / metabolism. Keratoacanthoma / pathology. Polymerase Chain Reaction. Reverse Transcriptase Polymerase Chain Reaction. S100 Proteins. Skin Neoplasms / metabolism. Skin Neoplasms / pathology

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15740587.001).
  • [ISSN] 0906-6705
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / Calgranulin B; 0 / S100 Proteins; 0 / S100A7 protein, human
  •  go-up   go-down


27. Hansen CR, Pressler T, Nielsen KG, Jensen PØ, Bjarnsholt T, Høiby N: Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients. J Cyst Fibros; 2010 Jan;9(1):51-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adolescent. Adult. Anti-Bacterial Agents / therapeutic use. Biofilms. Breath Tests. Child. Drug Resistance, Bacterial. Female. Forced Expiratory Volume. Granulocyte Colony-Stimulating Factor / metabolism. Humans. Interferon-gamma / blood. Interferon-gamma / metabolism. Interleukin-10 / metabolism. Interleukin-1beta / metabolism. Interleukin-6 / blood. Interleukin-6 / metabolism. Interleukin-8 / metabolism. Male. Pneumonia, Bacterial / complications. Pneumonia, Bacterial / drug therapy. Pneumonia, Bacterial / immunology. Retrospective Studies. Sputum / metabolism. Sputum / microbiology. Tumor Necrosis Factor-alpha / metabolism. Young Adult

  • Genetic Alliance. consumer health - BabysFirstTest - Cystic Fibrosis.
  • Genetic Alliance. consumer health - Cystic Fibrosis.
  • MedlinePlus Health Information. consumer health - Cystic Fibrosis.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19939747.001).
  • [ISSN] 1873-5010
  • [Journal-full-title] Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
  • [ISO-abbreviation] J. Cyst. Fibros.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / IL10 protein, human; 0 / IL6 protein, human; 0 / Interleukin-1beta; 0 / Interleukin-6; 0 / Interleukin-8; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


28. Raaby L, Otkjær K, Salvskov-Iversen ML, Johansen C, Iversen L: A Characterization of the expression of 14-3-3 isoforms in psoriasis, basal cell carcinoma, atopic dermatitis and contact dermatitis. Dermatol Reports; 2010 Aug 31;2(2):e14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Characterization of the expression of 14-3-3 isoforms in psoriasis, basal cell carcinoma, atopic dermatitis and contact dermatitis.
  • 14-3-3 is a highly conserved protein involved in a number of cellular processes including cell signalling, cell cycle regulation and gene transcription.
  • To investigate the expression of the seven 14-3-3 isoforms in involved and uninvolved skin from psoriasis, basal cell carcinoma (BCC), atopic dermatitis and nickel induced allergic contact dermatitis.
  • These results demonstrate a disease specific expression profile of the 14-3-3τ and 14-3-3σ iso-forms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25386251.001).
  • [ISSN] 2036-7392
  • [Journal-full-title] Dermatology reports
  • [ISO-abbreviation] Dermatol Reports
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC4211473
  • [Keywords] NOTNLM ; 14-3-3 proteins / allergic contact dermatitis / atopic dermatitis. / basal cell carcinoma / psoriasis
  •  go-up   go-down


29. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, Rouzier R, Broglio KR, Hortobagyi GN, Valero V: Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol; 2007 Nov 1;25(31):4952-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We estimated the probabilities of death resulting from breast cancer and from other causes, and analyzed associations of patient and tumor characteristics with OS, BCSM, and non-breast cancer-related mortality using the log-rank test, Cox proportional hazards models, and a competing-risk model.
  • Characteristics associated with increased probability of BCSM included age younger than 50 years at diagnosis, high tumor grade, estrogen receptor-negative status, progesterone receptor-negative status, and fewer than six nodes removed at axillary dissection.
  • [MeSH-major] Breast Neoplasms / mortality. Breast Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. SEER Program. Survival Analysis. United States

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17971593.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


30. Thompson DJ, Healey CS, Baynes C, Kalmyrzaev B, Ahmed S, Dowsett M, Folkerd E, Luben RN, Cox D, Ballinger D, Pharoah PD, Ponder BA, Dunning AM, Easton DF, Studies in Epidemiology and Risks of Cancer Heredity Team: Identification of common variants in the SHBG gene affecting sex hormone-binding globulin levels and breast cancer risk in postmenopausal women. Cancer Epidemiol Biomarkers Prev; 2008 Dec;17(12):3490-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Haplotype analysis suggested that rs858518, rs727428, or a variant in linkage disequilibrium with them acts to decrease SHBG levels but that this effect is neutralized by rs6259 (D356N).
  • [MeSH-major] Breast Neoplasms / genetics. Genetic Variation. Polymorphism, Single Nucleotide. Postmenopause. Sex Hormone-Binding Globulin / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res. 2008;10(3):R47 [18507837.001]
  • [Cites] Clin Endocrinol (Oxf). 2008 Jul;69(1):129-35 [18598274.001]
  • [Cites] J Steroid Biochem Mol Biol. 1999 Sep-Oct;70(4-6):115-21 [10622399.001]
  • [Cites] N Engl J Med. 2000 Jul 13;343(2):78-85 [10891514.001]
  • [Cites] Breast Cancer Res. 1999;1(1):14-7 [11250676.001]
  • [Cites] J Biol Chem. 2001 Sep 28;276(39):36383-90 [11473114.001]
  • [Cites] Am J Hum Genet. 2002 Feb;70(2):425-34 [11791212.001]
  • [Cites] J Natl Cancer Inst. 2002 Apr 17;94(8):606-16 [11959894.001]
  • [Cites] Carcinogenesis. 2002 Aug;23(8):1315-20 [12151349.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Dec;88(12):5976-80 [14671199.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):153-9 [14710223.001]
  • [Cites] J Natl Cancer Inst. 2004 Jun 16;96(12):936-45 [15199113.001]
  • [Cites] Metabolism. 1997 Sep;46(9):988-91 [9284884.001]
  • [Cites] J Biol Chem. 1998 Dec 18;273(51):34105-14 [9852068.001]
  • [Cites] Br J Cancer. 1999 Jul;80 Suppl 1:95-103 [10466767.001]
  • [Cites] Bioinformatics. 2005 Jan 15;21(2):263-5 [15297300.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):2198-204 [15634719.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1096-101 [15894658.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jun;90(6):3653-8 [15755867.001]
  • [Cites] Nat Genet. 2005 Nov;37(11):1217-23 [16244653.001]
  • [Cites] Endocr Relat Cancer. 2005 Dec;12(4):1071-82 [16322344.001]
  • [Cites] Nat Rev Cancer. 2005 Dec;5(12):977-85 [16341085.001]
  • [Cites] JAMA. 2006 Mar 15;295(11):1288-99 [16537739.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):675-82 [16614108.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Dec;91(12):5029-37 [16926255.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):165-7 [17200668.001]
  • [Cites] BMC Cancer. 2007;7:60 [17411440.001]
  • [Cites] PLoS Genet. 2007 Mar 16;3(3):e42 [17367212.001]
  • [Cites] Nature. 2007 Jun 28;447(7148):1087-93 [17529967.001]
  • [Cites] PLoS Genet. 2008 May;4(5):e1000072 [18464913.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):917-24 [14764814.001]
  • (PMID = 19064566.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / 10118; United Kingdom / Cancer Research UK / / A10118; United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Sex Hormone-Binding Globulin
  • [Other-IDs] NLM/ PMC2660245; NLM/ UKMS4231
  • [Investigator] Abraham J; Ahmed S; Antoniou A; Baynes C; Benusiglio P; Blows F; Cebrian A; Conroy D; Curzon B; Dew G; Driver K; Field H; Ghoussaini M; Harrington P; Healey C; Irvine S; Kalmyrzaev B; Jordan C; Lesueur F; Luccarini C; Mayes R; Maranian M; Morrison J; Munday H; Perkins B; Pooley K; Redman K; Scollen S; Shadforth D; Shah M; Simpson A; Stafford A; Thompson D; Tyrer J; Smith P; West J
  •  go-up   go-down


31. Laitman Y, Kaufman B, Lahad EL, Papa MZ, Friedman E: Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer. Isr Med Assoc J; 2007 Nov;9(11):791-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To evaluate whether CHEK2 germline mutations contribute to a breast cancer predisposition in Ashkenazi** Jewish high risk families.
  • [MeSH-major] Breast Neoplasms / genetics. Genetic Predisposition to Disease / ethnology. Germ-Line Mutation / genetics. Jews / genetics. Mutation, Missense / genetics. Protein-Serine-Threonine Kinases / genetics
  • [MeSH-minor] Adult. Aged. Checkpoint Kinase 2. Electrophoresis, Gel, Pulsed-Field. Female. Humans. Israel. Middle Aged. Nucleic Acid Denaturation. Ovarian Neoplasms / epidemiology. Pedigree. Sequence Analysis, DNA

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18085035.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Israel
  • [Chemical-registry-number] EC 2.7.1.11 / Checkpoint Kinase 2; EC 2.7.11.1 / CHEK2 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


32. Malone KE, Daling JR, Doody DR, Hsu L, Bernstein L, Coates RJ, Marchbanks PA, Simon MS, McDonald JA, Norman SA, Strom BL, Burkman RT, Ursin G, Deapen D, Weiss LK, Folger S, Madeoy JJ, Friedrichsen DM, Suter NM, Humphrey MC, Spirtas R, Ostrander EA: Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res; 2006 Aug 15;66(16):8297-308
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years.
  • Although well studied in families at high-risk, the roles of mutations in the BRCA1 and BRCA2 genes are poorly understood in breast cancers in the general population, particularly in Black women and in age groups outside of the very young.
  • We examined the prevalence and predictors of BRCA1 and BRCA2 mutations in 1,628 women with breast cancer and 674 women without breast cancer who participated in a multicenter population-based case-control study of Black and White women, 35 to 64 years of age.
  • Among cases, 2.4% and 2.3% carried deleterious mutations in BRCA1 and BRCA2, respectively.
  • BRCA1 mutations were significantly more common in White (2.9%) versus Black (1.4%) cases and in Jewish (10.2%) versus non-Jewish (2.0%) cases; BRCA2 mutations were slightly more frequent in Black (2.6%) versus White (2.1%) cases.
  • Numerous familial and demographic factors were significantly associated with BRCA1 and, to a lesser extent, BRCA2 carrier status, when examined individually.
  • In models considering all predictors together, early onset ages in cases and in relatives, family history of ovarian cancer, and Jewish ancestry remained strongly and significantly predictive of BRCA1 carrier status, whereas BRCA2 predictors were fewer and more modest in magnitude.
  • Both the combinations of predictors and effect sizes varied across racial/ethnic and age groups.
  • These results provide first-time prevalence estimates for BRCA1/BRCA2 in breast cancer cases among understudied racial and age groups and show key predictors of mutation carrier status for both White and Black women and women of a wide age spectrum with breast cancer in the general population.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Res. 2007 May 15;67(10):5057; author reply 5057-8 [17510441.001]
  • (PMID = 16912212.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / N01 HD 3-3175; United States / NICHD NIH HHS / HD / N01 HD 2-3166; United States / NICHD NIH HHS / HD / N01 HD 3-3176; United States / NCI NIH HHS / CN / N01-CN-0532; United States / NCI NIH HHS / PC / N01-PC-67006; United States / Intramural NIH HHS / / ; United States / NICHD NIH HHS / HD / Y01 HD 7022; United States / NICHD NIH HHS / HD / N01 HD 3-3174; United States / NCI NIH HHS / CN / N01-CN-67010; United States / NICHD NIH HHS / HD / N01 HD 3-3168; United States / NCI NIH HHS / CN / N01-CN-65064; United States / NCI NIH HHS / CA / T32 CA080416
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BRCA1 Protein; 0 / BRCA2 Protein
  •  go-up   go-down


33. Hu MB, Xie W, Xiong B, Han DF, Li Y, Feng MH, Zhou YF: [Study on the relationship between polymorphisms of genes (CYP17, CYP19 and SULT1A1) and susceptibility to breast cancer in Chinese women]. Zhonghua Liu Xing Bing Xue Za Zhi; 2006 Apr;27(4):351-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Aromatase / genetics. Arylsulfotransferase / genetics. Breast Neoplasms / genetics. Genetic Predisposition to Disease. Steroid 17-alpha-Hydroxylase / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16875543.001).
  • [ISSN] 0254-6450
  • [Journal-full-title] Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi
  • [ISO-abbreviation] Zhonghua Liu Xing Bing Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 1.14.14.1 / Aromatase; EC 1.14.99.9 / Steroid 17-alpha-Hydroxylase; EC 2.8.2.1 / Arylsulfotransferase; EC 2.8.2.1 / SULT1A1 protein, human
  •  go-up   go-down


34. Karppinen SM, Barkardottir RB, Backenhorn K, Sydenham T, Syrjäkoski K, Schleutker J, Ikonen T, Pylkäs K, Rapakko K, Erkko H, Johannesdottir G, Gerdes AM, Thomassen M, Agnarsson BA, Grip M, Kallioniemi A, Kere J, Aaltonen LA, Arason A, Møller P, Kruse TA, Borg A, Winqvist R: Nordic collaborative study of the BARD1 Cys557Ser allele in 3956 patients with cancer: enrichment in familial BRCA1/BRCA2 mutation-negative breast cancer but not in other malignancies. J Med Genet; 2006 Nov;43(11):856-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: BARD1 was originally identified as a BRCA1-interacting protein but has also been described in tumour-suppressive functions independent of BRCA1.
  • [MeSH-major] Alleles. Breast Neoplasms / genetics. Mutation, Missense. Tumor Suppressor Proteins / genetics. Ubiquitin-Protein Ligases / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Breast Neoplasms, Male / genetics. Case-Control Studies. Cohort Studies. Colorectal Neoplasms / genetics. DNA Mutational Analysis. Female. Genes, BRCA1. Genes, BRCA2. Genetic Predisposition to Disease. Genetic Testing. Humans. Male. Middle Aged. Ovarian Neoplasms / genetics. Prostatic Neoplasms / genetics


35. Rodust PM, Stockfleth E, Ulrich C, Leverkus M, Eberle J: UV-induced squamous cell carcinoma--a role for antiapoptotic signalling pathways. Br J Dermatol; 2009 Nov;161 Suppl 3:107-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] UV-induced squamous cell carcinoma--a role for antiapoptotic signalling pathways.
  • The incidence of nonmelanoma skin cancer including squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) has dramatically increased in the last decades, and chronic sun exposure was identified as a main etiologic agent.
  • As mutations caused by UV may lead to skin cancer due to oncogene activation and tumor suppressor gene inactivation, efficient safeguard mechanisms have been developed during evolution.
  • The keratinocyte apoptotic machinery in response to UV consists of both intrinsic/mitochondrial and extrinsic/death receptor-mediated cell-death pathways, which are particularly regulated by mitogen-activated protein kinases (MAPKs, JNK and p38) and the tumor-suppressor protein p53.
  • [MeSH-major] Apoptosis. Carcinoma, Squamous Cell / etiology. DNA Damage. Signal Transduction / radiation effects. Ultraviolet Rays / adverse effects
  • [MeSH-minor] Carcinoma, Basal Cell / etiology. Carcinoma, Basal Cell / genetics. Carcinoma, Basal Cell / pathology. Humans. Mitochondria / genetics. Mitochondria / pathology. Mitochondria / radiation effects. Neoplasms, Radiation-Induced / etiology. Neoplasms, Radiation-Induced / genetics. Neoplasms, Radiation-Induced / pathology. Skin Neoplasms / etiology. Skin Neoplasms / genetics. Skin Neoplasms / pathology. TNF-Related Apoptosis-Inducing Ligand / metabolism


36. Kurdi P, Smitinont T, Valyasevi R: Isolation and characterization of acid-sensitive mutants of Pediococcus acidilactici. Food Microbiol; 2009 Feb;26(1):82-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Cell Membrane / metabolism. Meat Products / microbiology. Mutation. Pediococcus. Proton-Translocating ATPases / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19028310.001).
  • [ISSN] 1095-9998
  • [Journal-full-title] Food microbiology
  • [ISO-abbreviation] Food Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Fatty Acids; EC 3.6.3.14 / Proton-Translocating ATPases
  •  go-up   go-down


37. Wang X, Wu X, Liang Z, Huang Y, Fenech M, Xue J: A comparison of folic acid deficiency-induced genomic instability in lymphocytes of breast cancer patients and normal non-cancer controls from a Chinese population in Yunnan. Mutagenesis; 2006 Jan;21(1):41-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The results showed that 30 nM FA was associated with increased frequencies of micronucleated binucleated cell (MNed BNC), nucleoplasmic bridges (NPB), nuclear buds (BUD), apoptosis (APO) and necrosis (NEC) relative to 120 and 240 nM FA (P<0.001) in lymphocytes of case and control groups in vitro, however there were no significant differences between the 120 and 240 nM FA within each sampling group.
  • We concluded that (i) increased concentrations of FA abolished the genome-damaging effect of FA deficiency in lymphocytes of both breast cancer patients and controls to a similar extent and (ii) FA concentration is much more important than breast cancer status in determining genomic instability and cell death.
  • [MeSH-major] Breast Neoplasms. Folic Acid Deficiency / metabolism. Genomic Instability. Lymphocytes / drug effects

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Folic Acid.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16339195.001).
  • [ISSN] 0267-8357
  • [Journal-full-title] Mutagenesis
  • [ISO-abbreviation] Mutagenesis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 935E97BOY8 / Folic Acid
  •  go-up   go-down


38. Guldner L, Multigner L, Héraud F, Monfort C, Thomé JP, Giusti A, Kadhel P, Cordier S: Pesticide exposure of pregnant women in Guadeloupe: ability of a food frequency questionnaire to estimate blood concentration of chlordecone. Environ Res; 2010 Feb;110(2):146-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pesticide exposure of pregnant women in Guadeloupe: ability of a food frequency questionnaire to estimate blood concentration of chlordecone.
  • CONTEXT: Chlordecone, an environmentally persistent organochlorine insecticide used intensively in banana culture in the French West Indies until 1993, has permanently polluted soils and contaminated foodstuffs.
  • Consumption of contaminated food is the main source of exposure nowadays.
  • We sought to identify main contributors to blood chlordecone concentration (BCC) and to validate an exposure indicator based on food intakes.
  • MATERIAL AND METHODS: We used a food frequency questionnaire (FFQ) completed by a sample of 194 pregnant women to estimate their dietary exposure to chlordecone and compared it to blood levels.
  • In a first approach, chlordecone daily intake was estimated as the product of daily eaten quantity of 214 foodstuffs, multiplied by their chlordecone content, and summed over all items.
  • We then predicted individual blood chlordecone concentration with empirical weight regression models based on frequency of food consumption, and without contamination data.
  • RESULTS: Among the 191 subjects who had BCC determination, 146 (76%) had detectable values and mean BCC was 0.86 ng/mL (range < LOD-13.2).
  • Mean per capita dietary intake of chlordecone was estimated at 3.3 microg/day (range: 0.1-22.2).
  • Blood chlordecone levels were significantly correlated with food exposure predicted from the empirical weight models (r=0.47, p<0.0001) and, to a lesser extent, with chlordecone intake estimated from food consumption and food contamination data (r=0.20, p=0.007).
  • Main contributors to chlordecone exposure included seafood, root vegetables, and Cucurbitaceous.
  • CONCLUSION: These results show that the Timoun FFQ provides valid estimates of chlordecone exposure.
  • Estimates from empirical weight models correlated better with blood levels of chlordecone than did estimates from the dietary intake assessment.
  • [MeSH-major] Chlordecone / blood. Food Contamination. Pesticides / blood. Pregnancy / blood. Soil Pollutants / blood
  • [MeSH-minor] Adolescent. Adult. Cohort Studies. Diet. Environmental Exposure. Female. Guadeloupe. Humans. Middle Aged. Prospective Studies. Regression Analysis. Socioeconomic Factors. Surveys and Questionnaires. Young Adult

  • MedlinePlus Health Information. consumer health - Foodborne Illness.
  • MedlinePlus Health Information. consumer health - Pesticides.
  • MedlinePlus Health Information. consumer health - Pregnancy.
  • HAL archives ouvertes. Full text from .
  • Hazardous Substances Data Bank. KEPONE .
  • ORBi (University of Liege). Free full Text at ORBi .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Elsevier Inc. All rights reserved.
  • (PMID = 20003965.001).
  • [ISSN] 1096-0953
  • [Journal-full-title] Environmental research
  • [ISO-abbreviation] Environ. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pesticides; 0 / Soil Pollutants; RG5XJ88UDF / Chlordecone
  •  go-up   go-down


39. Soulairol R, Fu CC, Barreteau C: Structure and magnetism of bulk Fe and Cr: from plane waves to LCAO methods. J Phys Condens Matter; 2010 Jul 28;22(29):295502
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Structure and magnetism of bulk Fe and Cr: from plane waves to LCAO methods.
  • Magnetic, structural and energetic properties of bulk Fe and Cr were studied using first-principles calculations within density functional theory (DFT).
  • We aimed to identify the dependence of these properties on key approximations of DFT, namely the exchange-correlation functional, the pseudopotential and the basis set.
  • We found a smaller effect of pseudopotentials (PPs) on Fe than on Cr.
  • For instance, the local magnetism of Cr was shown to be particularly sensitive to the potentials representing the core electrons, i.e. projector augmented wave and Vanderbilt ultrasoft PPs predict similar results, whereas standard norm-conserving PPs tend to overestimate the local magnetic moments of Cr in bcc Cr and in dilute bcc FeCr alloys.
  • This drawback is suggested to be closely correlated to the overestimation of Cr solution energy in the latter system.
  • On the other hand, we point out that DFT methods with very reduced localized basis sets (LCAO: linear combination of atomic orbitals) give satisfactory results compared with more robust plane-wave approaches.
  • A minimal-basis representation of '3d' electrons comes to be sufficient to describe non-trivial magnetic phases including spin spirals in both fcc Fe and bcc Cr, as well as the experimental magnetic ground state of bcc Cr showing a spin density wave (SDW) state.
  • In addition, a magnetic 'spd' tight binding model within the Stoner formalism was proposed and validated for Fe and Cr.
  • The respective Stoner parameters were obtained by fitting to DFT data.
  • This efficient semiempirical approach was shown to be accurate enough for studying various collinear and non-collinear phases of bulk Fe and Cr.
  • It also enabled a detailed investigation of different polarization states of SDW in bcc Cr, where the longitudinal state was suggested to be the ground state, consistent with existing experimental data.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21399309.001).
  • [ISSN] 1361-648X
  • [Journal-full-title] Journal of physics. Condensed matter : an Institute of Physics journal
  • [ISO-abbreviation] J Phys Condens Matter
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


40. de Longueville F, Lacroix M, Barbuto AM, Bertholet V, Gallo D, Larsimont D, Marcq L, Zammatteo N, Boffe S, Leclercq G, Remacle J: Molecular characterization of breast cancer cell lines by a low-density microarray. Int J Oncol; 2005 Oct;27(4):881-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular characterization of breast cancer cell lines by a low-density microarray.
  • We designed a low-density microarray carrying 132 DNA capture sequences highly specific for genes known to be differentially expressed among breast tumors and BCC lines or associated with specific tumor properties (cell-cycle alteration, proteolysis, adhesion, hormone sensitivity, etc).
  • Some data obtained were verified or extended by real-time polymerase chain reaction (real-time PCR), Northern blotting, Western blotting, immunohistochemistry and cell growth studies.
  • A few genes that are highly and specifically expressed in one cell line were identified, such as MGB1 (mammaglobin 1) in Evsa-T cells, and PIP (prolactin-inducible protein) in MDA-MB-453 BCC, suggesting an apocrine origin for these latter cells.
  • In conclusion, our results support the utility of a low-density microarray approach in cases where the cost and exhaustiveness of high-density microarrays may constitute a drawback; for instance, in obtaining a rapid phenotype evaluation in cell populations freshly isolated from breast tumors.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Oligonucleotide Array Sequence Analysis
  • [MeSH-minor] Biotinylation. Blotting, Northern. Blotting, Western. Cell Adhesion. Cell Line, Tumor. Cell Proliferation. Cluster Analysis. DNA, Complementary / metabolism. Estrogen Receptor alpha / metabolism. Humans. Image Processing, Computer-Assisted. Immunohistochemistry. Mammaglobin A. Neoplasm Proteins / metabolism. Nucleic Acid Hybridization. Phenotype. Polymerase Chain Reaction. RNA / metabolism. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Time Factors. Uteroglobin / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cell lines described in this publication .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142302.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Estrogen Receptor alpha; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / SCGB2A2 protein, human; 63231-63-0 / RNA; 9060-09-7 / Uteroglobin
  •  go-up   go-down


41. Bianchini G, Iwamoto T, Qi Y, Coutant C, Shiang CY, Wang B, Santarpia L, Valero V, Hortobagyi GN, Symmans WF, Gianni L, Pusztai L: Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer. Cancer Res; 2010 Nov 1;70(21):8852-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Four hundred twenty-eight protein kinases in gene expression data were examined from 684 cases of breast cancer and 51 breast cancer cell lines to identify kinase expression patterns.
  • Downregulation of these kinases caused significant subtype-specific inhibition of cell growth in vitro.
  • [MeSH-major] Breast Neoplasms / classification. Breast Neoplasms / metabolism. Protein Kinases / chemistry. Protein Kinases / metabolism. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Female. Gene Expression Profiling. Humans. Prognosis. RNA, Small Interfering / pharmacology. Survival Rate. Tumor Cells, Cultured


42. Moore AB, Shannon J, Chen C, Lampe JW, Ray RM, Lewis SK, Lin M, Stalsberg H, Thomas DB: Dietary and stored iron as predictors of breast cancer risk: A nested case-control study in Shanghai. Int J Cancer; 2009 Sep 1;125(5):1110-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Increases in risk of breast cancer in successive generations of migrants to the United States from China and rapid temporal changes in incidence rates in China following social and economic changes clearly implicate environmental factors in the etiology of this disease.
  • Iron, an essential element necessary for cell function, has also been demonstrated to have potential carcinogenic and co-carcinogenic activities.
  • In conclusion, this study finds significant associations between iron (stored and dietary) and fibrocystic disease and breast cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IRON COMPOUNDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 UICC.
  • [Cites] Free Radic Biol Med. 1996;20(4):553-66 [8904296.001]
  • [Cites] Cancer Res. 1990 Jun 1;50(11):3176-81 [2334913.001]
  • [Cites] Exp Cell Res. 1985 Dec;161(2):277-84 [2998833.001]
  • [Cites] Int J Vitam Nutr Res. 1986;56(3):281-6 [3781753.001]
  • [Cites] Cancer Res. 1987 Nov 1;47(21):5771-6 [3664480.001]
  • [Cites] Cancer Lett. 1988 Aug 30;41(3):251-6 [3409203.001]
  • [Cites] Anticancer Res. 1989 Nov-Dec;9(6):1477-82 [2560618.001]
  • [Cites] J Natl Cancer Inst. 1997 Mar 5;89(5):355-65 [9060957.001]
  • [Cites] Int J Cancer. 1997 May 2;71(3):333-9 [9139863.001]
  • [Cites] Br J Radiol. 1997 Apr;70(832):375-82 [9166074.001]
  • [Cites] Carcinogenesis. 1997 Sep;18(9):1757-62 [9328172.001]
  • [Cites] Arch Biochem Biophys. 1997 Oct 15;346(2):180-6 [9343364.001]
  • [Cites] Cancer Causes Control. 1998 Jan;9(1):19-27 [9486460.001]
  • [Cites] J Epidemiol Community Health. 1998 Feb;52(2):105-10 [9578857.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):81-90 [15668480.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):243-50 [15668501.001]
  • [Cites] Int J Cancer. 2005 Jul 20;115(6):981-93 [15723298.001]
  • [Cites] Am J Epidemiol. 2005 Jun 15;161(12):1115-22 [15937020.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2889-97 [16365006.001]
  • [Cites] Phys Med Biol. 2007 Jul 7;52(13):3895-911 [17664584.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1682-5 [17684146.001]
  • [Cites] Lancet Oncol. 2008 Aug;9(8):803-7 [18672216.001]
  • [Cites] Int J Cancer. 2003 Sep 20;106(5):771-83 [12866039.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1159-67 [14652275.001]
  • [Cites] J Nutr. 2003 Nov;133(11 Suppl 2):3898S-3906S [14672288.001]
  • [Cites] Nutr Cancer. 2003;46(2):131-7 [14690788.001]
  • [Cites] Phys Med Biol. 2004 Jan 7;49(1):99-110 [14971775.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):205-12 [14973098.001]
  • [Cites] Ann Epidemiol. 2004 Mar;14(3):195-201 [15036223.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1106-13 [15247120.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1450-8 [15150082.001]
  • [Cites] N Engl J Med. 1974 May 30;290(22):1213-6 [4825851.001]
  • [Cites] N Engl J Med. 1975 May 1;292(18):951-6 [1090831.001]
  • [Cites] Scand J Haematol Suppl. 1977;32:87-98 [272039.001]
  • [Cites] Clin Chem. 1981 Jan;27(1):78-82 [7449126.001]
  • [Cites] IARC Sci Publ. 1980;(32):5-338 [7216345.001]
  • [Cites] Public Health Nutr. 1998 Sep;1(3):139-45 [10933411.001]
  • [Cites] Int J Cancer. 2001 Jan 15;91(2):260-3 [11146455.001]
  • [Cites] Curr Med Chem. 2001 Jun;8(7):839-49 [11375754.001]
  • [Cites] J Natl Cancer Inst. 2002 Oct 2;94(19):1445-57 [12359854.001]
  • [Cites] Anticancer Res. 2002 Sep-Oct;22(5):2685-92 [12529982.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3797-9 [12552996.001]
  • [Cites] Biomed Environ Sci. 2002 Dec;15(4):271-6 [12642982.001]
  • [Cites] Environ Health Perspect. 1990 Jul;87:291-300 [2269234.001]
  • [Cites] Carcinogenesis. 1991 Jan;12(1):111-4 [1988169.001]
  • [Cites] Cancer. 1991 Mar 15;67(6):1707-12 [2001562.001]
  • [Cites] Am J Clin Nutr. 1991 Oct;54(4):729-35 [1897480.001]
  • [Cites] Med Oncol Tumor Pharmacother. 1991;8(4):229-33 [1820488.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):3896-907 [8389654.001]
  • [Cites] J Natl Cancer Inst. 1993 Nov 17;85(22):1819-27 [8230262.001]
  • [Cites] Int J Cancer. 1994 Feb 1;56(3):364-9 [8314323.001]
  • [Cites] Int J Cancer. 1994 Feb 1;56(3):379-82 [8314326.001]
  • [Cites] Jpn J Cancer Res. 1994 Jun;85(6):572-7 [8063609.001]
  • [Cites] Br J Cancer. 1995 Jun;71(6):1353-8 [7779738.001]
  • [Cites] J Natl Cancer Inst. 1995 Aug 2;87(15):1154-61 [7674320.001]
  • [Cites] Int J Cancer. 1996 Jan 17;65(2):140-4 [8567108.001]
  • [Cites] Eur J Cancer Prev. 1996 Feb;5(1):19-36 [8664805.001]
  • [Cites] Toxicol Appl Pharmacol. 1996 Aug;139(2):356-64 [8806853.001]
  • [Cites] Am J Epidemiol. 1996 Oct 1;144(7):653-60 [8823061.001]
  • [Cites] Cancer Causes Control. 1996 Jan;7(1):56-68 [8850435.001]
  • [Cites] Am J Clin Nutr. 1982 May;35(5 Suppl):1180-5 [7044096.001]
  • [Cites] J Nutr. 1985 Mar;115(3):369-74 [3973748.001]
  • [Cites] Exp Cell Res. 1996 Nov 25;229(1):60-8 [8940249.001]
  • (PMID = 19444907.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA075332-05; United States / NCI NIH HHS / CA / R01 CA075332; United States / NCI NIH HHS / CA / R01 CA075332-05; United States / NCI NIH HHS / CA / R01-CA75332
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iron Compounds; 0 / Iron, Dietary; 9007-73-2 / Ferritins
  • [Other-IDs] NLM/ NIHMS163587; NLM/ PMC2798105
  •  go-up   go-down


43. Zuccolo L, Pastore G, Pearce N, Mosso ML, Merletti F, Magnani C: Mortality from cancer and other causes in parents of children with cancer: a population-based study in Piedmont, Italy. Eur J Cancer Prev; 2007 Oct;16(5):390-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Neoplasms / genetics. Neoplasms / mortality. Parents

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17923808.001).
  • [ISSN] 0959-8278
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


44. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, Livasy C, Carey L, Earp HS, Perou CM: Epidemiology of basal-like breast cancer. Breast Cancer Res Treat; 2008 May;109(1):123-39
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of basal-like breast cancer.
  • Risk factors for the newly identified "intrinsic" breast cancer subtypes (luminal A, luminal B, basal-like and human epidermal growth factor receptor 2-positive/estrogen receptor-negative) were determined in the Carolina Breast Cancer Study, a population-based, case-control study of African-American and white women.
  • Basal-like cases exhibited several associations that were opposite to those observed for luminal A, including increased risk for parity and younger age at first term full-term pregnancy.
  • Longer duration breastfeeding, increasing number of children breastfed, and increasing number of months breastfeeding per child were each associated with reduced risk of basal-like breast cancer, but not luminal A.
  • Women with multiple live births who did not breastfeed and women who used medications to suppress lactation were at increased risk of basal-like, but not luminal A, breast cancer.
  • Elevated waist-hip ratio was associated with increased risk of luminal A in postmenopausal women, and increased risk of basal-like breast cancer in pre- and postmenopausal women.
  • The prevalence of basal-like breast cancer was highest among premenopausal African-American women, who also showed the highest prevalence of basal-like risk factors.
  • Among younger African-American women, we estimate that up to 68% of basal-like breast cancer could be prevented by promoting breastfeeding and reducing abdominal adiposity.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2006 Sep;37(9):1217-26 [16938528.001]
  • [Cites] Environ Health. 2006;5:21 [16859537.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8327-30 [16951137.001]
  • [Cites] CA Cancer J Clin. 2006 Sep-Oct;56(5):254-81; quiz 313-4 [17005596.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1871-7 [17035393.001]
  • [Cites] Arch Intern Med. 2006 Nov 13;166(20):2244-52 [17101943.001]
  • [Cites] Arch Intern Med. 2006 Nov 13;166(20):2253-9 [17101944.001]
  • [Cites] Breast Cancer Res. 2006;8(4):R34 [16846532.001]
  • [Cites] Breast Cancer Res. 2006;8(4):R43 [16859501.001]
  • [Cites] Hum Pathol. 2007 Feb;38(2):197-204 [17234468.001]
  • [Cites] Science. 2007 Feb 2;315(5812):592-4 [17272699.001]
  • [Cites] Obesity (Silver Spring). 2007 Feb;15(2):430-45 [17299117.001]
  • [Cites] Epidemiology. 2007 Mar;18(2):234-9 [17237733.001]
  • [Cites] Epidemiology. 2007 Mar;18(2):280-1 [17301710.001]
  • [Cites] Arch Intern Med. 2007 Feb 26;167(4):408-15 [17325304.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):439-43 [17372238.001]
  • [Cites] Cancer. 2007 May 1;109(9):1721-8 [17387718.001]
  • [Cites] Breast Cancer Res Treat. 2007 Mar;102(1):85-101 [17080310.001]
  • [Cites] Annu Rev Nutr. 2007;27:103-21 [17341160.001]
  • [Cites] Lancet. 2002 Jul 20;360(9328):187-95 [12133652.001]
  • [Cites] Nature. 2002 Aug 22;418(6900):823 [12192390.001]
  • [Cites] Cancer. 2003 Jan 1;97(1 Suppl):211-21 [12491484.001]
  • [Cites] Cancer. 2003 Jan 1;97(1 Suppl):222-9 [12491485.001]
  • [Cites] Cancer. 2003 Jan 1;97(1 Suppl):273-9 [12491491.001]
  • [Cites] J Nutr. 2003 Jan;133(1):305S-309S [12514315.001]
  • [Cites] Obes Res. 1998 Sep;6 Suppl 2:51S-209S [9813653.001]
  • [Cites] Epidemiology. 1999 Jan;10(1):37-48 [9888278.001]
  • [Cites] Ann Epidemiol. 1999 Apr;9(3):188-95 [10192651.001]
  • [Cites] Int J Epidemiol. 1999 Jun;28(3):396-402 [10405840.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9212-7 [10430922.001]
  • [Cites] Am J Epidemiol. 2005 Jan 1;161(1):40-51 [15615914.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):439-48 [15770008.001]
  • [Cites] Breast Cancer Res Treat. 1999 Nov;58(1):31-9 [10634516.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Jan;9(1):65-71 [10667465.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 16;92(4):302-12 [10675379.001]
  • [Cites] Am J Epidemiol. 2000 Apr 1;151(7):703-14 [10752798.001]
  • [Cites] Cancer Causes Control. 2000 Apr;11(4):345-57 [10843445.001]
  • [Cites] Am J Public Health. 2000 Jun;90(6):966-71 [10846517.001]
  • [Cites] J Appl Physiol (1985). 2000 Aug;89(2):636-43 [10926648.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 19;95(6):478-83 [12644541.001]
  • [Cites] Cancer Causes Control. 2003 Mar;14(2):151-60 [12749720.001]
  • [Cites] Breast Cancer Res Treat. 2003 Jun;79(3):355-64 [12846420.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • [Cites] Obes Rev. 2003 Aug;4(3):157-73 [12916817.001]
  • [Cites] J Natl Cancer Inst. 2004 Feb 4;96(3):218-28 [14759989.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1595-604 [15073845.001]
  • [Cites] Nat Rev Immunol. 2004 Jul;4(7):565-72 [15229475.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):353-62 [15241834.001]
  • [Cites] Int J Cancer. 2004 Sep 20;111(5):762-71 [15252848.001]
  • [Cites] J Natl Cancer Inst. 2004 Jul 21;96(14):1094-8 [15265971.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1558-68 [15466970.001]
  • [Cites] Am J Epidemiol. 1985 Nov;122(5):904-14 [4050778.001]
  • [Cites] Am J Pathol. 1989 Mar;134(3):571-9 [2466404.001]
  • [Cites] Am J Epidemiol. 1991 Aug 15;134(4):421-32 [1877602.001]
  • [Cites] Am J Epidemiol. 1992 Dec 15;136(12):1445-56 [1288274.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Mar;3(2):173-5 [8049640.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Jan-Feb;4(1):11-9 [7894319.001]
  • [Cites] Breast Cancer Res Treat. 1995 Jul;35(1):51-60 [7612904.001]
  • [Cites] Metabolism. 1996 Sep;45(9):1119-24 [8781299.001]
  • [Cites] JAMA. 1998 Mar 25;279(12):915-21 [9544765.001]
  • [Cites] Cell Mol Life Sci. 2007 Dec;64(24):3219-32 [17957336.001]
  • [Cites] Am J Epidemiol. 1998 May 1;147(9):826-33 [9583712.001]
  • [Cites] Am J Public Health. 1998 Jan;88(1):15-9 [9584027.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 May;7(5):371-8 [9610785.001]
  • [Cites] Eur J Cancer Prev. 2001 Feb;10(1):15-32 [11263588.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] J Natl Med Assoc. 2001 Sep;93(9):329-34 [11560288.001]
  • [Cites] Int J Cancer. 2002 May 20;99(3):445-52 [11992416.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):601-7 [12101106.001]
  • [Cites] Br J Surg. 2005 Apr;92(4):429-34 [15736216.001]
  • [Cites] Breast Cancer Res Treat. 2005 Mar;90(2):127-37 [15803359.001]
  • [Cites] Int J Cancer. 2005 Sep 1;116(3):340-50 [15818618.001]
  • [Cites] Am J Epidemiol. 2005 Aug 1;162(3):229-37 [15987723.001]
  • [Cites] Endocr Relat Cancer. 2005 Dec;12(4):1059-69 [16322343.001]
  • [Cites] Oncology. 2005;69(6):478-85 [16410686.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1447-53 [16533767.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1342-9 [16549828.001]
  • [Cites] J Clin Oncol. 2006 May 10;24(14):2170-8 [16682736.001]
  • [Cites] Cell Cycle. 2006 May;5(9):963-7 [16687925.001]
  • [Cites] BMC Genomics. 2006;7:96 [16643655.001]
  • [Cites] CA Cancer J Clin. 2006 May-Jun;56(3):168-83 [16737949.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2492-502 [16757721.001]
  • [Cites] BMC Genomics. 2006;7:127 [16729877.001]
  • [Cites] Eur J Cancer Prev. 2006 Aug;15(4):306-42 [16835503.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):560-9 [16899776.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):8297-308 [16912212.001]
  • [ErratumIn] Breast Cancer Res Treat. 2008 May;109(1):141. Dressler, Lynn G [added]
  • (PMID = 17578664.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA058223-140021; United States / NCI NIH HHS / CA / CA016086-259034; United States / NCI NIH HHS / CA / CA058223-150021; United States / NCI NIH HHS / CA / R01 CA101227; United States / NCI NIH HHS / CA / CA058223-09A10013; United States / NCI NIH HHS / CA / P30 CA016086; United States / NCI NIH HHS / CA / P30 CA016086-259034; United States / NCI NIH HHS / CA / P50 CA058223-150021; United States / NCI NIH HHS / CA / P50 CA058223; United States / NCI NIH HHS / CA / P50-CA58223; United States / NCI NIH HHS / CA / CA058223-100013; United States / NCI NIH HHS / CA / P50 CA058223-140021; United States / NCI NIH HHS / CA / P30-CA16086; United States / NCI NIH HHS / CA / P50 CA058223-100013; United States / NCI NIH HHS / CA / R01-CA101227; United States / NCI NIH HHS / CA / P50 CA058223-09A10013
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS50834; NLM/ PMC2443103
  •  go-up   go-down


45. Ortix C, Lorenzana J, Di Castro C: Coulomb-frustrated phase separation phase diagram in systems with short-range negative compressibility. Phys Rev Lett; 2008 Jun 20;100(24):246402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coulomb-frustrated phase separation phase diagram in systems with short-range negative compressibility.
  • Using numerical techniques and asymptotic expansions we obtain the phase diagram of a paradigmatic model of Coulomb-frustrated phase separation in systems with negative short-range compressibility.
  • The transition from the homogeneous phase to the inhomogeneous phase is generically first order in isotropic three-dimensional systems except for a critical point.
  • Close to the critical point, inhomogeneities are predicted to form a bcc lattice with subsequent transitions to a triangular lattice of rods and a layered structure.
  • Inclusion of a strong anisotropy allows for second- and first-order transition lines joined by a tricritical point.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18643604.001).
  • [ISSN] 0031-9007
  • [Journal-full-title] Physical review letters
  • [ISO-abbreviation] Phys. Rev. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Mehta S, Price GD, Alfè D: Ab initio thermodynamics and phase diagram of solid magnesium: a comparison of the LDA and GGA. J Chem Phys; 2006 Nov 21;125(19):194507
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ab initio thermodynamics and phase diagram of solid magnesium: a comparison of the LDA and GGA.
  • The finite temperature density functional theory and quasiharmonic lattice dynamics have been used to compute numerous thermodynamic properties of hexagonal close packed magnesium using both the local density approximation (LDA) and the generalized gradient approximation (GGA) for the exchange-correlation potential.
  • Generally, it is found that there exist only minor differences between the LDA and GGA computed properties, with both giving good agreement with experiment.
  • The hcp-bcc phase boundary has also been computed and is found to be in agreement with experimental observation.
  • Again, only slight differences are found between the LDA and GGA.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17129123.001).
  • [ISSN] 0021-9606
  • [Journal-full-title] The Journal of chemical physics
  • [ISO-abbreviation] J Chem Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Tai KP, Dai XD, Shen YX, Liu BX: Formation and structural anomaly of the metastable phases in an immiscible Ag-Mo system studied by ion beam mixing and molecular dynamics simulation. J Phys Chem B; 2006 Jan 12;110(1):595-606
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Formation and structural anomaly of the metastable phases in an immiscible Ag-Mo system studied by ion beam mixing and molecular dynamics simulation.
  • For the equilibrium immiscible Ag-Mo system characterized by a large positive heat of formation, the nanosized Ag-Mo multilayered samples are designed and prepared to include sufficient interfacial free energy to elevate their initial energetic states to be higher than that of either the amorphous phase or solid solution and then subject to 200 keV xenon ion irradiation.
  • The results show that a uniform amorphous alloy can be obtained within a composition range, at least, from 25 to 88 atom % of Mo.
  • Interestingly, in the intermediate stage of ion irradiation, a bcc phase, an amorphous phase, and an order (bcc)-disorder coexisting state appear simultaneously in the Ag12Mo88 multilayered sample and extend over the entire bright field image with unanimously homogeneous composition.
  • In thermodynamic modeling, a Gibbs free energy diagram of the Ag-Mo system is constructed, based on Miedema's model, and suggests that within a narrow composition regime of 85-90 atom % of Mo, the energy difference between the bcc and the amorphous phases is extremely small, which is probably the very reason for the order-disorder coexisting state to appear.
  • In atomistic modeling, an ab initio derived Ag-Mo potential is applied to perform molecular dynamics simulations.
  • The simulations not only determine an intrinsic glass-forming ability/range (GFA/GFR) of the Ag-Mo system to be from 10 to 88 atom % of Mo but also reveal the possibility of the formation/appearance of a crystalline and amorphous mixture in a narrow composition regime of 88-92 atom % of Mo.
  • Apparently, the theoretical results are in excellent agreement and/or compatible with the experimental observations in ion beam mixing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16471572.001).
  • [ISSN] 1520-6106
  • [Journal-full-title] The journal of physical chemistry. B
  • [ISO-abbreviation] J Phys Chem B
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Bunyapaiboonsri T, Yoiprommarat S, Khonsanit A, Komwijit S: Phenolic glycosides from the filamentous fungus Acremonium sp. BCC 14080. J Nat Prod; 2008 May;71(5):891-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenolic glycosides from the filamentous fungus Acremonium sp. BCC 14080.
  • New phenolic mono- and digalactopyranosides (1 and 2), their aglycone KS-501a (3), and a new phenolic 4-O-methylglucopyranoside (4) were isolated from the filamentous fungus Acremonium sp. BCC 14080.
  • Structures of these compounds were elucidated by extensive MS and NMR spectroscopic analyses.
  • Compound 1 displayed anti-HSV-1 activity with an IC(50) value of 7.2 microM.
  • Compound 3 exhibited activity against Plasmodium falciparum K1 with an IC(50) value of 9.9 microM.
  • [MeSH-major] Acremonium / chemistry. Antiviral Agents / isolation & purification. Antiviral Agents / pharmacology. Glycosides / isolation & purification. Glycosides / pharmacology. Herpesvirus 1, Human / drug effects. Phenols / isolation & purification. Phenols / pharmacology. Plasmodium falciparum / drug effects
  • [MeSH-minor] Animals. Cercopithecus aethiops. Drug Screening Assays, Antitumor. Humans. Hydroxybenzoates / chemistry. Hydroxybenzoates / isolation & purification. Hydroxybenzoates / pharmacology. Inhibitory Concentration 50. Molecular Structure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18363379.001).
  • [ISSN] 0163-3864
  • [Journal-full-title] Journal of natural products
  • [ISO-abbreviation] J. Nat. Prod.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Glycosides; 0 / Hydroxybenzoates; 0 / Phenols; 120634-86-8 / KS 501
  •  go-up   go-down


49. Iijima M, Brantley WA, Baba N, Alapati SB, Yuasa T, Ohno H, Mizoguchi I: Micro-XRD study of beta-titanium wires and infrared soldered joints. Dent Mater; 2007 Sep;23(9):1051-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Micro-XRD study of beta-titanium wires and infrared soldered joints.
  • OBJECTIVE: The purpose of this study was to investigate the metallurgical phases in beta-titanium soldered joints prepared by infrared soldering, using the Micro X-ray diffraction technique (Micro-XRD), and to characterize the Vickers hardness in the soldered beta-titanium wires.
  • METHODS: Beta-titanium wires with cross-section dimensions of 0.032in.x0.032in. (TMA, Ormco), and both titanium-based solder (Ti-30Ni-20Cu, Selec) and silver-based solder (Ag-22Cu-17Zn-5Sn, Tomy) were selected.
  • Soldering was performed using infrared radiation (RS-1, Morita) under argon atmosphere.
  • Micro-XRD analyses were performed at room temperature.
  • Micro-XRD spectra were obtained for the boundary region of the soldered beta-titanium wires using 50microm and 10microm diameter analysis regions.
  • Hardness was measured at 30microm intervals from boundary of the diffusion layer and beta-titanium wire.
  • The Kruskal-Wallis test with the Bonferroni and Wilcoxson Mann-Whitney tests for nonparametric means were employed as statistical methods (P<0.05).
  • RESULTS: For both types of soldered beta-titanium samples, the Micro-XRD spectra contained four major peaks for body-centered cubic (bcc) beta-titanium.
  • Additional peaks at about 41 and 45 degrees are attributed to Cu-Ti intermetallic phase(s), which may be metastable under soldering conditions.
  • The diffusion layer had greater hardness than bulk beta-titanium for both types of soldered specimens (P<0.05).
  • SIGNIFICANCE: Soldering of beta-titanium orthodontic wire by infrared radiation may be acceptable for clinical use, since Micro-XRD spectra revealed that both types of soldered specimens largely retained the bcc beta-titanium structure.
  • Further research is needed to investigate the mechanical properties and corrosion behavior of infrared-soldered beta-titanium wire.
  • [MeSH-major] Dental Soldering. Orthodontic Wires. Titanium / chemistry
  • [MeSH-minor] Alloys / chemistry. Copper / chemistry. Diffusion. Electron Probe Microanalysis. Hardness. Humans. Infrared Rays. Materials Testing. Mechanics. Metallurgy. Microspectrophotometry. Nickel / chemistry. Silver / chemistry. Surface Properties. Tin / chemistry. X-Ray Diffraction. Zinc / chemistry

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NICKEL, ELEMENTAL .
  • Hazardous Substances Data Bank. SILVER, ELEMENTAL .
  • Hazardous Substances Data Bank. TIN .
  • Hazardous Substances Data Bank. TITANIUM .
  • Hazardous Substances Data Bank. COPPER, ELEMENTAL .
  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17178150.001).
  • [ISSN] 0109-5641
  • [Journal-full-title] Dental materials : official publication of the Academy of Dental Materials
  • [ISO-abbreviation] Dent Mater
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alloys; 3M4G523W1G / Silver; 7440-31-5 / Tin; 789U1901C5 / Copper; 7OV03QG267 / Nickel; D1JT611TNE / Titanium; J41CSQ7QDS / Zinc
  •  go-up   go-down


50. Pinto Pereira SM, Hipwell JH, McCormack VA, Tanner C, Moss SM, Wilkinson LS, Khoo LA, Pagliari C, Skippage PL, Kliger CJ, Hawkes DJ, Silva IM: Automated registration of diagnostic to prediagnostic x-ray mammograms: evaluation and comparison to radiologists' accuracy. Med Phys; 2010 Sep;37(9):4530-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Five mammography film readers independently identified landmarks (tumor, nipple, and usually two other normal features) on pairs of diagnostic and corresponding prediagnostic digitized images from 52 breast cancer cases.
  • Mean accuracy (mm) of the affine registration varied between 3.16 (95% CI 2.56, 3.90) for nipple points in breasts with density 20%-39% and 5.73 (4.80, 6.84) for tumor points in breasts with density < 20%.
  • [MeSH-major] Breast Neoplasms / diagnostic imaging. Image Processing, Computer-Assisted / methods. Mammography / methods. Radiology / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20964170.001).
  • [ISSN] 0094-2405
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


51. Woditschka S, Habel LA, Udaltsova N, Friedman GD, Sieh W: Lipophilic statin use and risk of breast cancer subtypes. Cancer Epidemiol Biomarkers Prev; 2010 Oct;19(10):2479-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We conducted a large case-control study within Kaiser Permanente of Northern California (KPNC) to determine whether chronic use of lipophilic statins is associated with decreased risk of HR-negative breast cancer or other breast cancer subtypes.
  • Women who used lipophilic statins did not have a decreased risk of HR-negative breast cancer (odds ratio(adj), 0.98; 95% CI, 0.84-1.14) nor altered risk of HR-positive disease (odds ratio(adj), 1.03; 95% CI, 0.97-1.10).

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Statins.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Ann Med. 2000 Apr;32(3):164-76 [10821323.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):416-21 [17372235.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):18-27 [11134191.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Carcinogenesis. 2003 Mar;24(3):453-9 [12663504.001]
  • [Cites] Menopause. 2003 Jul-Aug;10(4):332-6 [12851516.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • [Cites] Carcinogenesis. 2004 Oct;25(10):1887-98 [15180944.001]
  • [Cites] Cancer Lett. 2007 Jun 8;250(2):220-8 [17125918.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2008 Jan;17(1):27-36 [17944002.001]
  • [Cites] Int J Cancer. 2008 Apr 15;122(8):1832-41 [18067133.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1026-7 [18463398.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1028-33 [18463402.001]
  • [Cites] BMJ. 2008;337:a540 [18621762.001]
  • [Cites] Oncology (Williston Park). 2008 Oct;22(11):1233-9; discussion 1239-40, 1243 [18980022.001]
  • [Cites] Eur J Cancer. 2008 Oct;44(15):2122-32 [18707867.001]
  • [Cites] Int J Cancer. 2009 Feb 1;124(3):698-712 [18988226.001]
  • [Cites] Cancer Prev Res (Phila). 2009 Feb;2(2):161-7 [19196723.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Ann Med. 1991 Dec;23(6):643-8 [1777219.001]
  • [Cites] Am J Public Health. 1992 May;82(5):703-10 [1566949.001]
  • [Cites] Lancet. 1996 Jun 22;347(9017):1713-27 [8656904.001]
  • [Cites] Epidemiology. 1997 May;8(3):275-80 [9115022.001]
  • [Cites] Lancet. 1997 Oct 11;350(9084):1047-59 [10213546.001]
  • [Cites] Lancet. 2005 Jan 1-7;365(9453):82-93 [15639683.001]
  • [Cites] Fundam Clin Pharmacol. 2005 Feb;19(1):117-25 [15660968.001]
  • [Cites] Arch Intern Med. 2005 Oct 24;165(19):2264-71 [16246993.001]
  • [Cites] Nat Rev Cancer. 2005 Dec;5(12):930-42 [16341084.001]
  • [Cites] JAMA. 2006 Jan 4;295(1):74-80 [16391219.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2006 May;15(5):291-303 [16447304.001]
  • [Cites] J Natl Cancer Inst. 2006 May 17;98(10):700-7 [16705124.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2492-502 [16757721.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8707-14 [16951186.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):118-45 [17159189.001]
  • [Cites] Int J Cancer. 2007 Feb 15;120(4):833-43 [17131313.001]
  • [ErratumIn] Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):1001-3
  • (PMID = 20729289.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098838; United States / NCI NIH HHS / CA / R01 CA 098838
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  • [Other-IDs] NLM/ NIHMS231480; NLM/ PMC2952055
  •  go-up   go-down


52. Surov A, Holzhausen HJ, Ruschke K, Arnold D, Spielmann RP: Breast plasmacytoma. Acta Radiol; 2010 Jun;51(5):498-504
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSION: In conclusion, BP does not have specific radiological or clinical features and can be misdiagnosed as primary breast carcinoma or even as a benign process.
  • [MeSH-major] Breast Neoplasms / diagnosis. Plasmacytoma / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Neoplasms, Male / diagnosis. Breast Neoplasms, Male / epidemiology. Breast Neoplasms, Male / etiology. Diagnosis, Differential. Female. Germany / epidemiology. Humans. Incidental Findings. Magnetic Resonance Imaging. Male. Mammography. Middle Aged. Multiple Myeloma / complications. Prevalence. Retrospective Studies. Ultrasonography, Mammary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20429767.001).
  • [ISSN] 1600-0455
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


53. Yang H, Zhao JS, Hawari J: Effect of 2,4-dinitrotoluene on the anaerobic bacterial community in marine sediment. J Appl Microbiol; 2009 Dec 1;107(6):1799-808
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of 2,4-dinitrotoluene on the anaerobic bacterial community in marine sediment.
  • AIMS: To study the impact of added 2,4-dinitrotoluene (DNT) on the anaerobic bacterial community in marine sediment collected from an unexploded ordnance dumping site in Halifax Harbour.
  • METHODS AND RESULTS: Marine sediment was spiked with 2,4-DNT and incubated under anaerobic conditions in the presence and absence of lactate.
  • Indigenous bacteria in the sediment removed 2,4-DNT with subsequent formation of its mono- and diamino-derivatives under both conditions.
  • PCR-DGGE and nucleotide sequencing were used to monitor the change in the bacterial population in sediment caused by the presence of 2,4-DNT.
  • The results showed that denaturing gradient gel electrophoresis banding patterns of sediment microcosms treated with 2,4-DNT were different from controls that did not receive 2,4-DNT.
  • Bacteroidetes, Firmicutes and delta-Proteobacteria were present in sediment incubated in the absence of 2,4-DNT.
  • However, several gamma-Proteobacteria became dominant in sediment in the presence of 2,4-DNT, two of which were 99% similar to Shewanella canadensis and Shewanella sediminis.
  • In the presence of both 2,4-DNT and lactate, two additional delta-Proteobacteria were enriched, one closely related (98% similarity) to Desulfofrigus fragile and the other affiliated (96% similarity) to Desulfovibrio sp.
  • In contrast, none of the above four Proteobacteria were enriched in sediment incubated with lactate alone.
  • CONCLUSIONS: Presence of 2,4-DNT led to a significant change in bacterial population of marine sediment with the enrichment of several gamma- and delta-Proteobacteria.
  • SIGNIFICANCE AND IMPACT OF THE STUDY: Our results provided the first evidence on the impact of the pollutant 2,4-DNT on the indigenous bacterial community in marine sediment, and provided an insight into the composition of bacterial community that degrade 2,4-DNT.
  • [MeSH-major] Bacteria, Anaerobic / drug effects. Bacteria, Anaerobic / isolation & purification. Dinitrobenzenes / toxicity. Geologic Sediments / microbiology. Water Pollutants, Chemical / toxicity
  • [MeSH-minor] Canada. DNA, Bacterial / genetics. Electrophoresis, Polyacrylamide Gel. Phylogeny. RNA, Ribosomal, 16S / genetics

  • Hazardous Substances Data Bank. 2,4-DINITROTOLUENE .
  • SILVA. SILVA SSU Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19486208.001).
  • [ISSN] 1365-2672
  • [Journal-full-title] Journal of applied microbiology
  • [ISO-abbreviation] J. Appl. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Bacterial; 0 / Dinitrobenzenes; 0 / RNA, Ribosomal, 16S; 0 / Water Pollutants, Chemical; 6741D310ED / 2,4-dinitrotoluene
  •  go-up   go-down


54. Sanguin H, Remenant B, Dechesne A, Thioulouse J, Vogel TM, Nesme X, Moënne-Loccoz Y, Grundmann GL: Potential of a 16S rRNA-based taxonomic microarray for analyzing the rhizosphere effects of maize on Agrobacterium spp. and bacterial communities. Appl Environ Microbiol; 2006 Jun;72(6):4302-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential of a 16S rRNA-based taxonomic microarray for analyzing the rhizosphere effects of maize on Agrobacterium spp. and bacterial communities.
  • Bacterial diversity is central to ecosystem sustainability and soil biological function, for which the role of roots is important.
  • The high-throughput analysis potential of taxonomic microarray should match the breadth of bacterial diversity.
  • Here, the power of this technology was evidenced through methodological verifications and analysis of maize rhizosphere effect based on a 16S rRNA-based microarray developed from the prototype of H.
  • Sanguin et al. (Environ. Microbiol.
  • 8:289-307, 2006).
  • The current probe set was composed of 170 probes (41 new probes in this work) that targeted essentially the Proteobacteria.
  • Cloning and sequencing of 16S rRNA amplicons were carried out on maize rhizosphere and bulk soil DNA.
  • All tested clones that had a perfect match with corresponding probes were positive in the hybridization experiment.
  • The hierarchically nested probes were reliable, but the level of taxonomic identification was variable, depending on the probe set specificity.
  • The comparison of experimental and theoretical hybridizations revealed 0.91% false positives and 0.81% false negatives.
  • The microarray detection threshold was estimated at 0.03% of a given DNA type based on DNA spiking experiments.
  • A comparison of the maize rhizosphere and bulk soil hybridization results showed a significant rhizosphere effect, with a higher predominance of Agrobacterium spp. in the rhizosphere, as well as a lower prevalence of Acidobacteria, Bacteroidetes, Verrucomicrobia, and Planctomycetes, a new taxon of interest in soil.
  • In addition, well-known taxonomic groups such as Sphingomonas spp., Rhizobiaceae, and Actinobacteria were identified in both microbial habitats with strong hybridization signals.
  • The taxonomic microarray developed in the present study was able to discriminate and characterize bacterial community composition in related biological samples, offering extensive possibilities for systematic exploration of bacterial diversity in ecosystems.
  • [MeSH-major] Proteobacteria / classification. Proteobacteria / genetics. RNA, Bacterial / genetics. RNA, Ribosomal, 16S / genetics. Rhizobium / classification. Rhizobium / genetics. Zea mays / microbiology
  • [MeSH-minor] Cloning, Molecular. Oligonucleotide Array Sequence Analysis. Phylogeny. Polymerase Chain Reaction. Soil Microbiology

  • COS Scholar Universe. author profiles.
  • SILVA. SILVA SSU Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Microbiol. 2004 Aug;12(8):386-93 [15276615.001]
  • [Cites] J Ind Microbiol Biotechnol. 2004 Jul;31(6):278-88 [15221668.001]
  • [Cites] BMC Bioinformatics. 2004 Jul 29;5:103 [15283861.001]
  • [Cites] Appl Environ Microbiol. 2004 Sep;70(9):5094-101 [15345387.001]
  • [Cites] Bioinformatics. 2004 Sep 22;20(14):2317-9 [15073015.001]
  • [Cites] Syst Appl Microbiol. 1999 Sep;22(3):434-44 [10553296.001]
  • [Cites] Nature. 2000 May 11;405(6783):228-33 [10821283.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):9834-9 [10963655.001]
  • [Cites] Environ Microbiol. 2001 Jan;3(1):19-31 [11225720.001]
  • [Cites] Appl Environ Microbiol. 2001 May;67(5):2284-91 [11319113.001]
  • [Cites] Appl Microbiol Biotechnol. 2001 Jul;56(1-2):40-57 [11499947.001]
  • [Cites] Appl Environ Microbiol. 2001 Oct;67(10):4708-16 [11571176.001]
  • [Cites] Appl Environ Microbiol. 2001 Oct;67(10):4742-51 [11571180.001]
  • [Cites] Appl Environ Microbiol. 2001 Dec;67(12):5780-90 [11722935.001]
  • [Cites] Appl Environ Microbiol. 2002 Mar;68(3):1425-30 [11872496.001]
  • [Cites] Appl Environ Microbiol. 2002 May;68(5):2391-6 [11976113.001]
  • [Cites] Appl Environ Microbiol. 2002 May;68(5):2535-41 [11976131.001]
  • [Cites] Appl Environ Microbiol. 1999 Apr;65(4):1662-9 [10103265.001]
  • [Cites] Can J Microbiol. 2004 Jul;50(7):469-74 [15381970.001]
  • [Cites] Microb Ecol. 2004 Apr;47(3):243-51 [14994173.001]
  • [Cites] Appl Environ Microbiol. 1992 Oct;58(10):3413-6 [1444376.001]
  • [Cites] Appl Environ Microbiol. 1995 Jun;61(6):2270-5 [7793948.001]
  • [Cites] Microbiology. 1995 Jul;141 ( Pt 7):1493-506 [7551018.001]
  • [Cites] Gene. 1995 Nov 7;165(1):81-6 [7489921.001]
  • [Cites] J Bacteriol. 1996 Jun;178(12):3496-500 [8655546.001]
  • [Cites] FEMS Microbiol Lett. 1997 Aug 1;153(1):181-90 [9252585.001]
  • [Cites] Appl Environ Microbiol. 1997 Nov;63(11):4516-22 [9361437.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6578-83 [9618454.001]
  • [Cites] J Bacteriol. 1998 Sep;180(18):4765-74 [9733676.001]
  • [Cites] Microbiology. 1998 Dec;144 ( Pt 12):3257-66 [9884217.001]
  • [Cites] Science. 1999 Oct 15;286(5439):542-4 [10521351.001]
  • [Cites] Appl Environ Microbiol. 2004 Dec;70(12):6998-7009 [15574893.001]
  • [Cites] Appl Environ Microbiol. 2004 Dec;70(12):7161-72 [15574913.001]
  • [Cites] Appl Environ Microbiol. 2005 Feb;71(2):826-34 [15691937.001]
  • [Cites] Appl Environ Microbiol. 2005 Mar;71(3):1373-86 [15746340.001]
  • [Cites] J Microbiol Methods. 2005 Jul;62(1):37-56 [15823393.001]
  • [Cites] FEMS Microbiol Lett. 2005 Apr 15;245(2):271-8 [15837382.001]
  • [Cites] Annu Rev Plant Biol. 2005;56:15-39 [15862088.001]
  • [Cites] J Exp Bot. 2005 Jul;56(417):1761-78 [15911555.001]
  • [Cites] BMC Genomics. 2005;6:78 [15918914.001]
  • [Cites] Appl Environ Microbiol. 2005 Nov;71(11):6910-7 [16269725.001]
  • [Cites] FEMS Microbiol Ecol. 2005 Feb 1;51(3):333-40 [16329881.001]
  • [Cites] Environ Microbiol. 2006 Feb;8(2):289-307 [16423016.001]
  • [Cites] Appl Environ Microbiol. 2002 Jul;68(7):3215-25 [12088997.001]
  • [Cites] Annu Rev Phytopathol. 2002;40:309-48 [12147763.001]
  • [Cites] Bioinformatics. 2002;18 Suppl 1:S105-10 [12169537.001]
  • [Cites] Appl Environ Microbiol. 2002 Dec;68(12):6121-8 [12450836.001]
  • [Cites] Mol Ecol. 2003 Jan;12(1):251-62 [12492893.001]
  • [Cites] Nucleic Acids Res. 2003 Jan 1;31(1):514-6 [12520066.001]
  • [Cites] Bioinformatics. 2003 Jan 22;19(2):185-93 [12538238.001]
  • [Cites] Appl Environ Microbiol. 2003 Mar;69(3):1482-7 [12620832.001]
  • [Cites] Appl Environ Microbiol. 2003 May;69(5):2684-91 [12732537.001]
  • [Cites] Environ Microbiol. 2003 Jun;5(6):441-52 [12755711.001]
  • [Cites] Environ Microbiol. 2003 Jul;5(7):566-82 [12823189.001]
  • [Cites] Curr Opin Biotechnol. 2003 Jun;14(3):311-8 [12849785.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]
  • [Cites] Environ Microbiol. 2003 Oct;5(10):896-907 [14510843.001]
  • [Cites] Environ Microbiol. 2003 Oct;5(10):933-43 [14510847.001]
  • [Cites] Appl Environ Microbiol. 2003 Oct;69(10):6143-51 [14532074.001]
  • [Cites] Appl Environ Microbiol. 2003 Nov;69(11):6875-87 [14602652.001]
  • [Cites] Appl Environ Microbiol. 2003 Dec;69(12):7354-63 [14660385.001]
  • [Cites] Nucleic Acids Res. 2004;32(4):1363-71 [14985472.001]
  • [Cites] Appl Environ Microbiol. 2004 Mar;70(3):1767-76 [15006803.001]
  • [Cites] Environ Microbiol. 2004 Apr;6(4):347-63 [15008813.001]
  • [Cites] Biotechniques. 2004 Apr;36(4):664-70, 672, 674-5 [15088384.001]
  • [Cites] BMC Biotechnol. 2004 Mar 8;4:3 [15113428.001]
  • [Cites] Environ Microbiol. 2004 Jun;6(6):638-45 [15142252.001]
  • [Cites] Appl Environ Microbiol. 2004 Jun;70(6):3541-51 [15184155.001]
  • [Cites] Curr Opin Microbiol. 2004 Jun;7(3):221-6 [15196488.001]
  • (PMID = 16751545.001).
  • [ISSN] 0099-2240
  • [Journal-full-title] Applied and environmental microbiology
  • [ISO-abbreviation] Appl. Environ. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Bacterial; 0 / RNA, Ribosomal, 16S
  • [Other-IDs] NLM/ PMC1489601
  •  go-up   go-down


55. Tworoger SS, Missmer SA, Eliassen AH, Spiegelman D, Folkerd E, Dowsett M, Barbieri RL, Hankinson SE: The association of plasma DHEA and DHEA sulfate with breast cancer risk in predominantly premenopausal women. Cancer Epidemiol Biomarkers Prev; 2006 May;15(5):967-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Breast Neoplasms / blood. Dehydroepiandrosterone / blood. Dehydroepiandrosterone Sulfate / blood

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16702378.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA50385; United States / NCI NIH HHS / CA / CA67262; United States / NCI NIH HHS / CA / P50 CA089393; United States / NCI NIH HHS / CA / R25 CA 098566-2; United States / NCI NIH HHS / CA / T32 CA090001
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 459AG36T1B / Dehydroepiandrosterone; 57B09Q7FJR / Dehydroepiandrosterone Sulfate
  •  go-up   go-down


56. Meibodi NT, Maleki M, Javidi Z, Nahidi Y: Clinicopathological evaluation of radiation induced basal cell carcinoma. Indian J Dermatol; 2008;53(3):137-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological evaluation of radiation induced basal cell carcinoma.
  • BACKGROUND: Development of skin neoplasms is one of the most important chronic complications of radiation therapy.
  • Basal cell carcinoma (BCC) is the most frequent carcinoma occurring at the region of the body to which radiotherapy was delivered.
  • AIM: The aim of this study was to evaluate clinical and histological aspects of basal cell carcinoma in patients with a history of radiotherapy.
  • MATERIALS AND METHODS: Medical records and microscopic slides of 80 patients with basal cell carcinoma who had received radiotherapy (1996-2006) were reviewed in pathology department of Imam Reza hospital of Mashhad, Iran.
  • Plaque was the most common clinical pattern of basal cell carcinoma.
  • Histologically, macronodular and pigmented carcinoma were the most predominant forms of basal cell carcinoma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6C):4767-70 [17214338.001]
  • [Cites] Clin Exp Dermatol. 2000 Jul;25(5):381-3 [11012589.001]
  • [Cites] J Craniomaxillofac Surg. 2005 Jun;33(3):197-200 [15878521.001]
  • [Cites] Ann Plast Surg. 2004 Dec;53(6):593-5 [15602259.001]
  • [Cites] Eur J Dermatol. 1998 Apr-May;8(3):180-2 [9649688.001]
  • [Cites] Pediatr Hematol Oncol. 1998 Mar-Apr;15(2):187-91 [9592846.001]
  • [Cites] Tex Med. 1997 Jul;93(7):57-9 [9226992.001]
  • [Cites] J Natl Cancer Inst. 1996 Dec 18;88(24):1848-53 [8961975.001]
  • [Cites] Radiat Res. 1991 Mar;125(3):318-25 [2000456.001]
  • [Cites] Radiat Res. 1984 Oct;100(1):192-204 [6494429.001]
  • [Cites] Cancer Radiother. 2004 Aug;8(4):270-3 [15450522.001]
  • [Cites] Eur J Dermatol. 2004 May-Jun;14(3):182-5 [15246946.001]
  • [Cites] Cancer Radiother. 2004 Apr;8(2):81-7 [15063875.001]
  • [Cites] Dermatol Surg. 2003 Dec;29(12):1233-5 [14725670.001]
  • [Cites] Radiat Res. 2002 Apr;157(4):410-8 [11893243.001]
  • [Cites] Dermatol Surg. 2001 Jul;27(7):667-9 [11442620.001]
  • [Cites] Presse Med. 2006 Jan;35(1 Pt 1):55-7 [16462665.001]
  • (PMID = 19882013.001).
  • [ISSN] 1998-3611
  • [Journal-full-title] Indian journal of dermatology
  • [ISO-abbreviation] Indian J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2763736
  • [Keywords] NOTNLM ; Basal cell carcinoma / basal cell epithelioma / radiotherapy
  •  go-up   go-down


57. Oh ST, Schramme A, Stark A, Tilgen W, Gutwein P, Reichrath J: The disintegrin-metalloproteinases ADAM 10, 12 and 17 are upregulated in invading peripheral tumor cells of basal cell carcinomas. J Cutan Pathol; 2009 Apr;36(4):395-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The disintegrin-metalloproteinases ADAM 10, 12 and 17 are upregulated in invading peripheral tumor cells of basal cell carcinomas.
  • BACKGROUND: Members of the a disintegrin and metalloproteinase (ADAM) family are expressed in malignant tumors and participate in the pathogenesis of cancer.
  • However, the presence of ADAM 10, 12, 17 and their role in basal cell carcinoma (BCC) have not been described.
  • RESULTS: Immunoreactivity of ADAM 10, 12 and 17 was increased at the peripheral tumor margin compared with central areas of BCC tumor cell nests.
  • Immunoreactivity of ADAM 10 and 12 was increased in the deep margin of invading tumor cell nests in mixed BCC.
  • Focally increased expression of ADAM 12 was detected in squamous differentiated tumor cells of nodular BCC.
  • [MeSH-major] ADAM Proteins / biosynthesis. Amyloid Precursor Protein Secretases / biosynthesis. Carcinoma, Basal Cell / enzymology. Membrane Proteins / biosynthesis. Skin Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19278423.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Membrane Proteins; EC 3.4.- / Amyloid Precursor Protein Secretases; EC 3.4.24.- / ADAM 12 protein; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / tumor necrosis factor-alpha convertase; EC 3.4.24.81 / ADAM10 protein, human
  •  go-up   go-down


58. Andreadis D, Epivatianos A, Poulopoulos A, Nomikos A, Christidis K, Papazoglou G, Antoniades D, Barbatis C: Immunohistochemical detection of the expression of the cell adhesion molecules E-cadherin, desmoglein-2, beta4-integrin, ICAM-1 and HCAM (CD44s) in Warthin's tumour of the parotid gland. Oral Oncol; 2005 Sep;41(8):799-805
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of the expression of the cell adhesion molecules E-cadherin, desmoglein-2, beta4-integrin, ICAM-1 and HCAM (CD44s) in Warthin's tumour of the parotid gland.
  • The study of the expression of cell adhesion molecules (CAMs), E-cadherin, desmoglein-2, beta4-integrin, HCAM (CD44s) and ICAM-1 in Warthin's tumours.
  • Beta4-integrin was strongly expressed in all cell-basement membrane and intercellular contacts of the epithelium, E-cadherin and desmoglein-2 in cell-cell contacts, but not in basal cell-basement membrane connections and on columnar cells' luminal surfaces, HCAM (CD44s) in intercellular contacts of both luminal (mainly), basal cells and also in the periphery of monocytic-lymphocytic stroma, and ICAM-1 was weak to moderate expressed in both luminal and basal epithelial cells and strongly in the germinal lymphocytic centres.
  • CAM expression suggests a bilayered excretory ductal structure of the neoplastic epithelium in Warthin's tumour, as a result of hyperplastic process of the glandular epithelium that interacts with the excessive lymphoid tissue of the stroma.
  • [MeSH-major] Adenolymphoma / metabolism. Cell Adhesion Molecules / metabolism. Integrin beta4 / metabolism. Neoplasm Proteins / metabolism. Parotid Neoplasms / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16043382.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cadherins; 0 / Cell Adhesion Molecules; 0 / Desmoglein 2; 0 / Integrin beta4; 0 / Neoplasm Proteins
  •  go-up   go-down


59. Khaled A, Ben Mbarek L, Zeglaoui F, Ezzine N, Fazaa B, Kamoun MR: [Epidemiologic study of cutaneous cancers in aged persons]. Tunis Med; 2008 Oct;86(10):895-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Basal cell carcinoma (BCC) represented 68.2% of all cutaneous cancers in aged persons and 53.84% of all BCC independently of age.
  • Squamous cell carcinoma (SCC) represented 23.5% of all cutaneous cancers in aged persons and 67.44% of all SCC independently of age.
  • Through this study we conclude that the geriatric patient is at a high risk of developing cutaneous neoplasms especially carcinomas.
  • [MeSH-major] Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19472808.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


60. Franz M, Spiegel K, Umbreit C, Richter P, Codina-Canet C, Berndt A, Altendorf-Hofmann A, Koscielny S, Hyckel P, Kosmehl H, Virtanen I, Berndt A: Expression of Snail is associated with myofibroblast phenotype development in oral squamous cell carcinoma. Histochem Cell Biol; 2009 May;131(5):651-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Snail is associated with myofibroblast phenotype development in oral squamous cell carcinoma.
  • To investigate the role of Snail in oral squamous cell carcinoma (OSCC), its immunohistochemical expression was analysed in 129 OSCC samples and correlated to nodal metastasis, histological grade, E-cadherin, and alpha smooth-muscle-actin (alpha SMA).
  • The results were compared to findings in 23 basal cell carcinomas (BCC).
  • Additionally, the influence of TGF beta 1 and EGF on Snail, E-cadherin, vimentin, and alpha SMA expression was analysed in two OSCC cell lines.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Carcinoma, Squamous Cell / metabolism. Fibroblasts / metabolism. Mouth Neoplasms / metabolism. Myoblasts / metabolism. Transcription Factors / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncol Rep. 2007 Mar;17 (3):517-23 [17273727.001]
  • [Cites] J Histochem Cytochem. 2006 Nov;54(11):1263-75 [16899764.001]
  • [Cites] Clin Chim Acta. 2007 Aug;383(1-2):51-6 [17537414.001]
  • [Cites] Nephrol Dial Transplant. 2006 Sep;21(9):2549-55 [16757496.001]
  • [Cites] Am J Dermatopathol. 1994 Jun;16(3):258-67 [7943632.001]
  • [Cites] Cell Cycle. 2007 Mar 15;6(6):638-42 [17374993.001]
  • [Cites] Invasion Metastasis. 1997;17(5):251-8 [9876219.001]
  • [Cites] Virchows Arch. 2008 Sep;453(3):267-74 [18712413.001]
  • [Cites] Oncogene. 2006 Aug 24;25(37):5134-44 [16568079.001]
  • [Cites] J Cell Biol. 2006 Mar 27;172(7):973-81 [16567498.001]
  • [Cites] Oral Oncol. 2008 Jul;44(7):646-51 [17996483.001]
  • [Cites] Cell. 2004 Jun 25;117(7):927-39 [15210113.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 2006 Oct 31;86(40):2821-5 [17200014.001]
  • [Cites] Histochem Cell Biol. 2008 Sep;130(3):509-25 [18496706.001]
  • [Cites] J Mol Histol. 2007 Jun;38(3):183-90 [17390227.001]
  • [Cites] Oral Oncol. 2008 May;44(5):509-17 [17826300.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):84-9 [10655587.001]
  • [Cites] Nucleic Acids Res. 2006 Apr 14;34(7):2077-84 [16617148.001]
  • [Cites] J Pathol. 2003 Jul;200(4):429-47 [12845611.001]
  • [Cites] Int J Oncol. 2005 Dec;27(6):1535-41 [16273209.001]
  • [Cites] Oncogene. 2002 May 9;21(20):3241-6 [12082640.001]
  • [Cites] Int J Oncol. 2006 Nov;29(5):1133-8 [17016644.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):76-83 [10655586.001]
  • [Cites] J Pathol. 1992 Apr;166(4):375-81 [1517891.001]
  • [Cites] J Clin Invest. 2002 Aug;110(3):341-50 [12163453.001]
  • [Cites] Breast Cancer Res. 2001;3(4):213-7 [11434871.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Mar;23 Suppl 1:S122-7 [18336655.001]
  • [Cites] Cancer Lett. 2008 Jun 18;264(2):256-64 [18329791.001]
  • [Cites] Hum Mol Genet. 2005 Nov 15;14 (22):3361-70 [16203744.001]
  • [Cites] Histochem Cell Biol. 2006 Jul;126(1):125-31 [16344911.001]
  • [Cites] J Cell Sci. 2005 May 15;118(Pt 10):2143-53 [15855236.001]
  • [Cites] Cell Tissue Res. 2006 Jun;324(3):457-66 [16505995.001]
  • [Cites] J Biol Chem. 2002 Oct 18;277(42):39209-16 [12161443.001]
  • [Cites] J Clin Invest. 1995 Feb;95(2):859-73 [7532191.001]
  • [Cites] J Clin Invest. 2003 Dec;112(12):1776-84 [14679171.001]
  • [Cites] Hua Xi Kou Qiang Yi Xue Za Zhi. 2001 Dec;19(6):377-9 [12539688.001]
  • [Cites] Mol Cancer Res. 2008 Jan;6(1):10-20 [18234959.001]
  • [Cites] J Cell Biochem. 2007 Jul 1;101(4):830-9 [17211838.001]
  • [Cites] Virchows Arch. 2004 Mar;444(3):231-4 [14758552.001]
  • [Cites] J Cell Sci. 2003 Feb 1;116(Pt 3):499-511 [12508111.001]
  • [Cites] J Cancer Res Clin Oncol. 2001 May;127(5):286-92 [11355143.001]
  • [Cites] Cells Tissues Organs. 2007;185(1-3):116-22 [17587817.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):391-402 [12547698.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2892-9 [15070660.001]
  • [Cites] J Cell Sci. 2006 Jan 15;119(Pt 2):283-91 [16390868.001]
  • [Cites] Br J Cancer. 2004 Feb 23;90(4):822-32 [14970860.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):153-70 [11812937.001]
  • [Cites] Int J Oncol. 2003 Apr;22(4):891-8 [12632084.001]
  • [Cites] Oncol Rep. 2008 Apr;19(4):993-8 [18357387.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • [Cites] Gastroenterology. 2005 Nov;129(5):1375-83 [16285938.001]
  • [Cites] Virchows Arch. 2002 Mar;440(3):298-303 [11889601.001]
  • (PMID = 19198871.001).
  • [ISSN] 1432-119X
  • [Journal-full-title] Histochemistry and cell biology
  • [ISO-abbreviation] Histochem. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Actins; 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Snail Family Transcription Factors; 0 / Transcription Factors; 0 / Transforming Growth Factor beta1; 0 / Vimentin; 62229-50-9 / Epidermal Growth Factor; 68238-35-7 / Keratins
  •  go-up   go-down


61. Beutelspacher SC, Serbecic N: [Potential endogenous immunological self-protection of uveal melanoma by indoleamine 2,3-dioxygenase]. Klin Monbl Augenheilkd; 2008 Aug;225(8):703-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although they represent less than 1% of all tumour cases, uveal melanomas are considerd to be rather aggressive due to early hepatic metastases.
  • MATERIALS AND METHODS: In this study, the L-kynurenine production of six uveal melanoma cell lines was examined and immunohistochemistry performed for detection of IDO expression within uveal melanomas.
  • RESULTS: In all the examined cell lines, a basal degradation of tryptophan to L-kynurenine was detectable.
  • Supplementation with interferon-gamma could up-regulate this basal L-kynurenine production.
  • CONCLUSIONS: The expression of IDO within the tumours may shed light on an important adaptive mechanism which allows the melanoma cells to escape T-cell-dependent immunosurveillance as soon as these cells metastise and enter non-immunologically privileged tissue.
  • [MeSH-major] Immunity, Innate / immunology. Indoleamine-Pyrrole 2,3,-Dioxygenase / administration & dosage. Indoleamine-Pyrrole 2,3,-Dioxygenase / immunology. Melanoma / immunology. Uveal Neoplasms / immunology
  • [MeSH-minor] Cell Line, Tumor. Humans

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18712654.001).
  • [ISSN] 1439-3999
  • [Journal-full-title] Klinische Monatsblätter für Augenheilkunde
  • [ISO-abbreviation] Klin Monbl Augenheilkd
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Indoleamine-Pyrrole 2,3,-Dioxygenase
  •  go-up   go-down


62. Beck B, Lehen'kyi V, Roudbaraki M, Flourakis M, Charveron M, Bordat P, Polakowska R, Prevarskaya N, Skryma R: TRPC channels determine human keratinocyte differentiation: new insight into basal cell carcinoma. Cell Calcium; 2008 May;43(5):492-505
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TRPC channels determine human keratinocyte differentiation: new insight into basal cell carcinoma.
  • Aberrant keratinocyte differentiation is considered to be a key mechanism in the onset of hyperproliferative dermatological diseases, including basal cell carcinoma (BCC).
  • This study was designed to investigate the role of calcium-permeable TRPC channels in human keratinocyte differentiation and BCC, using a combination of molecular and cell biology approaches, involving electrophysiology and Ca(2+)-imaging, on the HaCaT cell line, primary cultures of normal human keratinocytes, and BCC cells.
  • [MeSH-major] Calcium / metabolism. Carcinoma, Basal Cell / metabolism. Keratinocytes / metabolism. Skin Neoplasms / metabolism. TRPC Cation Channels / physiology
  • [MeSH-minor] Cell Differentiation. Cell Line. Down-Regulation. Electric Conductivity. Endoplasmic Reticulum / metabolism. Humans. Patch-Clamp Techniques. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17920677.001).
  • [ISSN] 0143-4160
  • [Journal-full-title] Cell calcium
  • [ISO-abbreviation] Cell Calcium
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / TRPC Cation Channels; 0 / TRPC4 ion channel; 0 / transient receptor potential cation channel, subfamily C, member 1; SY7Q814VUP / Calcium
  •  go-up   go-down


63. Lee S, Selva D, Huilgol SC, Goldberg RA, Leibovitch I: Pharmacological treatments for basal cell carcinoma. Drugs; 2007;67(6):915-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacological treatments for basal cell carcinoma.
  • Basal cell carcinoma (BCC) is the most common non-melanoma skin cancer, and its incidence continues to rise.
  • Current management options are numerous and focus on tumour eradication while maximising cosmetic and functional capacity.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / drug therapy. Photochemotherapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2006-11 [10473079.001]
  • [Cites] Lasers Surg Med. 1990;10(5):485-8 [2146455.001]
  • [Cites] Gen Pharmacol. 1998 Sep;31(3):357-60 [9703201.001]
  • [Cites] Br J Dermatol. 2003 Nov;149 Suppl 66:59-61 [14616354.001]
  • [Cites] Prim Care Update Ob Gyns. 1998 Jul 1;5(4):151 [10838279.001]
  • [Cites] Arch Dermatol. 2003 Oct;139(10 ):1325-32 [14568837.001]
  • [Cites] J Am Acad Dermatol. 2004 Sep;51(3):477-8 [15338000.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):2908-11 [8674038.001]
  • [Cites] Arch Dermatol. 2004 Dec;140(12 ):1490-5 [15611427.001]
  • [Cites] J Clin Oncol. 1990 Feb;8(2):342-6 [2405109.001]
  • [Cites] J Photochem Photobiol B. 1995 Jul;29(1):53-7 [7472803.001]
  • [Cites] Arch Dermatol. 1990 Aug;126(8):1029-32 [2383027.001]
  • [Cites] Arch Dermatol. 1983 Jan;119(1):44-50 [6849564.001]
  • [Cites] Br J Dermatol. 2003 Feb;148(2):195-202 [12588368.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 30;32(5):1347-50 [7635774.001]
  • [Cites] J Dermatol. 1996 Jun;23 (6):394-6 [8708151.001]
  • [Cites] Br J Cancer. 1994 Mar;69(3):605-8 [8123497.001]
  • [Cites] Clin Microbiol Rev. 2001 Oct;14(4):778-809, table of contents [11585785.001]
  • [Cites] J Dermatol Surg Oncol. 1992 Jul;18(7):549-54 [1624628.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):406-11 [15380573.001]
  • [Cites] Mol Carcinog. 2003 Sep;38(1):33-9 [12949841.001]
  • [Cites] Eur J Dermatol. 2002 Nov-Dec;12(6):562-4 [12459528.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Aug;55(2):143-52 [15886010.001]
  • [Cites] Australas J Dermatol. 2006 Feb;47(1):46-8 [16405483.001]
  • [Cites] Australas J Dermatol. 2006 Nov;47(4):258-65 [17034468.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15623-8 [9861020.001]
  • [Cites] J Am Acad Dermatol. 1993 Jan;28(1):17-21 [8318069.001]
  • [Cites] Clin Exp Dermatol. 2002 Sep;27(6):493-7 [12372093.001]
  • [Cites] Br J Plast Surg. 1995 Sep;48(6):360-70 [7551508.001]
  • [Cites] Cancer. 1997 Jun 15;79(12 ):2282-308 [9191516.001]
  • [Cites] J Am Acad Dermatol. 2005 Sep;53(3):452-7 [16112352.001]
  • [Cites] Nat Rev Immunol. 2001 Nov;1(2):135-45 [11905821.001]
  • [Cites] Histopathology. 1998 May;32(5):393-8 [9639112.001]
  • [Cites] Br J Cancer. 1999 Mar;79(9-10):1603-8 [10188913.001]
  • [Cites] Acta Derm Venereol. 1999 May;79(3):204-6 [10384917.001]
  • [Cites] Dermatologica. 1979;158(5):368-72 [437226.001]
  • [Cites] J Am Acad Dermatol. 1997 Oct;37(4):596-9 [9344200.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):722-33 [15097956.001]
  • [Cites] Arch Dermatol. 1985 Feb;121(2):207-13 [3977335.001]
  • [Cites] N Engl J Med. 1999 Dec 2;341(23):1767-8 [10610445.001]
  • [Cites] N Engl J Med. 2005 Nov 24;353(21):2262-9 [16306523.001]
  • [Cites] J Am Acad Dermatol. 1996 Dec;35(6):907-10 [8959949.001]
  • [Cites] Curr Opin Immunol. 1998 Jun;10(3):271-8 [9638363.001]
  • [Cites] Br J Dermatol. 2002 Apr;146(4):552-67 [11966684.001]
  • [Cites] Arch Dermatol. 1998 Jul;134(7):821-6 [9681345.001]
  • [Cites] Cancer. 1991 Nov 15;68(10):2134-7 [1913451.001]
  • [Cites] Br J Ophthalmol. 1991 Jul;75(7):407-10 [1854693.001]
  • [Cites] J Dermatol. 2000 Jan;27(1):10-5 [10692817.001]
  • [Cites] Plast Reconstr Surg. 2000 Jun;105(7):2544-51 [10845311.001]
  • [Cites] Br J Plast Surg. 2005 Sep;58(6):795-805 [16086990.001]
  • [Cites] Dermatologica. 1970;140:Suppl 1:47-54 [5471361.001]
  • [Cites] BMJ. 2003 Oct 4;327(7418):794-8 [14525881.001]
  • [Cites] J Am Acad Dermatol. 1990 May;22(5 Pt 2):905-8 [2335582.001]
  • [Cites] Arch Dermatol. 1978 Jul;114(7):1021-2 [686718.001]
  • [Cites] Br J Dermatol. 1995 Aug;133(2):282-8 [7547399.001]
  • [Cites] J Interferon Cytokine Res. 1999 Aug;19(8):817-28 [10476925.001]
  • [Cites] Arch Dermatol. 2002 Sep;138(9):1165-71 [12224977.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2003 Mar;17(2):167-70 [12705745.001]
  • [Cites] Med Lett Drugs Ther. 2004 Nov 8;46(1195):92 [15534568.001]
  • [Cites] J Am Acad Dermatol. 2000 Jul;43(1 Pt 2):S6-11 [10861101.001]
  • [Cites] Nat Immunol. 2002 Feb;3(2):196-200 [11812998.001]
  • [Cites] J Am Acad Dermatol. 2006 Jun;54(6):1033-8 [16713458.001]
  • [Cites] Br J Dermatol. 1994 Jun;130(6):743-51 [8011500.001]
  • [Cites] Br J Dermatol. 2002 Apr;146 Suppl 61:1-6 [11966724.001]
  • [Cites] Int J Dermatol. 1998 Dec;37(12):881-96 [9888327.001]
  • [Cites] Br J Pharmacol. 1997 Dec;122(7):1502-8 [9421302.001]
  • [Cites] N Engl J Med. 1998 Feb 26;338(9):616-8 [9475772.001]
  • [Cites] J Photochem Photobiol B. 2000 Jan;54(1):72-80 [10739146.001]
  • [Cites] Am J Epidemiol. 1996 Dec 1;144(11):1034-40 [8942434.001]
  • [Cites] J Dermatol. 1993 Aug;20(8):507-13 [8245314.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Aug;19(2):235-42 [2394605.001]
  • [Cites] Br J Dermatol. 2005 May;152(5):939-47 [15888150.001]
  • [Cites] Eur J Dermatol. 2002 Nov-Dec;12(6):558-61 [12459527.001]
  • [Cites] N Engl J Med. 1992 Dec 3;327(23):1649-62 [1435901.001]
  • [Cites] JAMA. 2005 Aug 10;294(6):681-90 [16091570.001]
  • [Cites] Br J Dermatol. 2000 Feb;142(2):338-9 [10730770.001]
  • [Cites] Arch Dermatol Res. 2004 Jun;296(1):6-11 [15083310.001]
  • [Cites] Am J Clin Oncol. 1999 Feb;22(1):32-4 [10025376.001]
  • [Cites] J Control Release. 2000 Apr 3;65(3):359-66 [10699294.001]
  • [Cites] J Dermatolog Treat. 2003;14 Suppl 3:15-22 [14522637.001]
  • [Cites] Int J Cancer. 1998 Nov 23;78(5):587-93 [9808527.001]
  • [Cites] Immunity. 2001 Jun;14(6):661-4 [11420036.001]
  • [Cites] J Am Acad Dermatol. 2002 Sep;47(3):390-8 [12196749.001]
  • [Cites] Int J Cancer. 2006 Aug 1;119(3):682-6 [16496410.001]
  • [Cites] Plast Reconstr Surg. 1988 Dec;82(6):1067-71 [3059383.001]
  • [Cites] Arch Dermatol. 2004 Oct;140(10 ):1284-5 [15492200.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):17-23 [14732655.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 17;85(6):443-56 [8445672.001]
  • [Cites] Arch Dermatol. 1978 May;114(5):739-42 [646395.001]
  • [Cites] Eur J Dermatol. 2005 Sep-Oct;15(5):374-81 [16172048.001]
  • [Cites] Br J Dermatol. 2004 Jul;151(1):141-7 [15270883.001]
  • [Cites] Dermatol Surg. 2000 Apr;26(4):338-40 [10759821.001]
  • [Cites] Curr Med Chem Anticancer Agents. 2004 May;4(3):301-16 [15134506.001]
  • [Cites] Br J Dermatol. 2005 Apr;152(4):765-72 [15840111.001]
  • [Cites] Antiviral Res. 2006 Sep;71(2-3):181-91 [16831473.001]
  • [Cites] J Am Acad Dermatol. 1999 Dec;41(6):1002-7 [10570388.001]
  • [Cites] Arch Dermatol. 1995 Jun;131(6):737-8 [7778936.001]
  • [Cites] Dermatol Surg. 2006 Jan;32(1):63-9 [16393600.001]
  • [Cites] Lancet Oncol. 2004 Aug;5(8):497-508 [15288239.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4289-94 [12154031.001]
  • [Cites] Clin Exp Dermatol. 2002 Oct;27(7):571-7 [12464152.001]
  • [Cites] Carcinogenesis. 1998 May;19(5):723-9 [9635856.001]
  • [Cites] Cancer Res. 1990 Mar 15;50(6):1757-63 [2407343.001]
  • [Cites] N Z Med J. 2005 Oct 07;118(1223):U1682 [16224506.001]
  • [Cites] Arch Dermatol. 1990 Dec;126(12):1660 [2256701.001]
  • [Cites] Dermatol Surg. 2004 Dec;30(12 Pt 1):1462-9 [15606733.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2151-6 [11929837.001]
  • [Cites] Recent Results Cancer Res. 2002;160:246-50 [12079220.001]
  • [Cites] J Immunol. 1996 Jun 15;156(12):4746-56 [8648121.001]
  • [Cites] Br J Dermatol. 2001 Apr;144(4):832-40 [11298545.001]
  • [Cites] Arch Dermatol. 2004 Oct;140(10 ):1286-7 [15492202.001]
  • [Cites] J Invest Dermatol. 2000 Jan;114(1):135-41 [10620129.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4334-42 [10485481.001]
  • [Cites] Arch Dermatol. 1998 Feb;134(2):248-9 [9487227.001]
  • [Cites] J Am Acad Dermatol. 1981 Jun;4(6):633-49 [7016939.001]
  • [Cites] J Photochem Photobiol B. 1990 Jun;6(1-2):143-8 [2121931.001]
  • [Cites] Arch Med Res. 2001 Jul-Aug;32(4):273-6 [11440782.001]
  • [Cites] Arch Dermatol. 1992 Dec;128(12):1597-601 [1456752.001]
  • [Cites] Hepatology. 1997 Sep;26(3 Suppl 1):112S-121S [9305675.001]
  • [Cites] J Dermatol Surg Oncol. 1989 Mar;15(3):315-28 [2646336.001]
  • [Cites] Br J Dermatol. 2000 Dec;143(6):1270-5 [11122032.001]
  • [Cites] J Natl Cancer Inst. 1998 Jun 17;90(12):889-905 [9637138.001]
  • [Cites] Photochem Photobiol. 2000 Jun;71(6):724-9 [10857368.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):3904-9 [9307269.001]
  • [Cites] Dermatol Surg. 2005 Mar;31(3):318-23 [15841634.001]
  • [Cites] Int J Cardiol. 1995 May;49(3):282-3 [7649677.001]
  • [Cites] J Am Acad Dermatol. 1997 Jan;36(1):72-7 [8996264.001]
  • [Cites] Antiviral Res. 1999 Aug;43(1):55-63 [10480263.001]
  • [Cites] J Invest Dermatol. 2004 Oct;123(4):634-8 [15373766.001]
  • [Cites] Br J Dermatol. 1999 Sep;141(3):415-23 [10583044.001]
  • [Cites] Oncogene. 2004 Feb 26;23(8):1608-17 [14647422.001]
  • [Cites] J Am Acad Dermatol. 2000 Mar;42(3):389-413; quiz 414-6 [10688709.001]
  • [Cites] J Photochem Photobiol B. 2001 Apr;60(1):37-43 [11386679.001]
  • [Cites] Lancet. 2004 Nov 13-19;364(9447):1766-72 [15541449.001]
  • [Cites] Arch Dermatol. 2003 Sep;139(9):1173-7 [12975159.001]
  • [Cites] J Am Acad Dermatol. 2005 Sep;53(3):526-7 [16112368.001]
  • [Cites] J Am Acad Dermatol. 1990 Dec;23(6 Pt 1):1167-8 [2273122.001]
  • [Cites] J Natl Cancer Inst. 2003 Aug 6;95(15):1138-49 [12902443.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3249-59 [10955811.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):748-55 [11697321.001]
  • [Cites] J Dermatol Surg Oncol. 1992 Jun;18(6):471-6 [1592998.001]
  • [Cites] J Clin Invest. 1997 Dec 1;100(11):2691-6 [9389732.001]
  • [Cites] Photochem Photobiol. 1992 Jan;55(1):145-57 [1603846.001]
  • [Cites] J Am Acad Dermatol. 1990 Oct;23 (4 Pt 1):694-700 [2229497.001]
  • [Cites] Clin Exp Dermatol. 2006 Jan;31(1):140-1 [16309513.001]
  • [Cites] Br J Dermatol. 2002 Dec;147(6):1227-36 [12452875.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4385-9 [15231643.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23 (34):8835-44 [16314644.001]
  • [Cites] Br J Pharmacol. 2003 Jun;139(4):854-62 [12813009.001]
  • [Cites] Br J Dermatol. 2003 Dec;149(6):1242-9 [14674903.001]
  • [Cites] J Am Acad Dermatol. 1992 Jul;27(1):65-9 [1619079.001]
  • [Cites] Dermatology. 1995;190(3):214-7 [7599384.001]
  • [Cites] Br J Dermatol. 2000 Dec;143(6):1224-9 [11122025.001]
  • [Cites] Br J Dermatol. 2004 Sep;151(3):656-62 [15377354.001]
  • [Cites] Arch Dermatol. 1991 Nov;127(11):1668-72 [1952970.001]
  • [Cites] JAMA. 2005 Jul 6;294(1):47-55 [15998890.001]
  • [Cites] Photochem Photobiol Sci. 2002 Jan;1(1):1-21 [12659143.001]
  • (PMID = 17428108.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; P1QW714R7M / imiquimod
  • [Number-of-references] 167
  •  go-up   go-down


64. Inoue S, Inoue M, Takahashi H, Inoue A, Kunitomo K, Fujii H: [Two advanced/recurrent breast cancer cases effectively treated by trastuzumab/capecitabine combination therapy]. Gan To Kagaku Ryoho; 2008 Feb;35(2):319-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Trastuzumab/capecitabine combination therapy was performed for two advanced/recurrent breast cancer cases with acute deterioration of the disease.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Deoxycytidine / analogs & derivatives. Fluorouracil / analogs & derivatives
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Biomarkers, Tumor / blood. Bone Neoplasms / blood. Bone Neoplasms / drug therapy. Bone Neoplasms / radiography. Bone Neoplasms / secondary. Capecitabine. Female. Humans. Immunotherapy. Liver Neoplasms / blood. Liver Neoplasms / drug therapy. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Middle Aged. Neoplasm Staging. Recurrence. Tomography, X-Ray Computed. Trastuzumab

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18281774.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Biomarkers, Tumor; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; P188ANX8CK / Trastuzumab; U3P01618RT / Fluorouracil
  •  go-up   go-down


65. Chen GS, Yu HS, Lan CC, Chow KC, Lin TY, Kok LF, Lu MP, Liu CH, Wu MT: CXC chemokine receptor CXCR4 expression enhances tumorigenesis and angiogenesis of basal cell carcinoma. Br J Dermatol; 2006 May;154(5):910-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CXC chemokine receptor CXCR4 expression enhances tumorigenesis and angiogenesis of basal cell carcinoma.
  • BACKGROUND: Chemokines and their receptors, well known for their ability to attract leucocytes, also play important roles for tumour progression.
  • OBJECTIVES: To investigate the possible involvement of chemokine receptors in the pathogenesis of cutaneous basal cell carcinoma (BCC).
  • METHODS: We performed an expression analysis of chemokine receptors using a well-characterized human BCC cell line.
  • Upon the finding of CXCR4 expression by BCC, retroviral transduction of BCC cells with the CXCR4 gene was employed to address its functional significance for BCC in vitro and in vivo.
  • RESULTS: We found expression of the CXC chemokine receptor CXCR4 by a human cell line and a subset of tissue samples from BCC, especially in noduloulcerative and sclerosing types.
  • Moreover, xenograft tumour transplants produced by injection of CXCR4-BCC yielded significant tumour progression in nude mice, whereas additional serial injections of CXCR4-blocking peptides resulted in tumour regression.
  • CONCLUSIONS: CXCR4 expression may play a critical role in tumour progression and angiogenesis of certain subtypes of BCC with more aggressive nature, and functional blockade of CXCR4 could be a potential therapeutic strategy for these tumours.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Cell Transformation, Neoplastic / metabolism. Neovascularization, Pathologic / metabolism. Receptors, CXCR4 / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Animals. Apoptosis / radiation effects. Cell Proliferation. Chemokine CXCL12. Chemokines, CXC / physiology. Disease Progression. Female. Humans. Mice. Mice, Nude. Neoplasm Proteins / metabolism. Neoplasm Transplantation. Reverse Transcriptase Polymerase Chain Reaction / methods. Signal Transduction. Transduction, Genetic. Transplantation, Heterologous. Tumor Cells, Cultured. Ultraviolet Rays

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16634895.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CXC; 0 / Cxcl12 protein, mouse; 0 / Neoplasm Proteins; 0 / Receptors, CXCR4
  •  go-up   go-down


66. Nicolae I, Schipor S: PTH-independent hypercalcaemia and non-melanoma skin cancer. J Eur Acad Dermatol Venereol; 2010 Apr;24(4):449-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (1) To evaluate the relationship between tumour aggressiveness and hypercalcaemia in patients with non-melanoma skin cancer;.
  • From the 1232 cases that were investigated, there were 32 patients with keratoachantoma, 468 patients with basal cell carcinoma, 412 patients with squamous cell carcinoma and 320 healthy volunteers.
  • In tumour tissues and intact skin, calcium was assayed by physical methods of analysis: Instrumental Neutron Activation Analysis (INAA), Proton-Induced X-ray Emission (PIXE).
  • In these patients, intact PTH (iPTH) is normal, urinary calcium is decreased, serum albumin is reduced, and calcium concentration in tumour tissue is significantly increased compared to healthy tissue.
  • A possible mechanism is PTHrp hypersecretion by malignant keratinocytes.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Hypercalcemia / epidemiology. Keratoacanthoma / epidemiology. Skin Neoplasms / epidemiology
  • [MeSH-minor] Adult. Calcium / blood. Calcium / urine. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / metabolism. Extracellular Fluid / metabolism. Female. Humans. Male. Middle Aged. Models, Biological. Parathyroid Hormone / metabolism. Prevalence. Romania / epidemiology. Serum Albumin / metabolism. Severity of Illness Index

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19778357.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Parathyroid Hormone; 0 / Serum Albumin; SY7Q814VUP / Calcium
  •  go-up   go-down


67. Faupel-Badger JM, Sherman ME, Garcia-Closas M, Gaudet MM, Falk RT, Andaya A, Pfeiffer RM, Yang XR, Lissowska J, Brinton LA, Peplonska B, Vonderhaar BK, Figueroa JD: Prolactin serum levels and breast cancer: relationships with risk factors and tumour characteristics among pre- and postmenopausal women in a population-based case-control study from Poland. Br J Cancer; 2010 Sep 28;103(7):1097-102
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolactin serum levels and breast cancer: relationships with risk factors and tumour characteristics among pre- and postmenopausal women in a population-based case-control study from Poland.
  • Using data from a population-based breast cancer case-control study conducted in two cities in Poland (2000-2003), we examined the association of PRL levels with breast cancer risk factors among controls and with tumour characteristics among the cases.
  • Mean serum PRL levels by tumour characteristics are reported.
  • Levels were not different by tumour size, grade, node involvement or oestrogen receptor, progesterone receptor, or human epidermal growth factor receptor 2 status.
  • [MeSH-major] Breast Neoplasms / blood. Prolactin / blood

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Causes Control. 2009 Mar;20(2):253-62 [18853263.001]
  • [Cites] Pituitary. 2008;11(2):209-18 [18404390.001]
  • [Cites] Obesity (Silver Spring). 2006 Sep;14(9):1662-77 [17030978.001]
  • [Cites] Endocrinology. 1999 Nov;140(11):5447-50 [10537179.001]
  • [Cites] Clin Endocrinol (Oxf). 1999 Nov;51(5):643-51 [10594527.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 1997 Jan;2(1):29-39 [10887517.001]
  • [Cites] Physiol Rev. 2000 Oct;80(4):1523-631 [11015620.001]
  • [Cites] Proc Nutr Soc. 2001 Feb;60(1):81-9 [11310427.001]
  • [Cites] Br J Cancer. 2002 Oct 7;87(8):876-82 [12373602.001]
  • [Cites] Endocr Rev. 2003 Feb;24(1):1-27 [12588805.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6814-9 [15375001.001]
  • [Cites] Int J Cancer. 1976 Apr 15;17(4):441-7 [945228.001]
  • [Cites] Am J Obstet Gynecol. 1977 May 1;128(1):60-74 [403765.001]
  • [Cites] Fertil Steril. 1978 Aug;30(2):141-5 [98356.001]
  • [Cites] Int J Cancer. 1981 Jul 15;28(1):31-4 [7309279.001]
  • [Cites] N Engl J Med. 1987 Jan 29;316(5):229-34 [3099198.001]
  • [Cites] Eur J Cancer Clin Oncol. 1988 Jul;24(7):1225-31 [3416905.001]
  • [Cites] Med J Aust. 1990 Oct 15;153(8):469-73 [2215338.001]
  • [Cites] Cancer Res. 1995 Jun 15;55(12):2591-5 [7780973.001]
  • [Cites] Cancer Causes Control. 1995 May;6(3):217-24 [7612801.001]
  • [Cites] J Reprod Med. 1995 Aug;40(8):556-60 [7473451.001]
  • [Cites] Gynecol Obstet Invest. 1997;44(2):124-6 [9286727.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 7;91(7):629-34 [10203283.001]
  • [Cites] Endocr Relat Cancer. 1999 Sep;6(3):389-404 [10516853.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2641-7 [16284390.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2476-82 [16489055.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):972-8 [16702379.001]
  • [Cites] Br J Cancer. 2006 Jul 3;95(1):123-9 [16755295.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Oct;10(4):325-35 [16900392.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2494-501 [17164375.001]
  • [Cites] Int J Cancer. 2007 Apr 1;120(7):1536-41 [17211859.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):439-43 [17372238.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1482-8 [17372279.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):895-9 [17507612.001]
  • [Cites] Int J Cancer. 2007 Sep 1;121(5):1079-85 [17487843.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10608-17 [17968031.001]
  • [Cites] Mol Cell Endocrinol. 2008 Jan 16;281(1-2):9-18 [18022314.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):43-50 [18199710.001]
  • [Cites] Breast Cancer Res Treat. 2008 Mar;108(1):57-67 [17468953.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2008 Mar;13(1):41-53 [18246319.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1880-3 [18708375.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):938-46 [20332276.001]
  • (PMID = 20736944.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Chemical-registry-number] 9002-62-4 / Prolactin
  • [Other-IDs] NLM/ PMC2965860
  •  go-up   go-down


68. Hashimoto K, Yonemori K, Katsumata N, Hotchi M, Kouno T, Shimizu C, Tamura K, Ando M, Takeuchi M, Fujiwara Y: Factors that affect the duration of the interval between the completion of palliative chemotherapy and death. Oncologist; 2009 Jul;14(7):752-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Neoplasms / drug therapy. Palliative Care / methods

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19596665.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Dünnebier T, Bermejo JL, Haas S, Fischer HP, Pierl CB, Justenhoven C, Brauch H, Baisch C, Gilbert M, Harth V, Spickenheuer A, Rabstein S, Pesch B, Brüning T, Ko YD, Hamann U: Common variants in the UBC9 gene encoding the SUMO-conjugating enzyme are associated with breast tumor grade. Int J Cancer; 2009 Aug 1;125(3):596-602
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Common variants in the UBC9 gene encoding the SUMO-conjugating enzyme are associated with breast tumor grade.
  • Genetic variability may affect expression and activity of UBC9 and may have an impact on breast tumor progression.
  • Model selection identified a recessive penetrance model for rs7187167 as the best representation of tumor grade (global p = 0.001).
  • Imputation of SNPs in a 300 kb region around the genotyped SNPs supported rs7187167 as a major contributor to tumor grade.
  • In addition to tumor size, nodal status and estrogen receptor status, multivariate analyses confirmed an independent role of rs7187167 as predictor of tumor grade (p = 0.0003).
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. Polymorphism, Single Nucleotide. SUMO-1 Protein / metabolism. Ubiquitin-Conjugating Enzymes / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19358266.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / SUMO-1 Protein; EC 6.3.2.19 / Ubiquitin-Conjugating Enzymes; EC 6.3.2.19 / ubiquitin-conjugating enzyme UBC9
  •  go-up   go-down


70. Lavie O, Barnett-Griness O, Narod SA, Rennert G: The risk of developing uterine sarcoma after tamoxifen use. Int J Gynecol Cancer; 2008 Mar-Apr;18(2):352-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Sarcoma / chemically induced. Tamoxifen / adverse effects. Uterine Neoplasms / chemically induced
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / drug therapy. Endometrial Neoplasms / chemically induced. Female. Humans. Incidence. Middle Aged. Registries. Risk Factors


71. Suzuki T, Matsuo K, Hirose K, Hiraki A, Kawase T, Watanabe M, Yamashita T, Iwata H, Tajima K: One-carbon metabolism-related gene polymorphisms and risk of breast cancer. Carcinogenesis; 2008 Feb;29(2):356-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Genetic Predisposition to Disease. Polymorphism, Genetic

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18174236.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 935E97BOY8 / Folic Acid; EC 1.18.1.- / methionine synthase reductase; EC 1.18.1.2 / Ferredoxin-NADP Reductase; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); EC 2.1.1.13 / 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase; EC 2.1.1.45 / Thymidylate Synthase
  •  go-up   go-down


72. Fair AM, Dai Q, Shu XO, Matthews CE, Yu H, Jin F, Gao YT, Zheng W: Energy balance, insulin resistance biomarkers, and breast cancer risk. Cancer Detect Prev; 2007;31(3):214-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Additional analyses were performed to evaluate whether the association of energy balance measures with breast cancer risk changed after adjustment for IGFs, IGFBP-3, and C-peptide biomarkers.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1997;76(12):1652-4 [9413957.001]
  • [Cites] Eur J Clin Nutr. 2004 Jan;58(1):17-23 [14679362.001]
  • [Cites] Mech Ageing Dev. 1999 Jun 1;109(1):21-34 [10405986.001]
  • [Cites] Clin Chem. 1999 Aug;45(8 Pt 2):1384-90 [10430822.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1496-501 [15941962.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2881-8 [16365005.001]
  • [Cites] J Womens Health Gend Based Med. 1999 Dec;8(10):1265-72 [10643834.001]
  • [Cites] Cancer. 2004 Feb 15;100(4):694-700 [14770423.001]
  • [Cites] Br J Cancer. 1992 Mar;65(3):311-20 [1313689.001]
  • [Cites] Br J Cancer. 1995 Nov;72(5):1065-6 [7577447.001]
  • [Cites] Int J Biochem Cell Biol. 1996 Jun;28(6):619-37 [8673727.001]
  • [Cites] Science. 1997 Jul 25;277(5325):531-2 [9254422.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1472-89 [10995803.001]
  • [Cites] BMJ. 2000 Oct 7;321(7265):847-8 [11021847.001]
  • [Cites] Br J Cancer. 2001 Apr 6;84(7):994-1001 [11286483.001]
  • [Cites] Endocr Relat Cancer. 2001 Sep;8(3):197-209 [11566611.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Nov;10(11):1207-11 [11700270.001]
  • [Cites] Int J Cancer. 2001 Nov 1;94(3):449-55 [11745429.001]
  • [Cites] Cancer Causes Control. 2001 Dec;12(10):951-8 [11808715.001]
  • [Cites] Lancet Oncol. 2002 May;3(5):298-302 [12067807.001]
  • [Cites] Semin Oncol. 2002 Jun;29(3 Suppl 11):86-95 [12138402.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):705-12 [12163322.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Sep;11(9):862-7 [12223430.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jan;88(1):337-46 [12519874.001]
  • [Cites] Cancer Causes Control. 2003 Feb;14(1):65-74 [12708727.001]
  • [Cites] Exerc Sport Sci Rev. 2003 Jul;31(3):144-8 [12882481.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):1067-73 [14578144.001]
  • [Cites] Med Sci Sports Exerc. 2003 Nov;35(11):1834-40 [14600547.001]
  • [Cites] Am J Epidemiol. 2003 Dec 1;158(11):1114-22 [14630608.001]
  • [Cites] Int J Cancer. 1998 Dec 18;79(6):624-8 [9842972.001]
  • (PMID = 17646056.001).
  • [ISSN] 0361-090X
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P20RR011792; United States / NCRR NIH HHS / RR / P20 RR011792; United States / NCI NIH HHS / CA / R01 CA064277; United States / NIMHD NIH HHS / MD / P20 MD000516; United States / NCI NIH HHS / CA / R01-CA64277; United States / NCI NIH HHS / CA / R01 CA064277-04; United States / NCI NIH HHS / CA / CA064277-04; United States / NIMHD NIH HHS / MD / 5 P20 MD000516-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / C-Peptide; 0 / Insulin-Like Growth Factor Binding Protein 3; 67763-96-6 / Insulin-Like Growth Factor I; 67763-97-7 / Insulin-Like Growth Factor II
  • [Other-IDs] NLM/ NIHMS29979; NLM/ PMC1994998
  •  go-up   go-down


73. Justenhoven C, Hamann U, Schubert F, Zapatka M, Pierl CB, Rabstein S, Selinski S, Mueller T, Ickstadt K, Gilbert M, Ko YD, Baisch C, Pesch B, Harth V, Bolt HM, Vollmert C, Illig T, Eils R, Dippon J, Brauch H: Breast cancer: a candidate gene approach across the estrogen metabolic pathway. Breast Cancer Res Treat; 2008 Mar;108(1):137-49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Biomarkers, Tumor / genetics. Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Estrogens / metabolism. Genetic Predisposition to Disease


74. Zhu Y, Brown HN, Zhang Y, Holford TR, Zheng T: Genotypes and haplotypes of the methyl-CpG-binding domain 2 modify breast cancer risk dependent upon menopausal status. Breast Cancer Res; 2005;7(5):R745-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genotypes and haplotypes of the methyl-CpG-binding domain 2 modify breast cancer risk dependent upon menopausal status.
  • INTRODUCTION: MBD2, the gene encoding methyl-CpG-binding domain (MBD)2, is a major methylation related gene and functions as a transcriptional repressor that can specifically bind to the methylated regions of other genes.
  • MBD2 may also mediate gene activation because of its potential DNA demethylase activity.
  • The present case-control study investigated associations between two single nucleotide polymorphisms (SNPs) in the MBD2 gene and breast cancer risk.
  • METHODS: DNA samples from 393 Caucasian patients with breast cancer (cases) and 436 matched control individuals, collected in a recently completed breast cancer case-control study conducted in Connecticut, were included in the study.
  • Because no coding SNPs were found in the MBD2 gene, one SNP in the noncoding exon (rs1259938) and another in the intron 3 (rs609791) were genotyped.
  • Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to estimate cancer risk associated with the variant genotypes and the reconstructed haplotypes.
  • RESULTS: The variant genotypes at both SNP loci were significantly associated with reduced risk among premenopausal women (OR = 0.41 for rs1259938; OR = 0.54 for rs609791).
  • Further haplotype analyses showed that the two rare haplotypes (A-C and A-G) were significantly associated with reduced breast cancer risk (OR = 0.40, 95% CI = 0.20-0.83 for A-C; OR = 0.47, 95% CI = 0.26-0.84 for A-G) in premenopausal women.
  • No significant associations were detected in the postmenopausal women and the whole population.
  • CONCLUSION: Our results demonstrate a role for the MBD2 gene in breast carcinogenesis in premenopausal women.
  • These findings suggest that genetic variations in methylation related genes may potentially serve as a biomarker in risk estimates for breast cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Menopause.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Clin North Am. 2003 Aug;83(4):803-19 [12875597.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Mar 21;302(4):759-66 [12646234.001]
  • [Cites] Cancer Res. 1988 Jan 15;48(2):246-53 [2825969.001]
  • [Cites] Cell. 1990 Aug 10;62(3):503-14 [1974172.001]
  • [Cites] Cancer Causes Control. 1992 Jul;3(4):313-22 [1617118.001]
  • [Cites] EXS. 1993;64:425-51 [8380354.001]
  • [Cites] Cancer Res. 1994 May 15;54(10):2552-5 [8168078.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6374-82 [7987831.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4525-30 [7553621.001]
  • [Cites] Ann N Y Acad Sci. 1995 Sep 30;768:91-100 [8526389.001]
  • [Cites] J Mol Biol. 1997 Mar 28;267(2):276-88 [9096225.001]
  • [Cites] Nat Genet. 1997 Jul;16(3):256-9 [9207790.001]
  • [Cites] Cancer Res. 1997 Aug 15;57(16):3347-50 [9269993.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2107-10 [9605753.001]
  • [Cites] Nature. 1998 May 28;393(6683):386-9 [9620804.001]
  • [Cites] EMBO J. 1998 Sep 1;17(17):4905-8 [9724627.001]
  • [Cites] Mol Cell Biol. 1998 Nov;18(11):6538-47 [9774669.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4515-8 [9788592.001]
  • [Cites] Br J Cancer. 1999 Jan;79(2):251-6 [9888465.001]
  • [Cites] Nature. 1999 Feb 18;397(6720):579-83 [10050851.001]
  • [Cites] Mamm Genome. 1999 Sep;10(9):906-12 [10441743.001]
  • [Cites] Nat Genet. 1999 Sep;23(1):58-61 [10471499.001]
  • [Cites] Nat Genet. 1999 Sep;23(1):62-6 [10471500.001]
  • [Cites] Ann N Y Acad Sci. 2003 Mar;983:213-9 [12724226.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Nov 2;264(3):962-6 [10544038.001]
  • [Cites] Trends Genet. 2000 Jan;16(1):20 [10647297.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Feb;9(2):167-74 [10698477.001]
  • [Cites] J Natl Cancer Inst. 2000 May 17;92(10):826-32 [10814678.001]
  • [Cites] FASEB J. 2000 Aug;14(11):1585-94 [10928993.001]
  • [Cites] Am J Hum Genet. 2001 Apr;68(4):978-89 [11254454.001]
  • [Cites] Gene. 2001 Oct 3;276(1-2):73-81 [11591473.001]
  • [Cites] Bioessays. 2001 Dec;23(12):1131-7 [11746232.001]
  • [Cites] Oncol Rep. 2002 Mar-Apr;9(2):393-5 [11836615.001]
  • [Cites] Mol Carcinog. 2002 Mar;33(3):163-71 [11870882.001]
  • [Cites] Oncogene. 2002 Apr 18;21(17):2704-12 [11965543.001]
  • [Cites] Oncogene. 2002 Oct 10;21(46):7034-41 [12370825.001]
  • [Cites] Cancer Res. 2003 Jan 15;63(2):498-504 [12543808.001]
  • [Cites] Cancer. 2004 May 1;100(9):1853-8 [15112265.001]
  • (PMID = 16168120.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA081810; United States / NCI NIH HHS / CA / CA62986; United States / NCI NIH HHS / CA / CA108369; United States / NCI NIH HHS / CA / R03 CA110937; United States / NCI NIH HHS / CA / CA81810; United States / NCI NIH HHS / CA / CA110937; United States / NCI NIH HHS / CA / R03 CA108369
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / MBD2 protein, human
  • [Other-IDs] NLM/ PMC1242141
  •  go-up   go-down


75. Zanetti-Dällenbach R, Wight E: [Chemotherapy for gynecological malignancies--a contraindication during pregnancy?]. Ther Umsch; 2005 Jan;62(1):53-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Chemotherapie bei gynäkologischen Tumoren--kontraindiziert in der Schwangerschaft?
  • Even though a malignant tumor during pregnancy is very rare it occurs in 0.02-0.1%.
  • The coincidence of malignant disease with pregnancy leads to an enormous emotional burden to the patient, the couple and the medical staff.
  • Surgery for malignant tumors during pregnancy seems to be save.
  • The most frequent malignant disorders during pregnancy are cervical cancer, breast cancer, melanoma and Hodgkin lymphoma.
  • [MeSH-major] Abnormalities, Drug-Induced / etiology. Abnormalities, Drug-Induced / prevention & control. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / contraindications. Genital Neoplasms, Female / drug therapy. Pregnancy Complications, Neoplastic / drug therapy. Risk Assessment / methods

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Pregnancy and Medicines.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15702707.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 46
  •  go-up   go-down


76. Lear W, Mittmann N, Barnes E, Breen D, Murray C: Cost comparisons of managing complex facial basal cell carcinoma: Canadian study. J Cutan Med Surg; 2008 Mar-Apr;12(2):82-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost comparisons of managing complex facial basal cell carcinoma: Canadian study.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common human malignancy and accounts for over 60,000 new cases of cancer in Canada annually.
  • All were located on the head and neck and were either recurrent disease or located in "at risk" sites such as the eye, ear, lip, or nose.
  • Although we did notice a trend toward greater costs in patients with recurrent disease, in males, younger patients, and tumors present for > 1 year, these did not reach significance within our sample size.
  • [MeSH-major] Carcinoma, Basal Cell / economics. Cost of Illness. Facial Neoplasms / economics. Mohs Surgery / economics. Skin Neoplasms / economics
  • [MeSH-minor] Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / economics. Ontario. Radiotherapy / economics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18346405.001).
  • [ISSN] 1203-4754
  • [Journal-full-title] Journal of cutaneous medicine and surgery
  • [ISO-abbreviation] J Cutan Med Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Gudbjartsson DF, Sulem P, Stacey SN, Goldstein AM, Rafnar T, Sigurgeirsson B, Benediktsdottir KR, Thorisdottir K, Ragnarsson R, Sveinsdottir SG, Magnusson V, Lindblom A, Kostulas K, Botella-Estrada R, Soriano V, Juberías P, Grasa M, Saez B, Andres R, Scherer D, Rudnai P, Gurzau E, Koppova K, Kiemeney LA, Jakobsdottir M, Steinberg S, Helgason A, Gretarsdottir S, Tucker MA, Mayordomo JI, Nagore E, Kumar R, Hansson J, Olafsson JH, Gulcher J, Kong A, Thorsteinsdottir U, Stefansson K: ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. Nat Genet; 2008 Jul;40(7):886-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma.
  • Fair color increases risk of cutaneous melanoma (CM) and basal cell carcinoma (BCC).
  • [MeSH-major] Agouti Signaling Protein / genetics. Carcinoma, Basal Cell / genetics. Melanoma / genetics. Monophenol Monooxygenase / genetics. Pigmentation / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Case-Control Studies. Europe. Eye Color / genetics. Gene Frequency. Genetic Predisposition to Disease. Humans. Membrane Glycoproteins / genetics. Middle Aged. Neoplasm Metastasis. Odds Ratio. Oxidoreductases / genetics. Polymorphism, Single Nucleotide. Receptor, Melanocortin, Type 1 / genetics. Registries


78. Birch-Johansen F, Jensen A, Mortensen L, Olesen AB, Kjær SK: Trends in the incidence of nonmelanoma skin cancer in Denmark 1978-2007: Rapid incidence increase among young Danish women. Int J Cancer; 2010 Nov 1;127(9):2190-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data for basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) were obtained from the Danish Cancer Registry and the Danish Registry of Pathology.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20473901.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


79. Häfner HM, Bräuer K, Radke C, Eichner M, Strölin A: Wavelet analysis of Laser Doppler Flux time series of tumor and inflammatory associated neoangiogenesis. Differences in rhythmical behavior. Clin Hemorheol Microcirc; 2009;43(3):191-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wavelet analysis of Laser Doppler Flux time series of tumor and inflammatory associated neoangiogenesis. Differences in rhythmical behavior.
  • We use continuous wavelet analysis (WA) of Laser Doppler Flux (LDF) time series measured in basal cell carcinomas (BCC) and plaque psoriasis (PP) in order to investigate the rhythmical behavior of blood flow in tumor or inflammatory associated neoangiogenesis.A total of 68 patients with primary BCCs and 40 patients with PP were included in the study.
  • These increases were not found in PP.Rhythmical behavior of blood flow in malignant tumors is totally different from that in regions with inflammation.
  • WA of tumor perfusion could open a new noninvasive monitor system for controlling tumor therapy.
  • [MeSH-major] Microcirculation / physiology. Neoplasms, Basal Cell / blood supply. Psoriasis / physiopathology. Regional Blood Flow / physiology. Skin / blood supply. Skin Neoplasms / blood supply

  • MedlinePlus Health Information. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19847053.001).
  • [ISSN] 1875-8622
  • [Journal-full-title] Clinical hemorheology and microcirculation
  • [ISO-abbreviation] Clin. Hemorheol. Microcirc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


80. Boondaeng A, Ishida Y, Tamura T, Tokuyama S, Kitpreechavanich V: Microbispora siamensis sp. nov., a thermotolerant actinomycete isolated from soil. Int J Syst Evol Microbiol; 2009 Dec;59(Pt 12):3136-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microbispora siamensis sp. nov., a thermotolerant actinomycete isolated from soil.
  • An actinomycete, strain DMKUA 245(T), isolated from soil, was investigated using a polyphasic approach.
  • The isolate formed longitudinally paired spores on the tips of short sporophores that branched alternately from aerial hyphae.
  • The morphological and chemotaxonomic properties clearly demonstrated that the new isolate belonged to the genus Microbispora.
  • 16S rRNA gene sequence analysis supported the assignment of the novel strain to the genus Microbispora.
  • The gene sequence similarity values between the novel strain and the closely related species Microbispora corallina, Microbispora rosea subsp. rosea, Microbispora rosea subsp. aerata and Microbispora amethystogenes were 98.4 %, 97.4 %, 97.0 % and 96.9 %, respectively.
  • The DNA-DNA hybridization values and some physiological and biochemical properties indicated that strain DMKUA 245(T) could be distinguished from its phylogenetically closest relatives.
  • Based on these genotypic and phenotypic data, strain DMKUA 245(T) represents a novel species in the genus Microbispora for which the name Microbispora siamensis sp. nov. is proposed.
  • The type strain is strain DMKUA 245(T) (=BCC 14407(T)=NBRC 104113(T)).
  • In addition, DNA-DNA relatedness values in reciprocal hybridization experiments showed that M. amethystogenes was a separate genomic species from M. rosea subsp. rosea.
  • A combination of genotypic and phenotypic data supported the classification of M. amethystogenes as a separate species.
  • [MeSH-major] Actinomycetales / classification. Actinomycetales / isolation & purification. Soil Microbiology
  • [MeSH-minor] DNA, Bacterial / genetics. DNA, Ribosomal / genetics. Hot Temperature. Molecular Sequence Data. Phylogeny. RNA, Ribosomal, 16S / genetics

  • SILVA. SILVA SSU Database .
  • StrainInfo. culture/stock collections - online strain list (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19643881.001).
  • [ISSN] 1466-5026
  • [Journal-full-title] International journal of systematic and evolutionary microbiology
  • [ISO-abbreviation] Int. J. Syst. Evol. Microbiol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ FJ199993
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Bacterial; 0 / DNA, Ribosomal; 0 / RNA, Ribosomal, 16S
  •  go-up   go-down


81. Yoon J, Jung SY, Ahn B, Heo K, Jin S, Iyoda T, Yoshida H, Ree M: Order-order and order-disorder transitions in thin films of an amphiphilic liquid crystalline diblock copolymer. J Phys Chem B; 2008 Jul 24;112(29):8486-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Order-order and order-disorder transitions in thin films of an amphiphilic liquid crystalline diblock copolymer.
  • In this study, we quantitatively investigated the temperature-dependent phase transition behaviors of thin films of an interesting amphiphilic diblock copolymer, poly(ethylene oxide)-b-poly(11-[4-(4-butylphenylazo)phenoxy]undecyl methacrylate) (p(EO)-b-p(MAAZ)) and the resulting morphological structures by using synchrotron grazing incidence X-ray scattering (GIXS) and differential scanning calorimetry.
  • The quantitative GIXS analysis showed that the diblock copolymer in the homogeneous, isotropic melt state undergoes phase-separation near 190 degrees C and then forms a body-centered cubic (BCC) structure of spherical p(EO) domains in the p(MAAZ) matrix, at which point the p(EO) domains and the p(MAAZ) matrix are both in amorphous, liquid states.
  • The BCC structure of spherical p(EO) domains is converted to a hexagonal cylinder structure near 120 degrees C, which is induced by the transformation of the isotropic phase of the p(MAAZ) matrix to the smectic A phase, which is composed of a laterally ordered structure of p(MAAZ) blocks with fully extended side groups.
  • The resulting hexagonal cylinder structure is very stable below 120 degrees C.
  • This microscopic hexagonal cylinder structure is retained as the smectic A phase of the p(MAAZ) matrix undergoes further transitions to smectic C near 104 degrees C and to a smectic X phase near 76 degrees C, while the amorphous, liquid phase of the p(EO) cylinders undergoes crystallization near -15 degrees C.
  • These complicated temperature-dependent disorder-order and order-order phase transitions in the films were found to take place reversibly during the heating run.
  • A face-centered orthorhombic structure of p(EO) domains was also found during the heating run and is an intermediate structure in the hexagonal cylinder structure to BCC structure transformation.
  • We use these structural analysis results to propose molecular structure models at various temperatures for thin films of the diblock polymer.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18588338.001).
  • [ISSN] 1520-6106
  • [Journal-full-title] The journal of physical chemistry. B
  • [ISO-abbreviation] J Phys Chem B
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Jiang J, He QQ, Yang XH, Liang Y, Fan LJ, Zhang Y, Guo MQ: Contribution of minute axillary lymph nodes to accurate staging for patients with breast cancer. Chin Med J (Engl); 2007 Oct 20;120(20):1762-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Axillary lymph node metastasis is a very important metastatic pathway in breast cancer and its accurate detection is important for staging tumour and guiding therapy.
  • [MeSH-major] Breast Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Axilla. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18028767.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


83. Dinger JC, Heinemann LA, Möhner S, Thai do M, Assmann A: Breast cancer risk associated with different HRT formulations: a register-based case-control study. BMC Womens Health; 2006;6:13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A case-control study was performed within Germany in collaboration with regional cancer registries and tumor centers.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2003 Jun 25;289(24):3254-63 [12824206.001]
  • [Cites] Contraception. 1997 Dec;56(6):373-8 [9494771.001]
  • [Cites] Maturitas. 1999 Nov;33 Suppl 1:S65-72 [10661617.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 16;92(4):328-32 [10675382.001]
  • [Cites] JAMA. 2000 Oct 11;284(14):1837-8 [11025837.001]
  • [Cites] J Epidemiol Community Health. 2000 Nov;54(11):851-8 [11027200.001]
  • [Cites] JAMA. 2002 Jul 17;288(3):321-33 [12117397.001]
  • [Cites] MedGenMed. 2002 Aug 30;4(3):3 [12466746.001]
  • [Cites] Cancer. 2003 Mar 15;97(6):1387-92 [12627501.001]
  • [Cites] Lancet. 2003 Aug 9;362(9382):419-27 [12927427.001]
  • [Cites] Ann Intern Med. 1992 Dec 15;117(12):1016-37 [1443971.001]
  • [Cites] Int J Cancer. 2004 May 1;109(5):721-7 [14999781.001]
  • [Cites] Climacteric. 2003 Dec;6(4):302-10; discussion 310-3 [15006251.001]
  • [Cites] JAMA. 2004 Apr 14;291(14):1701-12 [15082697.001]
  • [Cites] Hum Reprod Update. 2004 Jul-Aug;10(4):281-93 [15192054.001]
  • [Cites] Int J Cancer. 2005 Apr 10;114(3):448-54 [15551359.001]
  • [Cites] Hum Reprod. 2005 Aug;20(8):2052-60 [15932918.001]
  • [Cites] Am J Epidemiol. 2005 Jul 1;162(1):1-2 [15961580.001]
  • [Cites] Cancer Causes Control. 1992 Jul;3(4):355-60 [1617123.001]
  • [Cites] Prev Med. 1991 Jan;20(1):47-63 [1826173.001]
  • [Cites] Am J Epidemiol. 1993 Nov 1;138(9):697-703 [8237985.001]
  • [Cites] Cancer Causes Control. 1995 Sep;6(5):416-24 [8547539.001]
  • [Cites] Maturitas. 1996 May;23 Suppl:S37-45 [8865138.001]
  • [Cites] Ann Intern Med. 1997 Dec 1;127(11):973-80 [9412302.001]
  • [Cites] Lancet. 1997 Oct 11;350(9084):1047-59 [10213546.001]
  • (PMID = 16965641.001).
  • [ISSN] 1472-6874
  • [Journal-full-title] BMC women's health
  • [ISO-abbreviation] BMC Womens Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1574290
  •  go-up   go-down


84. Hansen C, Wilkinson D, Hansen M, Soyer HP: Factors contributing to incomplete excision of nonmelanoma skin cancer by Australian general practitioners. Arch Dermatol; 2009 Nov;145(11):1253-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To study rates of incomplete excision of basal (BCC) and squamous (SCC) cell cancer by Australian general practitioners with a special interest.
  • MAIN OUTCOME MEASURES: Rates of incomplete excision according to physician, clinic, anatomic location of the lesion, and whether a previous biopsy had been performed.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Clinical Competence. Dermatology / methods. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19917954.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Du J, Sun X, Meng D, Zhang P, Jiang G: Geometrical and electronic structures of small W(n) (n = 2-16) clusters. J Chem Phys; 2009 Jul 28;131(4):044313
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Geometrical and electronic structures of small W(n) (n = 2-16) clusters.
  • The geometrical and electronic structures of W(n) (n=2-16) clusters are investigated within the framework of a gradient-corrected density functional theory.
  • The close-packed configurations are preferred for small tungsten clusters up to n=16.
  • The most energetic favorable structures of W(14), W(15), and W(16) clusters, exhibiting similar electronic band structures, are all formed based on body centered cubic (bcc) unit.
  • The clusters with size of n=8, 12, and 15 are found to be more stable with respect to their respective neighbors.
  • The analyses of atomic orbit projected density of states and highest occupied molecular orbital, lowest unoccupied molecular orbital isosurfaces indicate that 5d electrons play a dominant role in the chemical activities of tungsten clusters.
  • The clearly s-d hybridizations are primary presented in bonding W atoms of smaller clusters, as the cluster sizes increase, the 6p orbitals are gradually involved in chemical bonding.
  • Our calculated vertical ionization potentials (VIPs) indicate that the W(8) and W(12) clusters correspond to the high VIPs.
  • The vertical electron affinities are slightly underestimated in our investigation, but follow the trends of experimental data in principle.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19655873.001).
  • [ISSN] 1089-7690
  • [Journal-full-title] The Journal of chemical physics
  • [ISO-abbreviation] J Chem Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. dos Santos VM, Cintra Osterne EM, de Castro RA, Marques HV Jr: Bilateral male breast cancer: too many concerns? Asian Pac J Cancer Prev; 2007 Oct-Dec;8(4):640-1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Breast Neoplasms, Male / chemically induced. Estrogens / adverse effects. Prostatic Neoplasms / drug therapy


87. Linos E, Spanos D, Rosner BA, Linos K, Hesketh T, Qu JD, Gao YT, Zheng W, Colditz GA: Effects of reproductive and demographic changes on breast cancer incidence in China: a modeling analysis. J Natl Cancer Inst; 2008 Oct 1;100(19):1352-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although some risk factors associated with economic development are largely unavoidable, the substantial predicted increase in new cases of breast cancer calls for urgent incorporation of this disease in future health care infrastructure planning.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Causes Control. 1990 Jul;1(1):51-8 [2102277.001]
  • [Cites] Int J Cancer. 2000 Jul 15;87(2):295-300 [10861490.001]
  • [Cites] Am J Epidemiol. 2000 Nov 15;152(10):950-64 [11092437.001]
  • [Cites] Int J Cancer. 2001 Nov 1;94(3):449-55 [11745429.001]
  • [Cites] Lancet. 2002 Mar 16;359(9310):909-19 [11918907.001]
  • [Cites] Int J Cancer. 2002 Jun 10;99(5):747-50 [12115511.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Sep;11(9):795-800 [12223421.001]
  • [Cites] Br J Cancer. 2002 Oct 21;87(9):982-8 [12434289.001]
  • [Cites] J Clin Epidemiol. 2003 Sep;56(9):856-61 [14505770.001]
  • [Cites] Int J Cancer. 2004 Mar 1;108(6):901-6 [14712495.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5508-17 [15328190.001]
  • [Cites] Am J Epidemiol. 1992 Jan 15;135(2):153-68 [1536132.001]
  • [Cites] Epidemiol Rev. 1993;15(1):110-32 [8405195.001]
  • [Cites] J Am Med Womens Assoc. 1995 Mar-Apr;50(2):40-4 [7722205.001]
  • [Cites] J Natl Cancer Inst. 1996 Mar 20;88(6):359-64 [8609645.001]
  • [Cites] Int J Epidemiol. 1996 Feb;25(1):40-5 [8666502.001]
  • [Cites] Cancer. 1997 Aug 15;80(4):725-31 [9264356.001]
  • [Cites] JAMA. 1997 Nov 5;278(17):1407-11 [9355998.001]
  • [Cites] Int J Cancer. 2005 Jan 10;113(2):302-6 [15386413.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):243-50 [15668501.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1986-90 [16103449.001]
  • [Cites] N Engl J Med. 2005 Sep 15;353(11):1124-34 [16162883.001]
  • [Cites] N Engl J Med. 2005 Sep 15;353(11):1171-6 [16162890.001]
  • [Cites] Maturitas. 2005 Nov-Dec;52(3-4):277-85 [15950409.001]
  • [Cites] Lancet. 2005 Nov 19;366(9499):1821-4 [16298221.001]
  • [Cites] Am J Epidemiol. 2005 Dec 1;162(11):1123-31 [16236996.001]
  • [Cites] BMJ. 2006 Aug 19;333(7564):371-3 [16690642.001]
  • [Cites] BMJ. 2006 Aug 19;333(7564):362-3 [16916811.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1849-55 [17035391.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):e49-50 [17114650.001]
  • [Cites] Int J Obes (Lond). 2007 Feb;31(2):272-8 [16788569.001]
  • [Cites] J Clin Oncol. 2007 Feb 20;25(6):617-24 [17308266.001]
  • [Cites] N Engl J Med. 2007 Apr 19;356(16):1670-4 [17442911.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jul;16(7):1443-8 [17623805.001]
  • [Cites] Int J Cancer. 2007 Oct 1;121(7):1556-63 [17437268.001]
  • [Cites] Cancer. 2007 Aug 15;110(4):885-95 [17607668.001]
  • [Cites] Breast Cancer Res. 2008;10(4):R55 [18598349.001]
  • [CommentIn] J Natl Cancer Inst. 2008 Oct 1;100(19):1339-41 [18812546.001]
  • (PMID = 18812552.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA087969; United States / NCI NIH HHS / CA / R25 CA098566.
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2556703
  •  go-up   go-down


88. Loncaster JA, Moore JV, Allan D, Allan E: An ultrasound analysis of the response of Gorlin syndrome-related and sporadic basal cell carcinomas to aminolaevulinic acid photodynamic therapy. Photodiagnosis Photodyn Ther; 2005 Jun;2(2):149-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An ultrasound analysis of the response of Gorlin syndrome-related and sporadic basal cell carcinomas to aminolaevulinic acid photodynamic therapy.
  • BACKGROUND: Gorlin Syndrome (naevoid basal cell carcinoma syndrome, NBCCS) predisposes the patient to the development of basal cell carcinomas (BCCs) throughout their life.
  • This study evaluates PDT as a treatment modality for Gorlin Syndrome and compares the treatment response of Gorlin-related basal cell carcinomas with that of the sporadic lesions.
  • METHODS: In this un-randomized study, basal cell carcinomas in 25 Gorlin syndrome patients (with 36 lesions) and 145 sporadic patients (with 189 lesions) were treated by photodynamic therapy, using δ-5-aminolaevulinic acid (ALA) as a photosensitizer and 100Jcm(-2) of red light (630±15nm).
  • Those BCC less than 1.5mm thick prior to treatment were significantly more likely to have no US evidence of disease at 4-6 weeks than and were more likely to be controlled at 12 months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25048674.001).
  • [ISSN] 1572-1000
  • [Journal-full-title] Photodiagnosis and photodynamic therapy
  • [ISO-abbreviation] Photodiagnosis Photodyn Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


89. Kurta RP, Bugaev VN, Stierle A, Dosch H: Incommensurate strain-induced ordering of interstitial oxygen in Nb. J Phys Condens Matter; 2008 Jul 9;20(27):275206
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incommensurate strain-induced ordering of interstitial oxygen in Nb.
  • We present a semi-phenomenological theory of the strain-induced interaction between interstitial oxygen dissolved in Nb and predict an incommensurate oxygen ordering wave which is mediated by the intrinsic bcc instability at k = 2/3(111).
  • We discuss the stability range of this ordering phenomenon, which may play a role in the performance of Nb radio frequency (RF) cavities for high energy particle accelerators.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21694368.001).
  • [ISSN] 0953-8984
  • [Journal-full-title] Journal of physics. Condensed matter : an Institute of Physics journal
  • [ISO-abbreviation] J Phys Condens Matter
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


90. Wilkening S, Hemminki K, Rudnai P, Gurzau E, Koppova K, Kumar R, Försti A: Case-control study in basal cell carcinoma of the skin: single nucleotide polymorphisms in three interleukin promoters pre-analysed in pooled DNA. Br J Dermatol; 2006 Dec;155(6):1139-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case-control study in basal cell carcinoma of the skin: single nucleotide polymorphisms in three interleukin promoters pre-analysed in pooled DNA.
  • BACKGROUND: Basal cell carcinoma (BCC) is one of the most common neoplasms in the world.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Polymorphism, Single Nucleotide. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17107380.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interleukin-1beta; 0 / Interleukin-6; 130068-27-8 / Interleukin-10
  •  go-up   go-down


91. Luo HY, Yu SF, Li TJ: Differential expression of apoptosis-related proteins in various cellular components of ameloblastomas. Int J Oral Maxillofac Surg; 2006 Aug;35(8):750-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The staining intensity of the antigens in the 4 types of tumour cellular component, peripheral basal cells of tumour nests, central stellate reticulum-like cells, and foci of squamous and granular cells, was scored using a semi-quantitative scale, and comparisons were made by statistical analysis.
  • Expression of Fas, FasL and caspase-3 was detected in the majority of cases, with a similar pattern of strong staining in the foci of squamous metaplasia and granular cells usually situated in the central area of tumour islands.
  • In contrast, expression of Bcl-2 was predominantly seen in the peripheral basal cell layer.
  • There were significant differences in the staining intensity of Fas, caspase-3 and Bcl-2 among the 4 types of tumour cell.
  • The differential expression of apoptosis-related proteins in various cellular components of ameloblastomas, with pro-apoptotic proteins, Fas, FasL and caspase-3 being closely associated with squamous metaplasia and granular transformation of the tumour cells, suggests that Fas/FasL-induced apoptotic cell death may play a role in the disposal of terminally differentiated or degenerative tumour cells in ameloblastomas.
  • [MeSH-major] Ameloblastoma / chemistry. Caspases / analysis. Jaw Neoplasms / chemistry. Membrane Glycoproteins / analysis. Neoplasm Proteins / analysis. Proto-Oncogene Proteins c-bcl-2 / analysis. Receptors, Tumor Necrosis Factor / analysis. Tumor Necrosis Factors / analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. HGNC: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16690252.001).
  • [ISSN] 0901-5027
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / BCL2L15 protein, human; 0 / FAS protein, human; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Receptors, Tumor Necrosis Factor; 0 / Tumor Necrosis Factors; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  •  go-up   go-down


92. Johnson TM, Antrobus R, Johnson LN: Plk1 activation by Ste20-like kinase (Slk) phosphorylation and polo-box phosphopeptide binding assayed with the substrate translationally controlled tumor protein (TCTP). Biochemistry; 2008 Mar 25;47(12):3688-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plk1 activation by Ste20-like kinase (Slk) phosphorylation and polo-box phosphopeptide binding assayed with the substrate translationally controlled tumor protein (TCTP).
  • It is composed of a N-terminal kinase domain and a C-terminal polo-box domain (PBD).
  • In this work, we describe expression in Escherichia coli cells and purification of full-length Plk1 in quantities suitable for structural studies and use this material for quantitative characterization of the activation events with the substrate translationally controlled tumour protein (TCTP).
  • Native Plk1 exhibits a basal catalytic efficiency k cat/ K(M) of 9.9 x 10 (-5) s (-1) microM (-1).
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cell Cycle Proteins / metabolism. Nerve Tissue Proteins / metabolism. Protein-Serine-Threonine Kinases / metabolism. Proto-Oncogene Proteins / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18298087.001).
  • [ISSN] 0006-2960
  • [Journal-full-title] Biochemistry
  • [ISO-abbreviation] Biochemistry
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0400957
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Nerve Tissue Proteins; 0 / Phosphopeptides; 0 / Proto-Oncogene Proteins; 0 / tumor protein, translationally-controlled 1; EC 2.7.1.- / SLK protein, human; EC 2.7.1.- / STK24 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / polo-like kinase 1
  •  go-up   go-down


93. Jones SE, McMahon KD: Species-sorting may explain an apparent minimal effect of immigration on freshwater bacterial community dynamics. Environ Microbiol; 2009 Apr;11(4):905-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Species-sorting may explain an apparent minimal effect of immigration on freshwater bacterial community dynamics.
  • Long distance atmospheric transport of bacterial cells is often implied as a driver of the apparent cosmopolitan distribution of bacterial taxa.
  • Surprisingly, efforts to measure immigration in bacterial communities are rare.
  • An 8-week time series of within-lake bacterial community composition and atmospheric deposition rates and composition were used to estimate the influence of immigration on bacterial community dynamics in two north temperate lakes.
  • Characterization of bacterial community dynamics using automated ribosomal intergenic spacer analysis suggested moderate overlap in composition between the lakes and atmospherically deposited cells.
  • However, taxa that appeared to be delivered by atmospheric deposition had a relatively minor influence on lake bacterial community dynamics.
  • The weak influence of immigrating bacterial taxa suggests that a species-sorting concept best describes aquatic bacterial metacommunity dynamics.
  • [MeSH-major] Bacteria / classification. Bacteria / isolation & purification. Biodiversity. Fresh Water / microbiology
  • [MeSH-minor] Cluster Analysis. DNA Fingerprinting. DNA, Bacterial / genetics. DNA, Ribosomal Spacer / genetics. Ecosystem. Time Factors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19040451.001).
  • [ISSN] 1462-2920
  • [Journal-full-title] Environmental microbiology
  • [ISO-abbreviation] Environ. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Bacterial; 0 / DNA, Ribosomal Spacer
  •  go-up   go-down


94. Hu J, Zhou GW, Wang N, Wang YJ: GPX1 Pro198Leu polymorphism and breast cancer risk: a meta-analysis. Breast Cancer Res Treat; 2010 Nov;124(2):425-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Breast Neoplasms / genetics. Glutathione Peroxidase / genetics. Polymorphism, Genetic
  • [MeSH-minor] African Continental Ancestry Group / genetics. Case-Control Studies. European Continental Ancestry Group / genetics. Female. Genetic Predisposition to Disease. Humans. Odds Ratio. Risk Assessment. Risk Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20306294.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 1.11.1.- / glutathione peroxidase GPX1; EC 1.11.1.9 / Glutathione Peroxidase
  •  go-up   go-down


95. De Cecco L, Musella V, Veneroni S, Cappelletti V, Bongarzone I, Callari M, Valeri B, Pierotti MA, Daidone MG: Impact of biospecimens handling on biomarker research in breast cancer. BMC Cancer; 2009;9:409
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Biomarkers, Tumor / analysis. Biomedical Research / methods. Breast Neoplasms / genetics. Gene Expression Profiling / methods. Specimen Handling / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Biospecimen Research Database. Biospecimen Research Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Genome Biol. 2002 Jul 15;3(8):SOFTWARE0003 [12186655.001]
  • [Cites] Mol Endocrinol. 2002 Oct;16(10):2231-42 [12351689.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1743-8 [12414521.001]
  • [Cites] Nucleic Acids Res. 2003 Jan 1;31(1):219-23 [12519986.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1441-4 [12670886.001]
  • [Cites] Genome Biol. 2003;4(4):R27 [12702208.001]
  • [Cites] PLoS Biol. 2004 Feb;2(2):E7 [14737219.001]
  • [Cites] Anal Biochem. 2004 May 15;328(2):101-8 [15113684.001]
  • [Cites] Biotechniques. 2004 Jun;36(6):1030-7 [15211754.001]
  • [Cites] Exp Mol Pathol. 2004 Dec;77(3):222-30 [15507240.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8720-7 [15623657.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2817-26 [15591335.001]
  • [Cites] Lancet. 2005 Feb 19-25;365(9460):671-9 [15721472.001]
  • [Cites] Neoplasia. 2004 Nov-Dec;6(6):761-7 [15720802.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3309-14 [15867228.001]
  • [Cites] Cancer Res. 2005 Aug 1;65(15):6755-63 [16061657.001]
  • [Cites] BMC Genomics. 2006;7:96 [16643655.001]
  • [Cites] J Allergy Clin Immunol. 2006 Aug;118(2):403-9 [16890765.001]
  • [Cites] J Clin Oncol. 2006 Aug 10;24(23):3726-34 [16720680.001]
  • [Cites] Cell Signal. 2006 Dec;18(12):2272-82 [16843637.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10292-301 [17079448.001]
  • [Cites] Oncogene. 2007 Feb 8;26(6):802-12 [16878149.001]
  • [Cites] Nat Rev Immunol. 2007 Mar;7(3):191-201 [17290298.001]
  • [Cites] Eur J Cancer. 2007 Mar;43(5):828-34 [17329097.001]
  • [Cites] J Clin Oncol. 2007 Apr 1;25(10):1239-46 [17401012.001]
  • [Cites] Cancer Genomics Proteomics. 2007 May-Jun;4(3):121-34 [17878516.001]
  • [Cites] Nat Cell Biol. 2008 Feb;10(2):202-10 [18193036.001]
  • [Cites] Endocr Relat Cancer. 2008 Mar;15(1):101-11 [18310279.001]
  • [Cites] Endocr Relat Cancer. 2008 Jun;15(2):439-49 [18508997.001]
  • [Cites] BMC Genomics. 2008;9:394 [18717985.001]
  • [Cites] J Pharmacol Toxicol Methods. 2009 Jan-Feb;59(1):44-9 [19028589.001]
  • [Cites] Biotechnol Lett. 2006 Oct;28(19):1601-13 [16900335.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 21;93(4):309-14 [11181778.001]
  • [Cites] J Surg Res. 2001 Aug;99(2):222-7 [11469890.001]
  • [Cites] Nucleic Acids Res. 2002 Feb 15;30(4):e15 [11842121.001]
  • (PMID = 19930681.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2787533
  •  go-up   go-down


96. Gaudet MM, Milne RL, Cox A, Camp NJ, Goode EL, Humphreys MK, Dunning AM, Morrison J, Giles GG, Severi G, Baglietto L, English DR, Couch FJ, Olson JE, Wang X, Chang-Claude J, Flesch-Janys D, Abbas S, Salazar R, Mannermaa A, Kataja V, Kosma VM, Lindblom A, Margolin S, Heikkinen T, Kämpjärvi K, Aaltonen K, Nevanlinna H, Bogdanova N, Coinac I, Schürmann P, Dörk T, Bartram CR, Schmutzler RK, Tchatchou S, Burwinkel B, Brauch H, Torres D, Hamann U, Justenhoven C, Ribas G, Arias JI, Benitez J, Bojesen SE, Nordestgaard BG, Flyger HL, Peto J, Fletcher O, Johnson N, Dos Santos Silva I, Fasching PA, Beckmann MW, Strick R, Ekici AB, Broeks A, Schmidt MK, van Leeuwen FE, Van't Veer LJ, Southey MC, Hopper JL, Apicella C, Haiman CA, Henderson BE, Le Marchand L, Kolonel LN, Kristensen V, Grenaker Alnaes G, Hunter DJ, Kraft P, Cox DG, Hankinson SE, Seynaeve C, Vreeswijk MP, Tollenaar RA, Devilee P, Chanock S, Lissowska J, Brinton L, Peplonska B, Czene K, Hall P, Li Y, Liu J, Balasubramanian S, Rafii S, Reed MW, Pooley KA, Conroy D, Baynes C, Kang D, Yoo KY, Noh DY, Ahn SH, Shen CY, Wang HC, Yu JC, Wu PE, Anton-Culver H, Ziogoas A, Egan K, Newcomb P, Titus-Ernstoff L, Trentham Dietz A, Sigurdson AJ, Alexander BH, Bhatti P, Allen-Brady K, Cannon-Albright LA, Wong J, Australian Ovarian Cancer Study Group, Chenevix-Trench G, Spurdle AB, Beesley J, Pharoah PD, Easton DF, Garcia-Closas M, Breast Cancer Association Consortium: Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev; 2009 May;18(5):1610-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Breast Neoplasms / genetics. Polymorphism, Single Nucleotide
  • [MeSH-minor] Alleles. BH3 Interacting Domain Death Agonist Protein / genetics. Case-Control Studies. Caspase 10 / genetics. DNA-Binding Proteins / genetics. Europe. Female. Genetic Predisposition to Disease. Genotype. Humans. Intracellular Signaling Peptides and Proteins / genetics. Logistic Models. Nuclear Proteins / genetics. Risk. Tumor Necrosis Factor-alpha / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2007 Mar;39(3):352-8 [17293864.001]
  • [Cites] J Natl Cancer Inst. 2006 Oct 4;98(19):1382-96 [17018785.001]
  • [Cites] Cancer. 2007 May 15;109(10):1940-8 [17436274.001]
  • [Cites] BMC Bioinformatics. 2007;8:448 [18005446.001]
  • [Cites] J Natl Cancer Inst. 2001 May 16;93(10):776-82 [11353788.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5236-8 [14500352.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1200-4 [14652281.001]
  • [Cites] Int J Technol Assess Health Care. 1990;6(1):5-30 [2361819.001]
  • [Cites] J Natl Cancer Inst. 2004 Dec 15;96(24):1866-9 [15601643.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 5;97(1):51-9 [15632380.001]
  • [Cites] Mol Cell Biol. 2005 Apr;25(7):2808-18 [15767684.001]
  • [Cites] Exp Mol Med. 2005 Apr 30;37(2):86-90 [15886521.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2413-8 [16214925.001]
  • [Cites] Carcinogenesis. 2006 Mar;27(3):606-9 [16251207.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):675-82 [16614108.001]
  • [Cites] BMC Bioinformatics. 2006;7:209 [16620382.001]
  • [Cites] Int J Cancer. 2006 Jul 15;119(2):467-71 [16477637.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9420-7 [17018596.001]
  • [Cites] Hum Genet. 2007 May;121(3-4):483-90 [17216494.001]
  • (PMID = 19423537.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA54281; United Kingdom / Cancer Research UK / / A10123; United States / NCI NIH HHS / PC / N01-PC-35141; United States / NCI NIH HHS / CA / R01 CA058860; United States / NCI NIH HHS / CA / N01PC35141; United States / NCI NIH HHS / CA / CA2 R01 CA58860-14; United States / NCI NIH HHS / CA / CA63464; United States / NCI NIH HHS / CA / CA-95-003; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / R01 CA063464; United States / NCI NIH HHS / CA / U01 CA098233; United States / NCI NIH HHS / CA / R01 CA054281; United States / NCI NIH HHS / CA / U01 CA063464; United States / NCI NIH HHS / CA / K07 CA098364; United States / NCI NIH HHS / CA / CA98364; United States / NCI NIH HHS / CA / CA 0657245; United Kingdom / Cancer Research UK / / 10118; United States / NCI NIH HHS / CA / R01 CA104021-04; United States / NCI NIH HHS / CA / R37 CA054281; United States / NCI NIH HHS / CA / CA 098233
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BH3 Interacting Domain Death Agonist Protein; 0 / BID protein, human; 0 / DNA-Binding Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / MRFAP1 protein, human; 0 / Nuclear Proteins; 0 / TNF protein, human; 0 / Tumor Necrosis Factor-alpha; 0 / xeroderma pigmentosum group F protein; EC 3.4.22.- / Caspase 10; EC 3.4.22.63 / CASP10 protein, human
  • [Other-IDs] NLM/ NIHMS122664; NLM/ PMC2737177
  •  go-up   go-down


97. Duffy SW, Nagtegaal ID, Astley SM, Gillan MG, McGee MA, Boggis CR, Wilson M, Beetles UM, Griffiths MA, Jain AK, Johnson J, Roberts R, Deans H, Duncan KA, Iyengar G, Griffiths PM, Warwick J, Cuzick J, Gilbert FJ: Visually assessed breast density, breast cancer risk and the importance of the craniocaudal view. Breast Cancer Res; 2008;10(4):R64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Mammography / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] IARC Sci Publ. 1980;(32):5-338 [7216345.001]
  • [Cites] J Natl Cancer Inst. 2004 Apr 21;96(8):621-8 [15100340.001]
  • [Cites] Cancer Causes Control. 1995 Sep;6(5):431-8 [8547541.001]
  • [Cites] J Natl Cancer Inst. 1997 Apr 2;89(7):488-96 [9086005.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1052-9 [15894652.001]
  • [Cites] Am J Epidemiol. 2005 Oct 15;162(8):743-52 [16150892.001]
  • [Cites] Phys Med Biol. 2006 Jun 7;51(11):2695-713 [16723760.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1159-69 [16775176.001]
  • [Cites] Radiology. 2006 Oct;241(1):47-53 [16990670.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):43-9 [17220330.001]
  • [Cites] N Engl J Med. 2007 Jan 18;356(3):227-36 [17229950.001]
  • [Cites] Breast Cancer Res Treat. 2007 Jul;104(1):47-56 [17009106.001]
  • [Cites] Clin Radiol. 2007 Nov;62(11):1052-60 [17920863.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Oct;8(10):863-6 [10548313.001]
  • [Cites] Clin Radiol. 2001 Oct;56(10):833-7 [11895300.001]
  • [Cites] Med Phys. 2003 Mar;30(3):352-64 [12674236.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Apr;12(4):332-8 [12692108.001]
  • [Cites] J Natl Cancer Inst. 1995 Nov 1;87(21):1622-9 [7563205.001]
  • (PMID = 18651965.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / 10404
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2575537
  •  go-up   go-down


98. He C, Tamimi RM, Hankinson SE, Hunter DJ, Han J: A prospective study of genetic polymorphism in MPO, antioxidant status, and breast cancer risk. Breast Cancer Res Treat; 2009 Feb;113(3):585-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective study of genetic polymorphism in MPO, antioxidant status, and breast cancer risk.
  • Oxidative stress may be involved in breast carcinogenesis.
  • Myeloperoxidase (MPO) is an endogenous oxidant enzyme that generates reactive oxygen species (ROS).
  • A single nucleotide polymorphism (SNP) G-463A in the promoter region has been associated with a decrease in risk of breast cancer.
  • We assessed the association between this polymorphism and breast cancer risk in a nested case-control study within the Nurses' Health Study (1,269 incident breast cancer cases and 1,761 matched controls).
  • We further investigated potential gene-gene and gene-environment interactions.
  • There were no significant associations between MPO or COMT genotypes and risk of breast cancer.
  • However, the combination of a priori hypothesized low-risk genotypes in MPO and COMT genes was associated with a marginally significant decrease in breast cancer risk (OR, 0.28; 95% CI, 0.08-1.00).
  • Dietary intake and plasma antioxidant levels may modify the association between the MPO polymorphism and breast cancer risk.
  • Although the test for departure from multiplicative interaction was not significant, inverse associations with MPO genotype were more pronounced among women who consumed higher amounts of total fruits and vegetables (OR, 0.58; 95% CI, 0.30-1.12); this association was not found among the low-consumption group (OR, 1.11; 95% CI, 0.63-1.96).
  • The relative risk associated with the MPO homozygous variant genotype was 0.44 (95% CI, 0.18-1.09) for women who had the highest level of plasma carotenoids.
  • Results from this study suggest that exogenous and endogenous modulators of oxidative stress may modify the association between the MPO polymorphism and breast cancer risk.
  • Further research is needed to confirm these possible associations.